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ABSTRACT	  
Mechanisms	  of	  gemcitabine	  resistance	  in	  pancreatic	  cancer	  James	  Melling	  
Introduction:	   	   Gemcitabine	   is	   the	   chemotherapy	   of	   choice	   for	   pancreatic	  cancer	   in	   palliative	   and	   adjuvant	   settings	   but	   prognosis	   remains	   poor	   as	  patients	  may	  not	  respond	  or	  develop	  resistance.	  	  	  
Aims:	  	  To	  investigate	  the	  mechanisms	  of	  gemcitabine	  resistance	  developed	  in	  
vitro.	  	  	  
Methods:	  	  Previously,	  cell	  lines	  shown	  to	  be	  relatively	  resistant	  and	  sensitive	  to	  gemcitabine	  were	  produced	  and	  subjected	  to	  microarray	  analysis	  (Dajani,	  unpublished).	   	   Following	   these	   results,	   suggested	   differential	   RNA	   and	  protein	  expression	  was	  confirmed	  using	  qRT-­‐‑PCR	  or	  western	  blot.	  Candidate	  genes	   were	   then	   inhibited	   using	   siRNA	   knockdown	   and	   any	   effect	   on	  resistance	   to	   gemcitabine	   measured.	   	   Immunocytochemistry	   (ICC)	   and	  immunohistochemistry	  (IHC)	  were	  then	  optimised	  to	  allow	  human	  tissue	  to	  be	  probed	  for	  the	  presence	  of	  candidate	  proteins	  of	  interest	  in	  the	  future.	  
Results:	   	   The	   Illumina	   Human	   RNA	   v3Bead	   and	   810	   Protein	   Antibody	  microarrays	   indicated	  differential	  expression	  of	  4	  genes	  at	  RNA	   level	  and	  5	  proteins.	  	  The	  most	  significant	  transcript	  was	  SERPINA1	  (p=0.002).	  This	  was	  confirmed	  with	  qRT-­‐‑PCR	  (75%	  decreased	  expression	   in	  resistant	  Suit-­‐‑2	  cell	  line).	   	   Knockdown	   of	   SERPINA1	   did	   not	   affect	   resistance.	   	   The	   most	  significant	   protein	   was	   RRM2.	   	   Western	   blot	   confirmed	   differential	  expression	   in	   the	   resistant	   cell	   line	   and	   knockdown	   of	   RRM2	   decreased	  resistance	   in	  both	  parental	  Suit-­‐‑2	   cells	   (IC50	  value	  of	  0.1nM	  vs	  0.004nM	  of	  gemcitabine)	  and	  the	  resistant	  cells	  (IC50	  value	  of	  >300,000nM	  vs	  29,500nM	  of	  gemcitabine).	   	  Conditions	  for	  ICC	  and	  IHC	  were	  then	  optimised	  for	  RRM2	  expression.	  
Conclusion:	   Investigation	   by	   microarray	   identified	   RRM2	   as	   a	   candidate	  protein	  involved	  in	  gemcitabine	  resistance.	  RRM2	  was	  confirmed	  by	  protein	  levels	  and	  knockdown	  in	  vitro	  to	  affect	  resistance.	   	  RRM2	  should	  be	  further	  investigated	   as	   a	   potential	   prognostic	   marker	   and	   therapeutic	   target	   in	  adjuvant	  therapy	  of	  pancreatic	  cancer.	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   Magnesium	  chloride	  mls	   	   Mililitres	  MP	   	   MiaPaCa	  cell	  line	  mRNA	  	   Messenger	  RNA	  MTS	   3-­‐‑(4,5-­‐‑dimethylthiazol-­‐‑2-­‐‑yl)-­‐‑5-­‐‑(3-­‐‑carboxymethoxyphenyl)-­‐‑2-­‐‑(4-­‐‑sulfophenyl)-­‐‑2H-­‐‑tetrazolium	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1   INTRODUCTION	  	  
1.1  Pancreatic	  Ductal	  Adenocarcinoma	  (PDAC)	  
  Epidemiology	  
Pancreatic	  cancer	  is	  the	  11th	  most	  common	  cancer	  in	  the	  UK	  with	  9618	  new	  cases	   diagnosed	   in	   2014.	   	   This	   represents	   2.7%	   of	   the	   356,860	   people	  diagnosed	  with	  any	   form	  of	   cancer	   for	   the	  same	  year1.	   	  Worldwide,	  around	  278,684	  people	  were	  diagnosed	  with	  pancreatic	  cancer	  in	  20082.	  	  The	  overall	  5-­‐‑year	  survival	  rate	  is	  dismal	  with	  only	  4%	  of	  adults	  with	  pancreatic	  cancer	  in	   England	   surviving	   5	   years	   for	   the	   period	   2005-­‐‑2009.	   	   Due	   to	   this	   poor	  survival	  rate,	  pancreatic	  cancer	  represented	  the	  5th	  most	  common	  cause	  of	  all	  cancer	  deaths	  in	  the	  UK	  in	  2014	  with	  8,817	  deaths.	  
The	   incidence	   increases	  with	  age	  and	  approximately	  75%	  of	   cases	  occur	   in	  those	  over	  the	  age	  of	  65	  years	  (figure	  1).	  The	  age	  standardised	  rates	  show	  a	  higher	   incidence	   in	  men	  of	  10.5	  per	  100,000	  vs	  8.2	  per	  100,000	   in	  women.	  	  This	  reverses	  over	  the	  age	  of	  85	  due	  to	  the	  higher	  life	  expectancy	  of	  women.	  	  The	  lifetime	  risk	  of	  developing	  pancreatic	  cancer	  in	  the	  UK	  is	  estimated	  at	  1	  in	   77	   for	  men	   and	  1	   in	   79	   for	  women.	   	   The	   incidence	   of	   pancreatic	   cancer	  remained	  stable	  between	  1993	  and	  20081.	  	  
Worldwide,	  Europe	  and	  North	  America	  have	  the	  highest	  incidence	  rates,	  with	  Asia	  and	  Africa	  having	  the	  lowest	  incidences(figure	  2)1,3.	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More	   than	  95%	  of	   cancers	   are	  Pancreatic	  Ductal	  Adenocarcinomas	   (PDAC),	  arising	   from	   the	   exocrine	   part	   of	   the	   pancreas.	   	   Other	   histological	   types	   of	  pancreatic	   cancer	   include	  sarcomas	  and	  neuroendocrine	   tumours	  but	   these	  are	  rare	  and	  the	  work	  in	  this	  thesis	  relates	  specifically	  to	  PDAC.	  
	  
Figure	  1:   Pancreatic	  Cancer,	  Average	  Number	  of	  New	  Cases	  per	  Year	  
and	   Age-­‐‑Specific	   Incidence	   Rates	   per	   100,000	   population	   in	   the	   UK,	  
2012-­‐‑2014	  (www.cancerresearchuk.org)1	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Figure	  2:   Pancreatic	  cancer	  (C25),	  World	  Age-­‐‑Standardised	  Incidence	  
Rates,	   World	   Regions,	   2008	   Estimates	   (taken	   from	   the	   cancer	  
research	  UK	  website)1	  	  
  Aetiology	  
There	  are	  a	  number	  of	  familial	  factors	  which	  have	  been	  associated	  with	  PDAC.	  	  Certain	   familial	   pancreatic	   cancer	   families	   have	   been	   identified	   where	  despite	   the	   absence	   of	   an	   identifiable	   germline	  mutation,	   there	   remains	   an	  apparent	   inherited	   predisposition	   to	   the	   disease3.	   	   In	   these	   families,	   it	   has	  been	   shown	   that	   individuals	   with	   two	   first	   degree	   relatives	   affected	   with	  pancreatic	  cancer	  have	  a	  risk	  of	  developing	  the	  disease	  themselves	  18	  times	  that	  of	  those	  individuals	  with	  only	  one	  affected	  relative.	   	  This	  risk	  increases	  to	  57-­‐‑fold	  when	  3	  or	  more	  relatives	  are	  affected4.	   	  This	   is	  compared	  to	  first	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degree	   relatives	   of	   sporadic	   cases	   of	   pancreatic	   cancer	   who	   carry	   no	  significantly	  increased	  risk	  compared	  to	  the	  general	  population.	  
As	   well	   as	   these	   families,	   there	   are	   a	   number	   of	   well-­‐‑defined	   cancer	  susceptibility	   syndromes	   where	   a	   certain	   germline	   mutation	   has	   been	  identified.	   	   These	   include	   Familial	   Atypical	   Multiple	   Mole	   Melanoma	  Syndrome	   (FAMMM,	   a	   mutation	   of	   tumour	   suppressor	   CDKN2A),	   Peutz-­‐‑Jeghers	  Syndrome	  (mutation	  of	  STK11	  gene),	  familial	  hereditary	  pancreatitis	  (mutation	   of	   cationic	   trypsinogen	   gene	   PRSS1),	   cystic	   fibrosis,	   Lynch	  syndrome	   (mismatch	   repair	   pathway	   deficiency),	   Familial	   Adenomatous	  Polyposis	   (mutation	   of	   adenomatous	   polyposis	   coli	   gene),	   Li-­‐‑Fraumeni	  syndrome	  (mutation	  of	  TP53	  tumour	  suppressor	  gene),	  and	  familial	  breast-­‐‑ovarian	  cancer	  (mutations	  of	  tumour	  suppressor	  genes	  BRCA1	  +	  2).	  	  The	  risk	  conferred	  by	  these	  mutations	  varies	  but	  can	  be	  as	  high	  as	  high	  as	  a	   lifetime	  risk	  of	  developing	  pancreatic	  cancer	  of	  17%,	  such	  as	  in	  FAMM	  mutations3,5.	  
Various	   factors	  have	  also	  been	   implicated	   in	   the	  development	  of	  pancreatic	  cancer.	  	  These	  include	  chronic	  pancreatitis,	  obesity,	  diabetes	  mellitus,	  non-­‐‑O	  blood	  group,	   alcohol	   and	   smoking.	   	  These	   factors	   are	   all	   relatively	   low	   risk	  factors	  when	  compared	  with	  the	  familial	  factors3,5–7.	  
These	   familial	   and	   specific	   predisposing	   factors	   account	   for	   only	   a	   small	  number	  of	  cases	  of	  pancreatic	  cancer8.	   The	  majority	  of	  cases	  are	  related	  to	  acquired	  molecular	  changes	  as	  discussed	  below.	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  Molecular	  biology	  
1.1.3.1  Precursor	  lesions	  
The	   development	   of	   pancreatic	   cancer	   is	   now	   thought	   to	   result	   from	   the	  successive	   accumulation	   of	   genetic	   mutations,	   initially	   producing	   pre-­‐‑malignant	   lesions	  which	  evolve	  into	  fully	   invasive	  cancer.	   	  There	  are	  3	  such	  pre-­‐‑malignant	   lesions;	   pancreatic	   intraepithelial	   neoplasia	   (PanIN),	  intraductal	   papillary	   mucinous	   neoplasm	   (IPMN)	   and	   mucinous	   cystic	  neoplasm	   (MCN)8.	   	   The	  most	  well	   studied	   of	   these	   are	   PanINs	   from	  which	  most	  PDAC	  develops.	  	  These	  are	  classified	  histologically	  in	  a	  stepwise	  manner	  according	   to	   the	   degree	   of	   cellular	   atypia	   within	   pancreatic	   ducts	  characterised	  by	  loss	  of	  polarity,	  nuclear	  crowding,	  enlarged	  nuclei,	  pseudo-­‐‑stratification	   and	   hyperchromatism9.	   	   PanIN	   1A	   and	   1B	   representing	  hyperplasia	  through	  to	  PanIN3	  being	  carcinoma	  in	  situ10.	  	  These	  histological	  changes	  are	  also	  associated	  with	  defined	  stepwise	  genetic	  alterations	  starting	  with	  activating	  KRAS	  mutations	  and	  telomere	  shortening	  in	  PanIN	  1,	  moving	  through	   inactivation	   of	   CDKN2A	   in	   PanIN	   2	   and	   finally	   TP53	   and	   DPC4	  mutations	  in	  PanIN	  311,12	  (Figure	  3).	  	  This	  stepwise	  progression	  suggests	  that	  single	   gene	   alterations	   are	   not	   enough	   to	   cause	   development	   of	   PDAC	   in	  isolation.	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Figure	  3:   Model	   of	   stepwise	   pancreatic	   carcinogenesis.	   	   There	   is	   a	  
progressive	   accumulation	   of	   genetic	   mutations	   through	   progressive	  
grades	   of	   PanIN	   culminating	   in	   invasive	   PDAC.	   	   These	   are	   the	  most	  
common	   mutations	   and	   other	   genetic	   abnormalities	   may	   occur	  
alongside	  these11,12.	  In	   fact,	   comprehensive	   genetic	   analysis	   of	   24	   different	   pancreatic	   cancers	  found	  an	  average	  of	  63	  genetic	  alterations	  per	  cancer	  which	  were	  likely	  to	  be	  relevant.	   	   These	  were	  mostly	   point	  mutations	   and	   suggest	   that	   the	   genetic	  basis	  of	  pancreatic	   cancer	   is	   extremely	   complex	  and	  heterogeneous.	   	  These	  genetic	  abnormalities	  can	  be	  organised	  into	  13	  relevant	  pathways	  (Figure	  4)	  but	   the	   key	  mutations	   in	   each	   pathway	   differ	   from	   one	   tumour	   to	   another	  which	  is	  not	  surprising	  given	  a	  total	  of	  1562	  mutations	  were	  found	  in	  total	  in	  the	  24	  cancers13.	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Figure	  4:   The	   core	   signalling	   pathways	   in	   pancreatic	   cancer	  
development	   (GTP	   =	   guanosine	   triphosphate,	   TGFβ	   =	   transforming	  
growth	  factor	  β)12	  Of	  these	  13	  pathways,	  chromatin	  regulation	  is	  the	  more	  recently	  identified	  in	  pancreatic	   cancer.	   	  This	  has	  been	   identified	   through	  alterations	   in	  both	   the	  ARIDIA	   gene	   which	   encodes	   for	   a	   protein	   involved	   in	   SWI/SNF	   ATP-­‐‑dependent	  chromatin	  remodelling	  complex,	  and	  mutations	  in	  MLL3	  (mixed-­‐‑lineage	  leukaemia	  3)	  which	  encodes	  a	  histone	  methyltransferase.	  
Some	  of	  the	  other	  common	  genetic	  mutations,	  pathways	  and	  events	  involved	  in	   the	  development	  of	  pancreatic	  cancer	  shall	  be	  described	   in	   the	   following	  sections.	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1.1.3.2  KRAS	  
The	   KRAS	   oncogene	   codes	   for	   the	   21kDa	   membrane	   bound	   Kirsten	   rat	  sarcoma	   protein	   (K-­‐‑ras)	   and	   is	   located	   on	   chromosome	   12.	   	  Mutations	   are	  usually	   point	   mutations	   and	   occur	   at	   codon	   12,	   13	   or	   61.	   	   Mutations	   are	  found	   in	   80-­‐‑90%	   of	   pancreatic	   cancers15	   and	   are	   also	   commonly	   found	   in	  PanIN1A	   and	   1B	   lesions	   suggesting	   this	   is	   an	   important	   initiating	   step	   in	  carcinogenesis12.	   	   The	   K-­‐‑ras	   protein	   is	   a	   key	   mediator	   of	   a	   variety	   of	  signalling	  pathways.	  	  In	  its	  inactive	  form,	  it	  is	  bound	  to	  GDP	  but	  on	  activation	  by	  growth	  factor	  receptors	  such	  as	  epidermal	  growth	  factor	  receptor	  (eGFR),	  GDP	  is	  released	  in	  exchange	  for	  GTP.	   	  This	  converts	  the	  K-­‐‑ras	  protein	  to	  the	  ‘on’	  state	  in	  which	  it	  activates	  a	  number	  of	  downstream	  signalling	  pathways.	  	  	  
Mutations	  of	  the	  KRAS	  gene	  lead	  to	  impaired	  GTPase	  function	  which	  causes	  the	  K-­‐‑ras	  protein	  to	  be	  locked	  in	  the	  ‘on’	  state	  leading	  to	  various	  downstream	  actions.	   	   	  Activation	  of	  the	  Raf/MEK/ERK	  pathway	  leads	  to	  phosphorylation	  of	   the	   tumour	   suppressing	   retinoblastoma	   protein	   (pRb)	   which	   in	   turn	  controls	  transition	  from	  G1	  into	  S	  phase	  and	  cell	  cycle	  progression.	  	  Initiation	  of	   the	   phosphoinositide-­‐‑3-­‐‑kinase	   (P13K)/AKT	   signalling	   pathway	   leads	   to	  cellular	  proliferation,	  whereas	  p53	  inhibition	  is	  achieved	  by	  activation	  of	  the	  murine	  double	  minute	  protein	   (MDM2)	   leading	   to	  evasion	  of	  apoptosis	  and	  enhanced	  cell	  survival9,11,15–17.	  	  	  
1.1.3.3  CDKN2A	  
The	   tumour	   suppressor	   gene	   CDKN2A	   is	   located	   on	   chromosome	   9	   and	  through	   alternative	   splicing	   sites,	   codes	   for	   both	   the	   p16INK4A	   and	   P14ARF	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proteins.	   	  The	  p16INK4A	  protein	  inhibits	  the	  formation	  of	  complexes	  between	  cyclin	  and	  cyclin	  dependent	  kinases	  (CDKs)	  which	  affects	  phosphorylation	  of	  pRb	   and	   subsequently,	   the	   G1	   checkpoint	   and	   entry	   into	   S	   phase	   and	  progression	   through	   the	   cell	   cycle.	   	   The	   p14ARF	   protein	   sequesters	   MDM2	  which	  stabilises	  p53.	  
Therefore,	  silencing	  of	  the	  CDKN2A	  gene	  which	  occurs	  in	  over	  90%	  of	  PDACs	  leads	   to	   increased	   cellular	   proliferation,	   reduced	   apoptosis	   and	   survival	   of	  the	   mutated	   cell.	   	   The	   mutation	   can	   occur	   via	   a	   homozygous	   deletion	   or	  methylation	  of	  the	  promoter	  region	  among	  other	  methods18,19.	  	  	  
1.1.3.4  TP53	  
The	   TP53	   gene	   is	   found	   on	   chromosome	   17	   and	   codes	   for	   the	   tumour	  suppressing	  transcription	  factor	  p53.	  p53	  produces	  a	  transcription	  response	  including	  pro-­‐‑apoptotic	  factors	  and	  p21,	  which	  is	  a	  CDK	  inhibitor	  that	   leads	  to	   cell	   cycle	   arrest,	   usually	   in	   the	   G1	   phase.	   	   Levels	   of	   p53	   are	   usually	  maintained	  at	  a	  very	  low	  level	  by	  MDM2	  which	  both	  transports	  p53	  out	  of	  the	  nucleus	  and	  marks	  it	  for	  proteasomal	  degradation.	  	  	  
In	  conditions	  of	  cellular	  stress	  such	  as	  DNA	  damage	  or	  oncogene	  activation,	  MDM2	   is	   inhibited	  and	  p53	   therefore	   stabilised,	   leading	   to	   increased	   levels	  within	  the	  nucleus	  with	  subsequent	  apoptosis	  or	  cell	  senescence10,12.	  	  	  
1.1.3.5  DPC4	  
The	  Deleted	  in	  Pancreatic	  Cancer	  4	  gene	  (DPC4)	  codes	  for	  the	  SMAD4	  protein	  which	  plays	  a	  key	  role	  in	  the	  transforming	  growth	  factor	  β	  (TGFβ)	  signalling	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pathway.	   	   TGFβ	   is	   a	   cytokine	   secreted	   by	   epithelial,	   endothelial,	  haematopoietic	   and	   mesenchymal	   cells	   which	   when	   binding	   to	   TGFβ	  receptor	   causes	   phosphorylation	   of	   the	   receptor	   regulated	   cytoplasmic	  proteins	   SMAD2	   and	   SMAD3.	   	   These	   form	   a	   complex	   with	   SMAD4	   which	  accumulates	  in	  the	  nucleus.	  	  There	  it	  stimulates	  transcription	  of	  genes	  which	  cause	   cell	   cycle	   arrest.	   	   Thus,	   SMAD4	   has	   a	   pivotal	   role	   in	   the	   tumour	  suppressive	  effects	  of	  TGFβ.	  
The	  DPC4	  gene	  is	  located	  on	  chromosome	  18	  and	  is	  so	  called	  because	  it	  was	  originally	  isolated	  as	  a	  tumour	  suppressor	  gene	  for	  cancer.	  	  Mutations	  are	  not	  particularly	   common	   in	   cancer	   in	   general,	   but	   approximately	   90%	   of	  pancreatic	  cancers	  show	  mutations	  to	  at	  least	  one	  allele.	  	  Due	  to	  its	  recessive	  nature,	   the	   complete	   loss	   of	   SMAD4	   function	   only	   happens	   following	  homozygous	  deletion	  or	  intragenic	  mutation	  with	  the	  loss	  of	  the	  second	  allele,	  and	  this	  situation	  occurs	  in	  about	  55%	  of	  pancreatic	  cancers.	  	  As	  is	  seen	  with	  TP53,	  DPC4	  mutations	  are	  observed	  in	  high	  grade	  PanIN	  lesions.	  
Interestingly,	  DPC4	  mutation	  and	  loss	  of	  SMAD4,	  while	  abolishing	  the	  tumour	  suppressive	  effects	  of	  TGFβ,	  does	  not	  seem	  to	  affect	  TGFβ	  mediated	  tumour	  promoting	   functions	   such	   as	   epithelial	   to	   mesenchymal	   transition	  (EMT)9,10,12,15,16,20,21.	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1.1.3.6  Epithelial	   to	  mesenchymal	   transition	  and	  pancreatic	   cancer	  
stem	  cells	  
EMT	   represents	   a	   number	   of	   events	   leading	   to	   an	   epithelial	   cell,	   adherent	  within	   an	   organised	   tissue,	   to	   convert	   to	   an	   independent	   cell,	   capable	   of	  migration	  and	  invasion.	  	  During	  this	  process,	  the	  polarised,	  basal	  membrane	  anchored	  cell	  acquires	  a	  mesenchymal	   fibroblastic	  phenotype	  via	  a	  number	  of	   molecular	   changes.	   	   These	   include	   the	   loss	   of	   normal	   epithelial	   surface	  markers	  involved	  in	  cell	  to	  cell	  interaction	  including	  E-­‐‑cadherin,	  claudins	  and	  occludin,	   as	   well	   as	   gaining	   mesenchymal	   markers	   such	   as	   S100A4,	   N-­‐‑cadherin,	  vimentin	  and	  α-­‐‑smooth	  muscle	  actin.	  	  	  
This	   change	   is	   stimulated	   by	   a	   number	   of	   factors	   already	   present	   in	   the	  tumour	  micro-­‐‑environment	  including	  TGFβ,	  hepatocyte	  growth	  factor	  (HGF),	  bone	  morphogenic	   proteins	   (BMPs)	   and	   vascular	   endothelial	   growth	   factor	  (VEGF)	  as	  well	  as	  cellular	  stress22,23.	  
EMT	  has	  been	  shown	  to	  represent	  an	  important	  step	  in	  metastasis	  and	  until	  recently	  was	   felt	   to	   be	   a	   late	   event	   in	   the	   evolution	   of	   a	   pancreatic	   cancer.	  	  However,	  recent	  evidence	  in	  mouse	  models	  has	  shown	  that	  both	  EMT	  and	  the	  presence	  of	  pancreatic	  epithelial	  cells	   in	   the	  bloodstream	  occur	  early	   in	   the	  disease	  process,	  before	  histological	  evidence	  of	  cancer	  is	  demonstrable.	  	  This	  suggests	   a	  paradigm	  shift	   to	   considering	  pancreatic	   cancer	   a	  disease	  which	  metastasises	  early,	  even	  at	  the	  level	  of	  PanIN	  development24–26.	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Cancer	  stem	  cells	  were	  first	  identified	  when	  different	  cancer	  cells	  within	  the	  same	  tumours	  were	  assayed	  for	  their	  proliferative	  potential	  and	  this	  showed	  only	   a	   small	   minority	   demonstrating	   extensive	   proliferation.	   	   Further	  investigation	   showed	   this	   small	   subset	   to	   demonstrate	   distinct	   cell	   surface	  marker	  expression.	  	  In	  pancreatic	  cancer,	  these	  stem	  cells	  have	  been	  found	  to	  express	   the	   surface	   markers	   CD133,	   CD44,	   CD24	   and	   epithelial-­‐‑specific	  antigen	  (ESA)	  and	  are	  capable	  of	  unlimited	  self-­‐‑renewal	  (immortality)	  and	  to	  reproduce	   all	   derived	   cell	   phenotypes	   within	   the	   cancer.	   	   This	   subset	   of	  pancreatic	   cancer	   stem	   cells	   represents	   only	   0.2-­‐‑0.8%	  of	   pancreatic	   cancer	  cells	  and	  they	  have	  a	  tumorigenic	  potential	  100	  times	  that	  of	  the	  other	  cells,	  demonstrated	   by	   the	   ability	   to	   induce	   tumours	   in	   50%	   of	   animals	   injected	  with	  as	  few	  as	  100	  cells.	  	  	  
Pancreatic	   cancer	   stem	   cells	   are	   resistant	   to	   chemo	   and	   radiotherapy	   and	  may	  explain	  disease	  which	  relapses	  following	  a	  good	  initial	  response	  to	  such	  treatments.	   	   It	   is	   also	   thought	   that	   the	   stem	   cell	   and	  EMT	  phenotypes	  may	  overlap	   through	   shared	   molecular	   features.	   	   Dysregulation	   of	   various	  embryonic	  pathways	  including	  Notch,	  Wnt	  and	  Hedgehog	  signalling	  have	  also	  been	  linked	  to	  EMT	  and	  cancer	  stem	  cells.8,16,23,27.	  	  	  	  
1.1.3.7  Notch/Hedgehog/Wnt	  signalling	  
These	   pathways	   are	   all	   important	   in	   normal	   embryonic	   development	   of	  tissues	  but	  may	  be	  reactivated	  in	  the	  development	  of	  cancer.	  
The	  Notch	  pathway	  has	  a	  role	  in	  the	  developing	  pancreas	  and	  is	  activated	  by	  ligands	  of	  the	  delta	  and	  jagged	  families	  expressed	  on	  the	  cell	  surface	  binding	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to	   heterodimeric	   transmembrane	   Notch	   receptors	   of	   adjacent	   cells.	   	   This	  leads	  to	  cleavage	  of	  the	  notch	  receptors	  within	  the	  membrane,	  releasing	  their	  active	   intracellular	   domain	   which	   is	   then	   transferred	   to	   the	   nucleus	   and	  bound	  to	  the	  transcription	  factor	  CSL,	  leading	  to	  the	  expression	  of	  a	  variety	  of	  genes	  involved	  in	  tissue	  proliferation,	  differentiation	  and	  apoptosis.	  	  	  
In	   the	   normal	   adult	   pancreas,	   Notch	   and	   its	   ligands	   are	   expressed	   only	   at	  very	   low	   levels	   but	   aberrant	   expression	   of	   ligands,	   receptors	   and	   Notch	  transcription	  targets	  can	  be	  observed	  in	  pancreatic	  cancer	  and	  its	  precursor	  lesions.	   	   Also	   genetic	   downregulation	   of	   Notch	   can	   inhibit	   cell	   growth	   and	  induce	  apoptosis	  in	  pancreatic	  cancer	  cell	  lines	  in	  vitro28,29.	  
The	  Hedgehog	  signalling	  pathway	   is	  vital	   in	   the	  normal	  development	  of	   the	  embryonic	  gut	  amongst	  other	  tissues	  and	  involves	  3	  different	  ligands	  (sonic	  hedgehog	  (SHH),	  Indian	  hedgehog	  (IHH)	  and	  desert	  hedgehog	  (DHH).	  	  In	  the	  absence	  of	  these	  ligands,	  the	  membrane	  receptor	  patched	  (PTCH)	  blocks	  the	  smoothened	   receptor	   (SMO),	   inhibiting	   its	   activity.	   	   However,	   binding	   of	  hedgehog	   ligands	   to	   PTCH,	   reduces	   the	   inhibitory	   effect	   on	   SMO,	   allowing	  signal	  transduction	  which	  ends	  with	  activation	  of	  transcriptional	  factors.	  
There	  are	  a	  number	  of	  findings	  suggesting	  hedgehog	  signalling	  is	   important	  in	  the	  development	  of	  pancreatic	  cancer.	  	  Firstly,	  SHH	  is	  expressed	  in	  70%	  of	  human	  pancreatic	  cancers	  and	  there	  is	  35	  times	  increased	  expression	  of	  IHH	  in	  cancer	  compared	  to	  normal	  cells.	   	  Elements	  of	  the	  hedgehog	  pathway	  are	  found	   not	   just	   secreted	   from	   the	   cells	   comprising	  most	   of	   the	   tumour	   (so-­‐‑called	  ‘bulk’	  cancer	  cells)	  but	  also	  appear	  to	  be	  integral	  to	  the	  maintenance	  of	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pancreatic	   cancer	   stem	   cells	   as	   well	   as	   the	   ligand	   responsive	   stroma.	  	  Inhibition	  of	  the	  hedgehog	  pathway	  by	  cyclopamine	  which	  binds	  to	  SMO	  has	  been	   shown	   to	   enhance	   response	   to	   chemotherapy	   and	   reduce	   metastatic	  spread	  experimentally.	   	  Furthermore,	  the	  hedgehog	  pathway	  was	  one	  of	  the	  12	  core	  pathways	  previously	  identified10,16,30.	  	  	  
	  
Wnt	   signalling	   is	   important	   in	   the	   development	   of	   the	   endocrine	   pancreas	  and	   can	   be	   activated	   as	   part	   of	   pancreatic	   carcinogenesis.	   	   Wnt	   ligands	  interact	   with	   a	   family	   of	   membrane	   bound	   receptors	   known	   as	   Frizzled.	  	  Following	  this	  a	  number	  of	  different	  pathways	  can	  be	  followed,	  of	  which	  the	  canonical	   is	   the	   most	   investigated	   and	   understood.	   	   In	   this	   pathway,	   a	  cascade	   leads	   to	   inhibition	   of	   β-­‐‑Catenin	   phosphorylation,	   causing	  accumulation	   of	   β-­‐‑Catenin	   and	   translocation	   from	   the	   cytoplasm	   to	   the	  nucleus.	  Here	   it	   binds	   to	   the	  TCF-­‐‑LEF	   family	   of	   transcription	   factors	  which	  activate	  transcription	  of	  Wnt	  target	  genes.	  	  Upregulation	  of	  Wnt	  signalling	  is	  thought	   to	   result	   in	   carcinogenesis	   and	   progression	   of	   various	   cancers	  including	   pancreatic	   cancer.	   	  Wnt	   signalling	   is	   also	   thought	   to	   be	   activated	  downstream	  of	  the	  hedgehog	  pathway,	  which	  as	  discussed	  above	  is	  relevant	  to	  pancreatic	  cancer	  development.	  	  	  
Although	  the	  relevance	  of	  upregulated	  Wnt	  signalling	  in	  pancreatic	  cancer	  is	  controversial,	   the	   evidence	   is	   growing.	   	  Aberrant	   activation	   in	   the	  pathway	  has	  been	  found	  in	  65%	  of	  pancreatic	  cancers,	  and	  high	  levels	  of	  β-­‐‑catenin	  in	  the	   nucleus	   has	   been	   confirmed	   in	   both	   high	   grade	   PanINs	   and	   advanced	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cancers.	   	   Furthermore,	   Wnt	   inhibition	   has	   been	   shown	   to	   both	   block	  proliferation	  and	  induce	  apoptosis	  in	  cultured	  adenocarcinoma	  cells9,11,15,16,31.	  
1.1.3.8  Telomere	  shortening	  
Telomeres	   are	   located	   at	   the	   end	   of	   chromosomes	   and	   are	   repetitive	  nucleotide	  sequences	  which	  normally	  shorten	  with	  each	  cell	  division,	  thereby	  causing	   a	   cell	   to	   have	   a	   finite	   lifespan.	   To	   avoid	   entering	   senescence,	  telomeres	   can	   be	   lengthened	   via	   activation	   of	   telomerase	   (a	   reverse	  transcriptase	   containing	   an	   RNA	   template	   which	   elongates	   telomeres)	   or	  alternative	   lengthening	   of	   telomeres	   (ALT),	   potentially	   bypassing	   the	   cells	  natural	   finite	   lifespan.	   	   Telomerase	   is	   expressed	   in	   85-­‐‑90%	   of	   pancreatic	  cancers16,32,33.	  
1.1.3.9  Stroma	  and	  pancreatic	  stellate	  cells	  	  
One	  of	  the	  hallmarks	  of	  pancreatic	  cancer	  is	  a	  dynamic	  fibro-­‐‑inflammatory	  or	  desmoplastic	  response	  which	  surrounds	  the	  tumour	  and	  is	  known	  as	  stroma.	  	  Although	   a	   desmoplastic	   reaction	   has	   been	   noted	   in	   other	   cancers	   such	   as	  breast,	   prostate	   and	   ovarian	   cancer,	   pancreatic	   cancer	   shows	   the	   most	  extensive	   reaction	  with	   stroma	   estimated	   to	   account	   for	   up	   to	   90%	   of	   the	  whole	  tumour	  volume.	  	  The	  stroma	  is	  composed	  of	  activated	  fibroblasts	  and	  myofibroblasts	   including	   pancreatic	   stellate	   cells,	   inflammatory	   cells,	  extracellular	  matrix	  (ECM)	  and	  blood	  and	  lymphatic	  vessels34.	  	  	  
Previously,	   it	  was	  hypothesised	  that	  the	  stroma	  represented	  a	  host	  immune	  response	   to	   the	   tumour,	   attempting	   to	   wall	   off	   the	   threat,	   but	   evidence	   in	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recent	   years	   has	   emerged	   showing	   a	   highly	   complex	   and	   dynamic	   set	   of	  interactions	  between	  tumour	  and	  stroma	  cells	  which	  is	  critically	  involved	  in	  tumour	  formation,	  proliferation,	  invasion	  and	  metastasis8,34.	  	  	  
Pancreatic	   stellate	   cells,	   first	   isolated	   in	   199835,	   are	   pancreas	   specific	  mesenchymal	   cells	   which	   are	   important	   mediators	   of	   the	   desmoplastic	  reaction.	   	   Functionally	   and	   morphologically	   they	   are	   similar	   to	   hepatic	  stellate	   cells	   which	   had	   previously	   been	   implicated	   in	   liver	   fibrosis.	   	   They	  exist	   in	   2	   distinct	   states;	   the	   quiescent	   state	   and	   the	   activated	   or	  myofibroblastic	   state.	   	   They	   are	   characterised	   when	   quiescent	   by	   lipid	  droplets	   containing	   vitamin	   A	   and	   expression	   of	   desmin	   and	   glial	   fibrillar	  acidic	  protein.	   	  They	  are	  activated	  in	  the	  presence	  of	  growth	  factors	  such	  as	  TGFβ,	  platelet	  derived	  growth	   factor	   (PDGF)	  and	  VEGF	  secreted	  by	   tumour	  cells,	   	  and	  secrete	  excessive	  amounts	  of	   the	  components	  of	  ECM	  (leading	  to	  the	  characteristic	  stroma)	  express	  α-­‐‑smooth	  muscle	  actin	  (α-­‐‑SMA)	  and	  show	  loss	  of	  lipid	  droplets34,36.	  	  	  
Their	   importance	   in	   the	   stromal	   reaction	   has	   been	   shown	   by	  Bachem	  et	  al	  who	   showed	   increased	   stroma	   in	   orthotopic	   nude	   mouse	   cancers	   when	  cancer	  cells	  were	  transplanted	  along	  with	  pancreatic	  stellate	  cells	  as	  opposed	  to	   in	   isolation37.	   	  Vonlaufen	  et	  al	   also	   noted	   stellate	   cells	   along	  with	   cancer	  cells	   in	   liver	   metastases	   from	   cancer	   cells	   transplanted	   with	   pancreatic	  stellate	  cells	  in	  an	  orthotopic	  nude	  mice	  model,	  suggesting	  co-­‐‑migration	  and	  a	  possible	  role	  for	  stellate	  cells	  in	  promoting	  a	  favourable	  microenvironment	  for	  migration	  and	  implantation38.	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Immune	  cells	  have	  been	  shown	  to	  make	  up	  approximately	  50%	  of	  pancreatic	  tumour	  cell	  mass.	   	  Clarke	  et	  al	  showed	  that	  cells	  of	  the	  host	  immune	  system	  were	   present	   from	   the	   earliest	   stages	   of	   pre-­‐‑invasive	   lesions	   but	   the	  dominant	  immune	  cells	  were	  those	  involved	  in	  immune	  suppression	  with	  an	  absence	   of	   activated	   effector	   T	   cells,	   with	   a	   corresponding	   lack	   of	   anti-­‐‑tumour	   activity.	   	   This	   suggests	   that	   rather	   than	   the	   host	   immune	   response	  being	   overwhelmed	   following	   early	   immunosurveillance	   attempting	   to	  eliminate	   the	   tumour	   cells,	   the	   response	   is	   in	   fact	   undermined	   from	   the	  start36,39,40.	  
The	   components	   of	   the	   ECM	   promoted	   by	   stellate	   cells	   include	   collagen,	  fibronectin,	   proteoglycans	   and	   hyaluronic	   acid	   (HA).	   	   The	   accumulation	   of	  these	   distorts	   the	   normal	   architecture	   of	   the	   pancreatic	   tissue.	   	   This	  increased	   rigidity	   leads	   to	   compression	   of	   blood	   and	   lymphatic	   vessels,	  leading	  to	  decreased	  perfusion36.	  	  	  
Although	  most	  solid	  tumours	  contain	  areas	  of	  hypoxia	  as	  the	  high	  metabolic	  requirements	   of	   the	   tumour	   outstrip	   the	   developing	   vascular	   supply,	  pancreatic	   cancers	   actually	   appear	   to	   be	   globally	   hypoperfused,	   showing	   a	  paucity	   of	   blood	   vessels	   despite	   the	   hypoxic	   state	   and	   high	   levels	   of	   pro-­‐‑angiogenic	  factors.	  	  This	  is	  demonstrated	  by	  the	  characteristic	  appearance	  on	  contrast	  enhanced	  cross	  sectional	  imaging	  of	  a	  lack	  of	  contrast	  uptake36,40.	  	  	  
The	  observation	  that	  roughly	  75%	  of	  vessels	  in	  pancreatic	  cancer	  appear	  to	  be	   collapsed	   may	   suggest	   the	   presence	   of	   high	   interstitial	   pressures,	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exceeding	   the	   combined	   hydrostatic	   and	   oncotic	   pressures,	   along	  with	   the	  elastic	  forces	  of	  the	  vessel	  wall	  as	  described	  by	  Starling	  in	  1896.	  
In	   normal	   tissues,	   interstitial	   fluid	   pressure	   (IFP)	   ranges	   from	  ~8mmHg	   in	  the	  head	  of	   the	  pancreas	   through	  ~2mmHg	   in	  muscle	   to	  ~0.1mmHg	   in	   the	  liver.	   	  These	  measurements	  are	  all	   significantly	   lower	   than	   typical	  arteriole	  (40-­‐‑80mmHg)	   and	   capillary	   (15-­‐‑40mmHg)	   pressures	   meaning	   adequate	  perfusion	  of	  the	  tissues.	  	  	  
This	  high	  IFP	  has	  been	  extensively	  investigated.	  	  For	  example,	  Provenzano	  et	  
al	  used	  genetically	  engineered	  mouse	  models	  (GEMM),	  which,	  in	  contrast	  to	  xenograft	   tumour	   grafted	   mice,	   develop	   autochthonous	   tumours	   which	  faithfully	   replicate	   tumour	   structures	   in	   humans	   including	   the	   stroma	  formation.	  	  The	  IFP	  in	  such	  tumours	  was	  dramatically	  elevated,	  ranging	  from	  75-­‐‑130mmHg,	  which	  is	  similar	  to	  mean	  arterial	  pressure41.	  	  This	  explains	  the	  collapsed	  nature	  of	  vessels	  within	  the	  tumours.	  	  	  
The	   relevance	   of	   these	   findings	   of	   excessive	   ECM	  deposition	   and	   increased	  IFP	  within	  the	  stroma	  with	  regards	  to	  this	  thesis	  is	  the	  effect	  on	  resistance	  to	  systemic	  chemotherapy.	  	  	  
	  
  Clinical	  presentation	  	  
Early	   pancreatic	   cancer	   is	   often	   clinically	   silent	   which	   is	   the	   reason	   the	  disease	  often	  presents	   late	  at	  an	   incurable	  stage	  either	  once	   local	  disease	   is	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advanced	   or	   distant	   spread	   has	   occurred.	   	   Vague	   symptoms	   of	   abdominal	  discomfort	   and	   nausea	   are	   common,	   but	   non-­‐‑specific.	   	   Specific	   signs	   and	  symptoms	  can	  occur.	  	  Tumours	  of	  the	  pancreatic	  head	  are	  the	  most	  common	  and	  may	  cause	  obstructive	  jaundice	  by	  compression	  of	  the	  common	  bile	  duct,	  or	  more	   rarely,	   gastric	   outlet	   obstruction	   or	   gastrointestinal	   haemorrhage.	  	  Obstruction	   of	   the	   pancreatic	   duct	  may	   lead	   to	   pancreatitis.	   	   Patients	  with	  pancreatic	   cancer	  may	   also	   present	   with	   dysglycaemia,	   and	   this	   should	   be	  considered	   in	   anyone	   presenting	   with	   late	   onset	   diabetes	   mellitus8,42,43.	  	  However,	   although	   approximately	   25%	   of	   patients	   with	   pancreatic	   cancer	  have	  diabetes	  at	  diagnosis,	  and	  another	  40%	  have	  impaired	  glucose	  tolerance,	  most	  people	  with	  new	  late	  onset	  diabetes	  will	  not	  have	  pancreatic	  cancer44–46.	  
Features	   of	   more	   systemic	   disease	   also	   occur	   in	   the	   form	   of	   asthenia,	  anorexia	   and	   weight	   loss,	   or	   less	   commonly,	   deep	   or	   superficial	   venous	  thrombosis42.	  	  	  
	  
  Investigations	  
Initial	  investigations	  depend	  on	  the	  presentation	  but	  usually	  include	  routine	  blood	  tests	  which	  may	  confirm	  the	  presence	  of	  obstructive	   jaundice	  (raised	  serum	   bilirubin)	   or	   pancreatitis	   (raised	   serum	   amylase).	   	   Although	  carbohydrate	  antigen	  19-­‐‑9	  (CA19-­‐‑9)	  may	  be	  raised	  and	   levels	  of	  more	  than	  100-­‐‑200U/ml	  may	  predict	  unresectable	  disease	  or	  correlate	  with	  survival42,47,	  it	   has	   shown	   limited	   benefit	   in	   the	   screening	   situation	   due	   to	   a	   lack	   of	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specificity.	   	  Sensitivity	   is	  also	   impaired	  due	   to	   the	   fact	   that	  10%	  of	  patients	  with	  pancreatic	   cancer	   are	  negative	   for	   Lewis	   antigen	   a	   or	   b	   and	   therefore	  cannot	  synthesize	  CA19-­‐‑9,	  producing	  false	  negative	  results8.	   	  CA19-­‐‑9	  can	  be	  useful	   in	   confirmed	   cases	   of	   pancreatic	   cancer,	   particularly	   as	   a	  marker	   of	  early	  recurrence	  or	  progression	  during	  follow	  up48.	  	  	  
Although	   first	   line	   imaging	   again	   depends	   on	   the	   presentation,	   and	   may	  include	  ultrasound	  or	  magnetic	  resonance	  imaging,	  the	  imaging	  of	  choice	  is	  a	  triple	   phase	   pancreatic	   protocol	   computed	   tomography	   (CT),	   along	   with	   a	  chest	  CT	   looking	   for	  pulmonary	  spread.	   	  This	  allows	  detection	  of	  both	   local	  disease	  and	  distant	  metastases8.	  	  	  	  	  
When	   assessing	   disease	   stage,	   patients	   can	   be	   divided	   into	   those	   having	  resectable,	   borderline	   resectable,	   locally	   advanced/unresectable	   and	  metastatic	   disease.	   	   Local	   resectability	   depends	   on	   the	   relationship	   of	   the	  tumour	   to	   the	   surrounding	   vasculature;	   coeliac	   axis,	   superior	   mesenteric	  artery	   (SMA),	   superior	   mesenteric	   vein	   (SMV)	   and	   the	   portal	   vein	   (PV)49.	  	  	  	  While	   tumours	  which	  would	   require	   arterial	   resections	   are	   still	   considered	  unresectable	   other	   than	   in	   exceptional	   circumstances,	   vein	   resection	   and	  reconstruction	  is	  possible	  in	  the	  borderline	  group50.	  	  	  
In	   cases	  where	   biliary	   drainage	   is	   required	   or	   CT	   findings	   are	   equivocal	   in	  terms	   of	   diagnosis,	   then	   endoscopic	   techniques	   may	   be	   used.	   	   Endoscopic	  retrograde	   cholangiopancreatography	   (ERCP)	   allow	   drainage	   via	   the	  placement	   of	   stents	   into	   the	   biliary	   tree	   and	   also	   to	   take	   brushings.	   	   This	  technique	   is	  unreliable	   in	  gaining	  a	  definitive	  cytological	  diagnosis	  due	   to	  a	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poor	   sensitivity	   of	   33-­‐‑54%51.	   	   By	   comparison,	   the	   sensitivity	   of	   endoscopic	  ultrasound	  with	  fine	  needle	  aspiration	  is	  as	  high	  as	  92%	  in	  specialist	  centres	  and	  is	  now	  the	  method	  of	  choice	  where	  tissue	  diagnosis	  is	  required52.	  	  	  
  Staging	  
The	   staging	   system	   for	   pancreatic	   cancer	   is	   based	   on	   the	   tumour,	   node,	  metastases	  (TNM)	  system	  used	  for	  all	  cancers	  but	  modified	  for	  the	  pancreas.	  	  This	   is	  provided	  by	  the	  union	  for	   international	  cancer	  control	  (UICC)	  and	  is	  currently	  up	  to	  its	  8th	  edition53.	  	  This	  is	  shown	  in	  the	  following	  two	  tables.	  
	   T=Primary	  tumour	  
TX	   Primary	  tumour	  cannot	  be	  assessed	  
T0	   No	  evidence	  of	  primary	  tumour	  
Tis	   Carcinoma	  in	  situ	  (including	  PanIN3)	  
T1	   Tumour	  restricted	  to	  the	  pancreas,	  <2cm	  greatest	  dimension	  
T2	   Tumour	  restricted	  to	  the	  pancreas,	  >2cm	  greatest	  dimension	  
T3	   Tumour	  extends	  beyond	  the	  pancreas,	  but	  not	  involving	  the	  
SMA/coeliac	  axis	  
T4	   Tumour	  involves	  the	  SMA	  or	  coeliac	  axis	  
	   N=Regional	  lymph	  node	  status	  
NX	   Regional	  lymph	  nodes	  cannot	  be	  assessed	  
N0	   No	  regional	  lymph	  node	  metastases	  
N1	   1-­‐3	  regional	  lymph	  node	  metastases	  
N2	   4	  or	  more	  regional	  lymph	  node	  metastases	  
	   M=Distant	  metastases	  
M0	   No	  distant	  metastases	  
M1	   Distant	  metastases	  	  
Table	  1:   UICC	   TNM	   staging	   classification	   for	   pancreatic	  
cancer.	   This	   table	   shows	   the	   descriptions	   of	   the	   individual	   T,	  
N	  and	  M	  stage	  as	  applied	  to	  pancreatic	  cancer53.	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As	  can	  be	  seen	   from	   the	  second	   table	  below,	   the	   stage	  helps	  determine	   the	  potential	  surgical	  management	  of	  the	  patient.	  	  Resectable	  disease	  is	  any	  stage	  I	  or	  II	  disease.	  	  Stage	  III	  can	  be	  either	  borderline	  resectable	  or	  unresectable.	  	  Borderline	   includes	  disease	  with	   the	   tumour	   abutting	  <180O	   circumference	  of	  the	  SMA	  or	  coeliac	  axis,	  or	  involving	  a	  short	  segment	  of	  the	  hepatic	  artery,	  SMV,	  PV	  or	  confluence	  of	  the	  two42.	  	  	  
Stage	   TNM	   %	  presenting	  cases	  
0	   Tis,	  N0,	  M0	   	  
IA	   T1,	  N0,	  M0	   	  
IB	   T2,	  N0,	  M0	   10%	  
IIA	   T3,	  N0,	  M0	   	  
IIB	   T1,	  N1,	  M0	  
T2,	  N1	  M0	  
T3,	  N1,	  M0	  
	  
III	   T4,	  any	  N,N2,	  M0	   30%	  
IV	   Any	  T,	  any	  N,	  M1	   60%	  
	  
Table	  2:   UICC	   TNM	   staging	   classification	   for	   pancreatic	  
cancer.	   	   This	   table	   shows	   how	   the	   separate	   T,	   N	   and	   M	  
components	  combine	  to	  form	  a	  numbered	  stage.	  Also	  shown	  is	  
how	   these	   correlate	   clinically	   as	   to	   whether	   the	   tumour	   is	  
resectable	   and	   the	   percentage	   of	   patients	   presenting	   with	  
pancreatic	  cancer	  who	  fall	  into	  each	  category42,53.	  	  
  Surgery	  
Surgery	  remains	  the	  only	  potentially	  curative	  treatment	  option	  for	  resectable	  pancreatic	   cancer.	   	   Overall	   5-­‐‑year	   survival	   rates	   have	   been	   increased	   from	  less	  than	  5%	  to	  over	  20%	  in	  specialist	  centres	  due	  to,	  amongst	  other	  things,	  improved	  surgical	  management	  oncological	  therapy54–56.	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Kausch	  reported	  the	   first	  successful	   two	  stage	  pancreaticoduodenectomy	   in	  1912	   performed	   for	   an	   ampullary	   carcinoma57.	   	   	   The	   first	   single	   stage	  resection	  was	  reported	  by	  Whipple	  in	  194658.	   	  It	  is	  these	  two	  surgeons	  who	  give	   their	   name	   to	   the	   procedure	   now	   termed	   a	   Kausch-­‐‑Whipple	  pancreaticoduodenectomy.	   	   This	   involves	   removal	   of	   the	   gallbladder,	  common	   bile	   duct,	   duodenum	   and	   pancreatic	   head59.	   	   The	   operation	   has	  developed	  over	  time,	  and	  now	  having	  a	  pylorus	  preserving	  variant.	  
Tumours	  of	   the	  body	  and	   tail	  of	   the	  pancreas	  account	   for	  around	  a	   third	  of	  presenting	   patients	   and	   where	   resectable	   are	   treated	   by	   a	   left	  pancreatectomy	   combined	   with	   a	   splenectomy.	   	   Unfortunately,	   these	  tumours	   have	   an	   even	  more	   dismal	   prognosis	   compared	   to	   those	   affecting	  the	  head	  of	  the	  pancreas60.	  	  	  
Laparoscopic	  resection	  of	  the	  pancreas	  is	  emerging	  as	  a	  potential	  alternative	  to	   the	   traditional	   open	  procedure61.	   	  A	   recent	   systematic	   review	  and	  meta-­‐‑analysis	  concluded	  that,	  although	  minimally	  invasive	  resections	  are	  possible	  and	  reported	  results	  show	  improved	  outcomes,	   there	   is	  no	  robust	  evidence	  and	   no	   randomized	   or	   prospective	   studies	   yet	   available.	   	   Therefore,	   this	  cannot	  be	  recommended	  as	  standard	  practice	  at	  this	  time62.	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  Adjuvant	  therapy	  
The	   use	   of	   chemotherapeutic	   regimes	   in	   pancreatic	   cancer	   was	   initially	  reported	  in	  the	  1970s	  and	  1980s,	  but	  only	  in	  locally	  advanced	  or	  metastatic	  disease63.	   	   The	   first	   randomised	   study	   looking	   at	   adjuvant	   chemotherapy	  following	   resection	   was	   published	   in	   1993	   by	   a	   Norwegian	   group64.	   	   This	  compared	   surgery	   alone	  with	   surgery	   plus	   adjuvant	   chemotherapy	   of	   5FU,	  doxorubicin	   and	  mitomycin.	   	   Although	  median	   survival	   improved	   from	   11	  months	  to	  23	  months,	  this	  did	  not	  translate	  into	  long	  term	  survival.	  
The	  landmark	  ESPAC-­‐‑1	  trial65	  (European	  Study	  group	  for	  Pancreatic	  Cancer)	  was	   published	   in	   2001	   and	   was	   designed	   to	   determine	   whether	   adjuvant	  chemotherapy	  or	   adjuvant	   chemoradiotherapy	   improved	   survival	   following	  resection	   for	   pancreatic	   cancer.	   	   It	   was	   the	   first	   adequately	   powered	  randomised	  trial	  and	  recruited	  541	  patients	  in	  61	  international	  centres	  over	  a	   6-­‐‑year	   period.	   	   The	   patients	   were	   randomised	   either	   to	   a	   2x2	   design	   of	  chemoradiotherapy,	   chemotherapy,	   both	   or	   observation,	   or	   as	   individual	  treatment	  groups.	  The	  chemotherapy	  arms	  used	  folinic	  acid	  (initial	  IV	  bolus	  20mg/m2)	  and	  5FU	  (425mg/m2	  on	  days	  1-­‐‑5	  of	  a	  28-­‐‑day	  cycle	  for	  6	  cycles).	  	  	  
Initial	  analysis	  with	  a	  median	  follow	  up	  of	  10	  months	  suggested	  a	  significant	  improvement	   in	   survival	   for	   those	   randomised	   to	   receiving	   chemotherapy	  when	  compared	  to	  the	  entire	  study	  population	  (median	  survival	  19.7	  months	  vs	  14	  months,	  p=0.0005)	  but	   this	   significance	  was	   lost	  when	   looking	  at	   the	  2x2	  design	  alone	  (17.8	  months	  vs	  15.8	  months,	  p=0.09).	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Subsequent	  analysis	  of	  the	  2x2	  design	  published	  later	  in	  2004	  with	  a	  median	  follow	   up	   of	   47	   months	   	   showed	   median	   survival	   was	   now	   significantly	  improved	  in	  those	  receiving	  chemotherapy	  vs	  those	  not	  was;	  20.1	  months	  vs	  15.5	  months	  (HR=0.71	  (0.55-­‐‑0.92),	  p=0.009),	  with	  two	  and	  five	  year	  survival	  improving	   from	   21%	   and	   8%	   respectively	   to	   40%	   and	   21%	   for	   those	  receiving	  chemotherapy66.	  	  
These	   results	   from	   ESPAC-­‐‑1	   established	   5FU	   and	   folinic	   acid	   as	   the	  chemotherapy	  of	  choice	  in	  the	  adjuvant	  setting	  for	  pancreatic	  cancer.	  
In	  2002,	  Takada	  et	  al67	  recruited	  173	  patients	  with	  pancreatic	  cancer	  as	  part	  of	  a	  larger	  study	  of	  508	  patients	  with	  various	  pancreaticobiliary	  malignancies.	  	  Randomisation	  was	  between	  adjuvant	  mitomycin	  C	  and	  oral	  5FU	  or	  surgery	  alone.	   	   In	   the	   pancreatic	   subset,	   there	   was	   no	   significant	   improvement	   in	  survival.	  
In	  2006,	  Kosuge	  et	  al68	  (JSAP-­‐‑1	  (Japanese	  Study	  group	  of	  Adjuvant	  therapy	  for	  Pancreatic	   cancer)	   reported	   randomising	   89	   patients	   with	   R0	   pancreatic	  cancer	  resections	  to	  either	  cisplatin	  and	  5FU	  or	  surgery	  alone	  which	  showed	  no	  significant	  impact	  on	  survival.	  
Following	   demonstration	   of	   a	   clinical	   benefit	   of	   using	   the	   nucleoside	  analogue	   gemcitabine	   over	   5FU	   in	   palliative	   patients69,	   Oettle	   et	   al55	  randomised	  patients	  to	  adjuvant	  gemcitabine	  vs	  observation	  alone	  following	  attempted	  curative	  pancreatic	  resection.	   	  The	  results	  were	  published	  as	   the	  CONKO-­‐‑001	   trial	   initially	   in	   2007,	   with	   subsequent	   final	   results	   in	   200870.	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368	   patients	   were	   randomised	   with	   a	   median	   follow	   up	   of	   53	   months	  performed.	  	  The	  results	  showed	  a	  significant	  increase	  in	  disease	  free	  survival	  from	   6.9	   months	   to	   13.4	   months,	   but	   unfortunately,	   while	   remaining	  significant,	   the	  overall	   survival	  only	   increased	   slightly	   from	  20.2	  months	   to	  22.8	   months	   (p=0.005).	   	   This	   may	   be	   due	   to	   the	   fact	   that	   those	   with	  recurrence	  in	  the	  observation	  group	  went	  on	  to	  receive	  gemcitabine	  for	  their	  relapse.	  
The	  JSAP-­‐‑2	  trial	  was	  published	  in	  200971	  and	  had	  randomised	  119	  patients	  to	  adjuvant	  gemcitabine	  and	  surgery	  alone.	  	  This	  showed	  an	  increase	  in	  median	  disease	  free	  survival	  (11.4	  months	  vs	  5months)	  but	  this	  did	  not	  convert	  into	  a	  significant	  difference	  in	  overall	  survival.	  
For	  ESPAC-­‐‑3	  patients	  had	   initially	  been	  randomised	   to	  adjuvant	   folinic	  acid	  and	   5FU,	   adjuvant	   gemcitabine	   or	   surgery	   alone.	   	   However,	   publication	   of	  ESPAC-­‐‑1	   during	   the	   recruitment	   led	   to	   the	   surgery	   alone	   arm	   being	  abandoned	  and	  the	  study	  renamed	  ESPAC-­‐‑3(v2).	  
The	  patients	  from	  ESPAC-­‐‑3(v1)	  were	  placed	  in	  a	  meta-­‐‑analysis	  with	  patients	  from	  ESPAC-­‐‑1	  which	   confirmed	   the	   benefit	   of	   the	   chemotherapy	   regime	   of	  folinic	  acid	  and	  5FU	  as	  opposed	  to	  observation	  alone72.	  
ESPAC-­‐‑3(v2)54	   was	   published	   in	   2010	   and	   had	   randomised	   1088	   in	   159	  centres	   worldwide	   with	   a	   median	   follow	   up	   of	   34.2	   months.	   Although	   no	  difference	  was	   seen	   in	  progression	   free	   or	   overall	   survival	   between	   to	   two	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adjuvant	   therapy	   regimes,	   there	   were	   significantly	   less	   treatment	   related	  adverse	  events	  in	  the	  gemcitabine	  arm.	  
The	   JASPAC-­‐‑0173,	   published	   in	   2013,	   randomised	   385	   patients	   to	   either	  gemcitabine	  or	  the	  orally	  administered	  fluorinated	  pyrimidine	  S-­‐‑1	  following	  resection	  for	  pancreatic	  cancer.	  	  The	  oral	  drug	  was	  shown	  to	  improve	  disease	  free	   survival	   at	   2	   years	   from	   29%	   to	   49%	   compared	   to	   gemcitabine.	  	  However,	   this	  was	  an	  Asian	  population	  and	  concerns	  have	  been	  raised	   that	  due	   to	   genetic	   metabolic	   differences	   between	   Asian	   and	   Caucasian	  populations,	   the	   drug	   may	   be	   intolerable	   for	   the	   gastrointestinal	   tracts	   of	  western	  patients74.	  
Recently,	   the	   results	   of	   the	   ESPAC-­‐‑4	   study	   have	   been	   published75.	   	   730	  patients	   were	   randomised	   to	   receive	   adjuvant	   chemotherapy	   following	  resection	   with	   either	   gemcitabine	   alone	   or	   in	   combination	   with	   the	   oral	  prodrug	  of	  5-­‐‑FU;	  capecitabine.	  	  The	  median	  overall	  survival	  was	  28.0	  months	  in	   the	   combined	   group	   vs	   25.5	   months	   in	   the	   gemcitabine	   alone	   group	  (HR=0.82,	   p=0.032).	   	   This	   significantly	   increased	   survival	   was	   achieved	  without	   any	   significant	   increase	   in	   grade	   3-­‐‑4	   adverse	   events	   related	   to	  treatment.	  	  	  
The	  study	  concluded	  that	  the	  combination	  of	  gemcitabine	  with	  capecitabine	  should	  be	  the	  new	  standard	  of	  care	  for	  adjuvant	  therapy	  following	  attempted	  curative	   resection	   for	  pancreatic	   cancer.	   	  The	  results	  of	   the	   trials	  discussed	  are	  summarised	  in	  the	  table	  on	  the	  following	  page.	  	  	  
	   	   	   	   Survival	  (95%CI)	  
Year	  
publis
hed	   Author/Group	  
Treatment	  arms	  








1993	   Bakkevold64	   5FU,Doxorubicin	  MitomycinC	  (30)	   100	   23	   70	   4	  	  	   	  	   Surgery	  (31)	   	   11	  (p=0.02)	   45	   8	  (	  =0.1)	  2001	   ESPAC-­‐‑165	   (All	  patients)	   5FU/FA	   +/-­‐‑	   CRT	  (238)	   82	   19.7	  (16.4-­‐‑22.4)	   N/A	   N/A	  
	  	   	  	   No	   chemo	   +/-­‐‑	  CRT	  (235)	   	  
14	  (11.9-­‐‑16.5)	  (p=0.0005)	   N/A	   N/A	  
2002	   Takada67	   5FU/MitomycinC	  (89)	   58	   n/a	   N/A	   11.5	  
	  	   	  	   Surgery	   alone	  (84)	   	   	   N/A	  
18	  (log	  rank	  NS)	  
2004	   ESPAC-­‐‑1	   (2x2	   final	  analysis)66	   5FU/Folinic	   Acid	  (147)	   82	   20.1	  (16.5-­‐‑22.7)	   40	   21	  
	  	   	  	   No	   chemo	   +/-­‐‑	  CRT	  (142)	   	  
15.5	  (13-­‐‑17.7)	  (p=0.009)	   30	   8	  
2006	   JSAP-­‐‑168	  (Kosuge)	   Cisplatin/5FU	  (45)	   100	   12.50	   N/A	   26.40	  
	  	   	  	   Surgery	   alone	  (44)	   	   15.8	   N/A	   14.9	  (p=0.94)	  2007	   CONKO-­‐‑001	  55(Oettle)	   Gemcitabine	  (179)	   	   22.1	  (18.4-­‐‑25.8)	   47.5	   22.5	  	  	   	  	   Surgery	   alone	  (175)	   83	   20.2	  (17-­‐‑23.4)	  (p=0.06)	   42	   20.5	  
2008	   CONKO-­‐‑001	   Final	  70(Neuhaus)	   Gemcitabine	  (179)	   	   22.8	   N/A	   21	  	  	   	  	   Surgery	   alone	  (175)	   	   20.2	  (p=0.005)	   N/A	   9	  2009	   JSAP	  271	  (Ueno)	   Gemcitabine	   +/-­‐‑	  RT	  (58)	   84	   22.3	  (16.1-­‐‑30.7)	   48.3	   23.9	  
	  	   	  	   Surgery	  alone	  +/-­‐‑	  RT	  (60)	   	  
18.4	  (15.1-­‐‑25.3)	  (p=0.19)	   40	   10.6	  
2009	   Collated	   ESPAC	   data	  72	   5FU/Folinic	   Acid	  (233)	   75	   23.2	  (20.1-­‐‑26.5)	   49	   24	  
	  	   	  	   Surgery	   alone	  (225)	   	  
16.8	  (14.3-­‐‑19.2)	  (p=0.003)	   37	   14	  
2010	   ESPAC-­‐‑3(v2)	  54	   5FU/Folinic	   Acid	  (551)	   65	   23	  (21.1-­‐‑25)	   48.1	  (43.8-­‐‑52.4)	   N/A	  
	  	   	  	   Gemcitabine	  (537)	   	  
23.6	  (21.4-­‐‑26.4)	  (p=0.39)	   49.1	  (44.8-­‐‑53.4)	   N/A	  2013	   JASPAC-­‐‑0173	   S-­‐‑1	  (187)	   87	   46.3	   70	   N/A	  
	  	   	  	   Gemcitabine	  (191)	   	   25.5	  (p<0.0001)	  
53	  (p<0.0001)	   N/A	  
2017	   ESPAC-­‐‑475	   Gemcitabine	   40	   25.5	  (22.7-­‐‑27.9)	   52.1	  (46.7-­‐‑57.2)	   N/A	  
	   	   Gemcitabine/	  Capecitabine	   	   28	  (23.5-­‐‑31.5)	  (p=0.032)	   53.8	  (48.4-­‐‑58.8)	   	  
Table	  3:   Major	   adjuvant	   chemotherapy	   trials	   in	   pancreatic	   cancer	  
(adapted	  from	  Jones	  et	  al)77	  
As	  well	  as	  adjuvant	  chemotherapy,	  there	  has	  also	  historically	  been	  interest	  in	  the	   use	   of	   adjuvant	   chemoradiotherapy	   with	   or	   without	   additional	  chemotherapy	   to	   try	   and	   improve	   survival.	   	   A	   number	   of	   trials	   have	  addressed	   this	   and	   a	   meta-­‐‑analysis	   in	   2013	   by	   Liao	   et	   al76	   attempted	   to	  clarify	  the	  findings.	  
The	   results	   of	   this	   study	   confirmed	   that	   adjuvant	   5FU	   or	   gemcitabine	  improved	   survival	   (HR=0.65	   (0.49-­‐‑0.84)	   and	   0.59	   (0.41-­‐‑0.83)	   respectively)	  compared	   with	   observation	   alone.	   	   Chemoradiation,	   on	   the	   other	   hand,	  resulted	   in	  worse	   survival	   than	   5FU	   or	   gemcitabine	   (HR=	   1.69	   (1.12-­‐‑2.54)	  and	  1.86	  (1.04-­‐‑3.23)	  respectively).	  	  Furthermore,	  combining	  chemoradiation	  with	   chemotherapy	   resulted	   in	   significantly	  more	  haematological	   toxic	   side	  effects.	  
Therefore,	   there	   is	   now	   irrefutable	   evidence	   that	   adjuvant	   chemotherapy	  improves	  both	  disease	  free	  and	  overall	  survival.	  	  The	  current	  gold	  standard	  is	  based	  on	  gemcitabine	  and	  capecitabine.	  	  However,	  chemoradiation	  cannot	  be	  recommended	  at	  present78.	  	  
  Palliative	  therapy	  
Survival	  in	  advanced	  disease	  is	  expectedly	  poor.	  	  Locally	  advanced	  disease	  is	  associated	  with	  median	  survival	  of	  8-­‐‑12	  months	  and	  metastatic	  disease	  with	  median	   survival	   of	   only	   3-­‐‑6	   months43.	   	   These	   patients	   represent	  approximately	  80%	  of	  those	  presenting	  with	  pancreatic	  cancer.	   	  Until	  1997,	  5FU	  was	   the	   agent	   of	   choice	   in	   the	   palliative	   setting	   but	   results	  were	   poor	  with	  response	  rates	  of	  less	  than	  10%79.	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In	  1997,	  126	  patients	  were	  randomised	  to	  5FU	  or	  gemcitabine	  for	  advanced	  disease.	  	  gemcitabine	  was	  associated	  with	  a	  significantly	  better	  response	  rate	  of	   24%	   vs	   5%	   (p=0.0022)	   and	   an	   improved	  median	   overall	   survival	   of	   5.6	  months	  vs	  4.4	  months	  (p=0.0025)69.	  
Since	  1997,	  there	  have	  been	  a	  number	  of	  studies	  demonstrating	  the	  benefit	  of	  new	   regimes.	   	   Firstly,	   gemcitabine	   combined	   with	   erlotinib,	   an	   epidermal	  growth	   factor	   receptor	   (EGFR)	   inhibitor	   showed	   statistically	   significant	  improvement	   in	   overall	   survival	   but	   only	   of	   two	  weeks80.	   	   Understandably	  this	  regime	  was	  not	  adopted	  due	  to	  the	  limited	  improvement	  combined	  with	  added	  toxicity.	  
Next,	   a	   European	   trial	   found	   improved	   progression	   free	   survival	   and	  objective	   response	   rates	   when	   using	   gemcitabine	   plus	   capecitabine	   vs	  gemcitabine	   alone	   in	   advanced	   disease.	   	   This	   trial	   also	   suggested	   a	   trend	  towards	  improved	  overall	  survival	  (HR=0.86;	  0.72-­‐‑1.02;	  p=0.08)81.	  	  	  
More	   recently,	   2	   studies	   have	   shown	   improved	   survival	   when	   comparing	  single	   agent	   chemotherapy	   with	   gemcitabine	   compared	   with	   newer	  combined	  regimes82,83.	   	  In	  2011,	  Conroy	  et	  al84	  showed	  FOLFIRINOX	  (folinic	  acid,	   5FU,	   irinotecan	   (topoisomerase	   inhibitor)	   and	   oxaliplatin)	   plus	  gemcitabine	   to	   improve	   progression	   free	   survival	   (6.4	   vs	   3.3	   months,	  p=<0.001)	  and	  overall	  survival	  (11.1	  vs	  6.8	  months,	  p=<0.001)	  compared	  to	  gemcitabine	   monotherapy.	   	   Then	   in	   2013,	   von	   Hoff	   et	   al85	   reported	   that	  adding	   nanoparticle	   albumin	   bound	   (nab)-­‐‑paclitaxel	   (a	   taxane	   agent)	   to	  gemcitabine	  improved	  overall	  survival	  to	  8.5	  months	  from	  6.7	  months	  when	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gemcitabine	  alone	  was	  used	  (p=<0.001).	  	  Nanoparticle	  albumin	  bound	  (nab)-­‐‑paclitaxel	   (trade	   name	  Abraxane)	   uses	   albumin	   as	   a	   ‘stealth	   coating’	   to	   aid	  delivery	  of	  the	  therapeutic	  agent	  into	  the	  tumour	  microenvironment.	  
These	   have	   left	   combined	   regimens	   with	   gemcitabine	   plus	   either	  FOLFIRINOX	   or	   nab-­‐‑paclitaxel	   as	   the	   standard	   treatment	   for	   palliative	  disease86.	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1.2  Gemcitabine	  
PDAC	  is	  a	  significant	  problem	  with	  a	  dismal	  prognosis	  and	  although	  surgery	  is	  the	  only	  form	  of	  cure,	  only	  around	  20%	  of	  patients	  are	  suitable	  for	  surgery	  at	   presentation.	   	   Chemotherapy	   is	   therefore	   the	  mainstay	   of	   treatment	   for	  most	   patients	   and	   the	   most	   commonly	   used	   agent	   is	   gemcitabine.	  	  Gemcitabine	  is	  also	  widely	  used	  in	  the	  adjuvant	  setting.	  
  Indications,	  administration	  and	  side	  effects	  
gemcitabine	   (2’,2’difluorodeoxycytidine)	   is	   an	   analogue	   of	   the	   natural	  nucleoside	  cytidine	   in	   its	  deoxygenated	   form.	   	   It	  differs	   from	  deoxycytidine	  by	  the	  addition	  of	  2	  fluorine	  atoms.	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5:   Molecular	  structure	  of	  gemcitabine	  (left)	  and	  Deoxycytidine	  
(right)	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Gemcitabine	   is	   used	   as	   chemotherapy	   for	   several	   solid	   tumours	   including	  non-­‐‑small	  cell	  lung,	  ovarian,	  bladder,	  breast	  and	  head	  and	  neck	  cancers87.	  	  	  
It	   is	   now	   also	   used	   as	   the	   gold	   standard	   for	   pancreatic	   cancer	   in	   both	   the	  adjuvant	  and	  palliative	  settings88.	  	  	  
It	   is	  given	  via	   the	   IV	  route	  at	  a	  dose	  of	  1000mg/m2	  over	  30	  minutes,	  given	  weekly	   for	   3	   weeks	   followed	   by	   a	   week	   break89.	   	   Standard	   therapy	   in	  pancreatic	   cancer	   previously	   involved	   using	   gemcitabine	   alone	   but	   newer	  combinations	  of	  drugs	  are	  becoming	  more	  common90.	  	  	  
Haematological	   side	   effects	   include	   anaemia,	   neutropenia	   and	  thrombocytopenia	  whereas	  non-­‐‑haematological	  side	  effects	  include	  oedema,	  rash,	  fever	  and	  dyspnoea	  89.	  	  	  
	  
  Mode	  of	  action	  (see	  figures	  6	  and	  7)	  
Gemcitabine	  (difluorodeoxycytidine,	  dFdC)	  is	  transported	  into	  the	  cells	  by	  a	  variety	  of	  nucleoside	  transporters	  including	  Human	  Equilibrative	  Nucleoside	  Transporter	  1	  (hENT-­‐‑1)	  and	  Concentrative	  Nucleoside	  Transporters	  1	  and	  3	  (CNT-­‐‑1,	   CNT-­‐‑3),	   where	   it	   is	   phosphorylated	   into	   its	   monophosphate	   form	  (diflurodeoxycytidine	   monophosphate,	   dFdCMP)	   by	   deoxycitidine	   kinase	  (DCK).	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Gemcitabine	  is	  also	  known	  to	  cause	  ‘topoisomerase	  poisoning’.	  	  This	  is	  a	  term	  used	  to	  describe	  enhanced	  topoisomerase-­‐‑1	  cleavage	  during	  DNA	  replication	  and	  maintenance,	  which	  also	   leads	   to	   cell	  death	  via	   single	   and	  double	  DNA	  breaks92.	  	  	  
Gemcitabine	   is	   inactivated	   at	   two	   stages	  within	   the	   cell.	   	   Once	   transported	  into	   the	   cell,	   over	   90%	   of	   gemcitabine	   (dFdC)	   is	   converted	   to	  difluorodeoxyuridine	  (dFdU)	  by	  cytidine	  deaminase	  (CDA)	  which	  is	  removed	  from	   the	   cell.	   	   The	   monophosphate	   form	   of	   gemcitabine	   is	   converted	   to	  difluorodeoxyuridine	   phosphate	   (dFdUMP)	   by	   deoycytidylate	   deaminase	  (DCTD)	  which	  is	  subsequently	  converted	  to	  dFdU	  and	  removed	  from	  the	  cell.	  	  Nucleotidases	   also	   reduces	   the	   phosphorylated	   forms	   of	   gemcitabine	  providing	  another	  method	  of	  inactivation.	  	  	  
Gemcitabine	   also	   aids	   its	   cytotoxic	   effect	   in	   other	   ways.	   	   dFdCTP	   self-­‐‑potentiates	   by	   having	   a	   negative	   effect	   on	   DCTD,	   thereby	   increasing	   the	  amount	   of	   phosphorylated	   gemcitabine.	   	   Gemcitabine	   also	   has	   a	   negative	  effect	  on	  Ribonucleotide	  Reductase	  (RNR).	  
RNR	  is	  an	  enzyme	  made	  up	  of	  2	  subunits:	  RRM1	  containing	  the	  binding	  site	  and	   RRM2	   containing	   the	   organic	   free	   radical	   for	   enzymatic	   activity93.	   	   It	  catalyses	   the	   conversion	   of	   the	   natural	   nucleotide	   cytidine	   diphosphate	  (CDP)	   to	   deoxycytidine	   diphosphate	   (dCDP)	   which	   goes	   on	   to	   be	   further	  phosphorylated	  before	  being	   incorporated	   into	  DNA	  by	  DNA	  polymerase	   in	  competition	   with	   gemcitabine.	   	   By	   having	   a	   negative	   effect	   on	   RNR,	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gemcitabine	  decreases	  the	  amount	  of	  active	  natural	  nucleotide	  and	  therefore	  decreases	  the	  biosynthesis	  of	  DNA94	  (see	  figure	  below).	  	  	  
  
Figure	  7:   Main	   mechanisms	   of	   action	   of	   gemcitabine.	   	   A	   shows	  
gemcitabine	  (dFdCTP)	  being	  incorporated	  into	  the	  DNA	  chain	  by	  DNA	  
polymerase	   followed	   by	   a	   natural	   nucleotide	   triphosphate	   base	  
(dNTP).	  This	  terminates	  elongation	  of	  the	  chain	  as	  DNA	  polymerase	  is	  
unable	   to	   proceed.	   Some	   downstream	   pathways	   are	   not	   well	  
understood.	   B	   shows	   gemcitabine	   diphosphate	   (dFdCDP)	   covalently	  
binding	   to	   ribonucleotide	   reductase	   (RNR)	   which	   inactivates	   it,	   and	  
subsequently	   decreases	   the	   pool	   of	   natural	   nucleotides,	   decreases	  
deoxycytidine	   deaminase	   activity,	   and	   increases	   dFdCTP	   production.	  
Taken	  from	  De	  Sousa	  et	  al	  without	  permission95.	  	  
Two	  other	  interactions	  are	  of	  particular	  note.	  	  The	  first	  is	  the	  negative	  effect	  that	  dCTP	  has	  on	  DCK.	  	  Therefore,	  the	  more	  active	  natural	  nucleotide	  (dCTP)	  available,	  the	  less	  gemcitabine	  will	  be	  phosphorylated	  to	  its	  active	  forms.	  
The	   second	   is	   that	   the	   tri-­‐‑phosphate	   form	   of	   gemcitabine	   (dFdCTP)	   has	   a	  negative	  effect	  on	  DCTD	  and	  therefore	  reduces	  the	  conversion	  of	  dFdCMP	  to	  dFdUMP.	  	  This	  is	  therefore	  a	  further	  self-­‐‑potentiating	  effect	  of	  gemcitabine.	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  Mechanisms	  of	  Resistance	  
1.2.3.1  Membrane	  transporters	  
Due	   to	   the	   hydrophilic	   nature	   of	   gemcitabine,	   it	   does	   not	   readily	   diffuse	  across	  the	  cell	  membrane,	  instead	  requiring	  transport	  by	  various	  nucleoside	  transporters.	   	   These	   include	   the	   sodium	   independent	  hENT-­‐‑1	  which	   allows	  movement	   in	   both	   directions	   across	   the	   membrane	   and	   the	   sodium	  dependent	   CNT-­‐‑1	   and	   CNT-­‐‑3	   which	   concentrate	   gemcitabine	   within	   the	  cell96,97.	  	  	  
These	  transporters	  have	  been	  an	  area	  of	  much	  investigation	  as	  they	  directly	  affect	   the	   amount	   of	   gemcitabine	   available	   within	   the	   cell	   to	   exert	   its	  cytotoxic	  effects.	  	  	  
hENT-­‐‑1	   is	   one	   of	   the	   primary	   transporter	   of	   gemcitabine	   and	   a	   number	   of	  studies	  have	  now	  shown	  levels	  to	  affect	  sensitivity	  and	  survival	  both	  in	  vitro	  and	  in	  vivo.	  	  Mackey	  et	  al	  199896	  used	  pharmacological	  inhibition	  of	  hENT-­‐‑1	  and	  showed	  that	  this	  increased	  resistance	  to	  gemcitabine	  in	  vitro	  up	  to	  1000	  fold	  in	  some	  cell	  lines.	  	  	  
However,	   Nakano	   et	   al	   200793	   showed	   that	   expression	   of	   the	   mRNA	   for	  hENT-­‐‑1	  did	  not	  alter	  in	  vitro	  with	  changes	  in	  resistance.	   	  The	  hENT-­‐‑1	  levels	  were	  significant	  when	  examined	  in	  combination	  with	  other	  genes	  concerned	  with	   gemcitabine	   transport	   and	  metabolism	   but	   this	  will	   be	   discussed	   in	   a	  later	  section.	   	  This	  negative	  result	  appears	   to	  contradict	   the	  majority	  of	   the	  studies	  to	  date.	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A	   number	   of	   in	   vivo	   studies	   have	   been	   performed	  using	   either	  RT-­‐‑	   PCR	   or	  immunohistochemistry	  to	  assess	  the	  expression	  of	  nucleoside	  transporters	  in	  patients	  receiving	  adjuvant	  therapy	  for	  pancreatic	  cancer.	  	  	  
Giovanetti	   et	   al	   200698	   used	   qRT-­‐‑PCR	   to	   assess	   expression	   of	   hENT-­‐‑1	   in	  tumour	   tissue	   taken	   from	   biopsies	   or	   surgical	   resections.	   	   The	   patients	  included	   those	   having	   surgery	   or	   those	   treated	   palliatively	   with	  chemoradiation.	  	  They	  showed	  high	  levels	  of	  hENT-­‐‑1	  to	  be	  associated	  with	  a	  significantly	  longer	  overall	  survival	  compared	  to	  lower	  levels.	  	  Similar	  results	  were	   gained	   for	   time	   to	   disease	   progression	   and	   disease-­‐‑free	   survival.	   	   On	  multivariate	  analysis,	  hENT-­‐‑1	  was	  found	  to	  be	  independently	  significant	  with	  regards	   to	   prognosis.	   	   Kim	   et	   al	   201199	   also	   retrospectively	   isolated	   RNA	  from	  surgical	  specimens	  and	  performed	  qRT-­‐‑PCR	  looking	  for	  levels	  of	  hENT-­‐‑1.	   	   They	   showed	   that	   low	  hENT-­‐‑1	   levels	  were	   significantly	   associated	  with	  poor	   progression	   free	   and	   overall	   survival	   on	   the	   univariate	   analysis,	   but	  only	   significantly	   associated	   with	   poor	   progression	   free	   survival	   in	   the	  multivariate	  analysis.	  	  	  	  	  
Spatlin	   et	   al	   2004100	   looked	   at	   tissue	   samples	   from	   21	   patients	   with	  pancreatic	  cancer	  treated	  with	  gemcitabine,	  using	  immunohistochemistry	  to	  stain	   for	   hENT-­‐‑1	   and	   CNT-­‐‑3.	   	   They	   found	   that	   patients	   whose	   tumours	  consistently	   expressed	   hENT-­‐‑1	   in	   all	   cells	   (normal	   glandular	   cells	   did	   not	  express	   hENT-­‐‑1)	   had	   a	   significantly	   longer	   overall	   survival	   compared	   to	  lower	  levels	  of	  expression.	  	  They	  also	  found	  that	  CNT-­‐‑3	  showed	  high	  staining	  throughout	  all	  tumours.	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Maréchal	   et	  al101	   also	   looked	   at	   hENT-­‐‑1	   and	   CNT-­‐‑3	   in	   45	   patients	   treated	  adjuvantly	  with	  gemcitabine	  based	  chemoradiation	  after	   curative	   resection.	  	  Using	  immunohistochemistry	  they	  found	  that	  high	  expression	  of	  hENT-­‐‑1	  was	  associated	   with	   longer	   progression	   free	   and	   overall	   survival	   whereas	   high	  CNT-­‐‑3	   expression	   was	   associated	   with	   overall	   survival	   only.	   	   Farrell	   et	   al	  2009102	   looked	   at	   229	   patients	   treated	   in	   the	   RTOG9704	   trial.	   	   This	  was	   a	  prospective	  randomised	  trial	  where	  post-­‐‑surgery	  patients	  were	  randomised	  to	  treatment	  with	  gemcitabine	  or	  5-­‐‑FU	  pre	  and	  post	  chemoradiation	  therapy	  with	  5-­‐‑FU.	  	  Immunohistochemistry	  was	  used	  to	  stain	  for	  hENT-­‐‑1	  on	  a	  tissue	  microarray	  containing	  samples	  of	  all	  229	  patients.	   	  This	  showed	  once	  again	  that	  increased	  hENT-­‐‑1	  expression	  was	  associated	  with	  increased	  disease-­‐‑free	  and	   overall	   survival	   in	   those	   patients	   treated	  with	   gemcitabine.	   	   However,	  those	  treated	  with	  5-­‐‑FU	  showed	  no	  such	  association.	  	  	  
Morinaga	   et	   al	   2011103	   recently	   published	   a	   study	   using	  immunohistochemistry	   to	   assess	   hENT-­‐‑1	   expression	   in	   patients	   receiving	  adjuvant	  therapy	  with	  gemcitabine	  alone.	  	  Of	  the	  27	  patients,	  16	  were	  judged	  to	   have	   high	   levels	   of	   hENT-­‐‑1	   expression	   and	   these	   were	   found	   to	   have	  significantly	  longer	  disease-­‐‑free	  and	  overall	  survival.	  	  hENT-­‐‑1	  expression	  was	  confirmed	   to	   be	   a	   significant	   prognostic	   factor	   for	   overall	   survival	   on	   both	  univariate	  and	  multivariate	  analysis.	  	  	  
In	  2013,	  Greenhalf	  et	  al104	  reported	  retrospectively	  analysing	  tissue	  from	  434	  patients	   from	   the	   ESPAC-­‐‑3	   and	   ESPAC-­‐‑1	   trials	   for	   expression	   of	   hENT1.	  	  These	   patients	   had	   undergone	   potentially	   curative	   surgery	   and	   were	  randomised	   to	   receive	   either	   adjuvant	   gemcitabine	   or	   adjuvant	   5FU	   post	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operatively.	   	   Patients	   receiving	   gemcitabine	  with	   low	   expression	   of	   hENT1	  had	   significantly	   worse	   median	   overall	   survival	   than	   those	   who	   had	   high	  expression	  of	  hENT1	  (17.1	  months	  vs	  26.2	  months;	  p=0.002).	  	  There	  was	  no	  such	   significant	   difference	   in	   the	   patients	   who	   had	   received	   adjuvant	   5FU	  (25.6	   months	   vs	   21.9	   months;	   p=0.36).	   	   This	   study	   concluded	   that	   other	  treatment	   regimes	   should	   be	   considered	   for	   patients	   with	   low	   hENT1	  expression.	  
A	  recent	  systematic	  review	  concluded	  that	  immunohistochemically	  detected	  hENT1	   expression	   was	   significantly	   associated	   with	   disease	   free	   survival	  (HR=0.58;	   0.42-­‐‑0.79)	   and	   overall	   survival	   (HR=0.52;	   0.38-­‐‑0.72)	   for	   those	  patients	   receiving	   adjuvant	   gemcitabine,	   and	   was	   therefore	   a	   suitable	  prognostic	  biomarker105.	  
So	  there	  is	  now	  convincing	  evidence	  to	  show	  that	  high	  hENT-­‐‑1	  levels	  have	  a	  significant	   effect	   on	   the	   transport	   of	   gemcitabine	   into	   pancreatic	   cells	   and	  allows	  it	  to	  exert	  its	  cytotoxic	  effect.	  
	  
1.2.3.2  Gemcitabine	  metabolism	  
	  Once	   transported	   into	   the	   cell,	   gemcitabine	   is	   phosphorylated	   to	   its	  monophosphate	   form	  (dFdCMP).	   	  Two	   further	  phosphate	  groups	  are	  added	  to	  create	  the	  active	  forms	  of	  gemcitabine	  (dFdCDP	  and	  dFdCTP).	  	  The	  initial	  phosphorylation	   is	   the	   rate	   limiting	   step106	   whereas	   the	   second	   and	   third	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phosphate	  groups	  are	  added	  in	  reactions	  catalysed	  by	  non-­‐‑specific	  nucleotide	  kinases.	  	  	  
The	  rate	   limiting	  step	   is	  primarily	  catalysed	  by	  deoxycytidine	  kinase	  (dCK).	  	  dCK	   has	   a	   much	   higher	   affinity	   for	   gemcitabine	   compared	   to	   the	   natural	  nucleoside	   deoxycytidine	   (dCyd)	   as	   shown	   by	   its	  Km	  value	   of	   4.6µM	   versus	  1.5µM107(the	  Km	  value	   is	   the	   substrate	   concentration	   at	   which	   the	   reaction	  rate	   is	   half	   maximum).	   	   Gemcitabine	   is	   also	   phosphorylated	   by	   the	  mitochondrial	   enzyme	   thymidine	   kinase	   2	   (TK2).	   	   However,	   the	   substrate	  specificity	  for	  gemcitabine	  is	  only	  5-­‐‑10%	  that	  of	  dCyd108.	  	  	  
dCK	  has	   long	   been	   linked	  with	   acquired	   resistance	   to	   gemcitabine	   in	   vitro.	  	  The	   earliest	   report	   was	   by	   Ruiz	   van	  Haperen	  et	  al	   in	   1994.	   	   They	   created	  ovarian	   cancer	   cells	   resistant	   to	   gemcitabine	   by	   gradual	   exposure	   to	  increasing	   concentrations	   producing	   a	   30,000-­‐‑fold	   increase	   in	   resistance.	  	  They	  then	  showed	  that	  there	  was	  no	  detectable	  dCK	  protein	  in	  the	  resistant	  cells	  on	  western	  blot	  compared	  to	  normal	  levels	  in	  the	  sensitive	  cells109.	  	  	  
Following	   this	   further	   work	   demonstrated	   a	   similar	   correlation	   between	  gemcitabine	  resistance	  and	  dCK	  activity	  in	  various	  solid	  tumour	  cell	  lines	  in	  vitro110	   and	   in	   vivo111.	   	   Specifically,	  Blackstock	  et	  al112	   looked	  at	   the	   in	   vivo	  effects	  in	  xenografts.	  	  They	  developed	  human	  colon	  cancer	  xenografts	  in	  nude	  mice	  which	  were	  developed	  with	  and	  without	  transfection	  with	  a	  retroviral	  vector	   containing	   dCK,	   thereby	   creating	   wild-­‐‑type	   tumours	   and	   tumours	  overexpressing	   dCK.	   	   Following	   treatment	   with	   gemcitabine,	   they	   showed	  increased	   accumulation	   within	   the	   tumour	   cells	   overexpressing	   dCK	   of	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dFdCTP	   as	  well	   as	   a	  more	  marked	   tumour	   growth	   delay	   than	   in	  wild	   type	  tumours.	  	  	  
More	  recently,	  studies	  specifically	  looking	  at	  pancreatic	  cancer	  have	  emerged.	  	  In	  vitro,	  Nakano	  et	  al	  200793	  developed	  resistant	  pancreatic	  cancer	  cell	  lines	  and	   looked	   at	   the	   expression	   of	   4	   genes	   associated	   with	   gemcitabine	  metabolism	   and	   transport	   (namely	   hENT-­‐‑1,	   dCK,	   RRM1	   and	   RRM2).	   	   This	  showed	   that	   with	   increasing	   resistance,	   dCK	   RNA	   levels	   initially	   increased	  slightly	   but	   then	   fell	   to	   undetectable	   levels	   as	   cell	   lines	   developed	   more	  resistance.	   	  Ohhashi	  et	  al113	  looked	  at	  the	  same	  4	  genes	  in	  cells	  developed	  to	  acquire	  resistance	  to	  gemcitabine,	  but	  then	  went	  on	  t0	  inhibit	  these	  genes	  via	  RNA	  interference	  with	  siRNA.	  	  They	  found	  once	  again	  that	  expression	  of	  cDK	  was	  significantly	  reduced	  in	  the	  resistant	  compared	  to	  the	  parental	  cell	  line.	  	  They	   also	   showed	   that	   down	   regulation	   of	   dCK	   enhanced	   resistance	   to	  gemcitabine.	  	  	  
Tang	   et	   al	   2011114	   initially	   looked	   at	   the	   effect	   of	   overexpressing	   dCK	   via	  recombinant	  adenovirus	  vectors	  and	  found	  that	  this	   increased	  sensitivity	  to	  gemcitabine.	  	  They	  then	  went	  on	  to	  perform	  intratumoral	  injections	  of	  these	  vectors	   into	   established	   subcutaneous	   pancreatic	   cancer	   models	   in	   nude	  mice.	  	  This	  caused	  tumour	  inhibition	  and	  an	  increase	  in	  apoptosis.	  	  	  
Fujita	  et	  al	  2010115	  retrospectively	  examined	  40	  human	  cancers	  treated	  with	  gemcitabine	   looking	   for	   levels	   of	   dCK	   amongst	   other	   genes	   of	   gemcitabine	  metabolism	   and	   transport.	   	   They	   performed	   qRT-­‐‑PCR	   and	   found	   high	   dCK	  levels	  to	  be	  associated	  with	  significantly	  longer	  disease	  free	  survival.	  
	   	   	  	   55	  
These	  findings	  represent	  compelling	  evidence	  as	  to	  the	  importance	  of	  dCK	  in	  the	  metabolism	  of,	  and	  subsequently	  the	  resistance	  of	  cells	  to	  gemcitabine.	  	  	  
There	   is	   some	   evidence	   that	   TK2	   may	   also	   have	   a	   role	   despite	   playing	   a	  secondary	  role	  to	  dCK	  in	  gemcitabine	  phosphorylation.	  	  This	  is	  because	  TK2	  phosphorylates	   dCyd	   far	   more	   efficiently	   than	   it	   does	   gemcitabine.	  	  Deoxycytidine	  monophosphate	   is	   then	  converted	   to	   its	  diphosphate	   (dCDP)	  and	  subsequently	  its	  active	  triphosphate	  form	  (dCTP).	   	  This	  has	  2	  effects	  on	  the	  action	  of	  gemcitabine:	  firstly,	  the	  increased	  pool	  of	  dCTP	  competes	  with	  gemcitabine	   for	   incorporation	   into	   DNA,	   and	   secondly	   dCTP	   inhibits	   dCK,	  thereby	  reducing	  the	  active	  metabolite	  of	  gemcitabine.	  	  
This	  inhibition	  of	  dCK	  by	  dCTP	  has	  been	  suggested	  as	  the	  means	  for	  acquired	  resistance	  in	  human	  oropharyngea116l	  and	  	  human	  small	  cell	  lung	  cancer117.	  
It	  has	  also	  been	  reported	  that	   inhibiting	   the	  deamination	  of	  gemcitabine	  by	  CDA	  may	  increase	  sensitivity	  to	  the	  drug.	  	  Significant	  increases	  in	  sensitivity	  to	   gemcitabine	  were	  observed	   in	   various	  human	   cancer	   cell	   lines	   following	  treatment	   with	   tetrahydrouridine	   (an	   inhibitor	   of	   CDA	   activity)118,119.	  	  Furthermore,	  neuroblastoma	  cell	   lines	  highly	  sensitive	   to	  gemcitabine	  were	  found	  to	  have	  low	  levels	  of	  CDA	  mRNA.	  
1.2.3.3  Inhibition	  of	  Ribonucleotide	  Reductase	  (RNR)	  
As	   described	   above,	   RNR	   is	   responsible	   for	   the	   conversion	   of	   cytidine	  diphosphate	   (CDP)	   to	   deoxy-­‐‑cytidine	   diphosphate	   (dCDP),	   which	   is	   a	   vital	  step	  in	  the	  production	  of	  the	  natural	  nucleotide	  base	  pool	   for	   incorporation	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into	  DNA	  competitively	  against	  gemcitabine.	   	  The	  action	  of	  RNR	  is	   inhibited	  by	  gemcitabine.	  	  Therefore,	  alterations	  in	  the	  expression	  of	  either	  of	  the	  two	  subunits	  of	  RNR	  (RRM1	  and	  RRM2)	  could	  be	  expected	  to	  affect	  resistance	  to	  gemcitabine95.	  
This	   hypothesis	   has	   been	   confirmed	   in	   numerous	   studies.	   Increased	  expression	  of	  RRM1	  has	  been	  shown	  in	  relatively	  gemcitabine	  resistant	  cell	  lines	  in	  a	  variety	  of	  different	  cancers	  including	  pancreatic,	  colonic,	  biliary	  and	  non-­‐‑small	   cell	   lung	   cancer93,120–123.	   	   Equally,	   siRNA	  knockdown	  of	  RRM1	   in	  the	   resistant	   MiaPaCa	   pancreatic	   cancer	   cell	   line,	   increased	   sensitivity120.	  	  Similar	   results	  were	   shown	   for	  RRM2	  with	   overexpression	   associated	  with	  resistance	  to	  gemcitabine	  and	  knockdown	  reducing	  this	  resistance	  in	  vitro124.	  
1.2.3.4  Gemcitabine	   induced	   DNA	   damage	   and	   induction	   of	  
apoptosis	  
As	  discussed	  above,	  when	  gemcitabine	  is	  incorporated	  into	  the	  DNA	  chain,	  a	  further	   nucleotide	   is	   subsequently	   attached	   before	   DNA	   polymerase	   is	  dislodged.	  	  This	  ‘masking’	  of	  gemcitabine	  potentiates	  its	  effect	  as	  this	  makes	  it	   more	   difficult	   for	   DNA	   repair	   genes	   to	   excise	   mismatched	  deoxyribonucleotides	  from	  DNA125.	   	  Some	  repair	  enzymes	  are	  able	  to	  tackle	  this	   problem	   and	   may	   therefore	   be	   related	   to	   resistance.	   	   Excision	   repair	  cross-­‐‑complementation	  1	  (ERCC1)	  is	  a	  DNA	  endonuclease	  which	  incises	  DNA	  at	   the	   site	   of	   double	   strand	   breaks,	   meaning	   it	   can	   repair	   gemcitabine	  induced	   damage.	   	   It	   has	   been	   shown	   that	   overexpression	   of	   ERCC1	   is	  associated	  with	  poor	  response	  to	  gemcitabine126,127.	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Where	  DNA	  can	  be	  repaired	  after	  damage	  by	  gemcitabine,	  Polo-­‐‑like	  kinase	  1	  (Plk1)	   is	   involved	   in	   entering	   the	   cell	   in	   to	  mitosis.	   	  When	   Plk1	   levels	   are	  inhibited,	  sensitivity	  to	  gemcitabine	  increases128.	  	  
The	   effect	   of	   gemcitabine	   on	   topoisomerase-­‐‑1	   cleavage	   to	   produce	  topoisomerase	  poisoning	  has	  been	   investigated	  showing	   that	  acute	  myeloid	  leukaemia	  cells	  deficient	  in	  topoisomerase	  1	  are	  resistant	  to	  gemcitabine92.	  	  	  
In	   regards	   to	   apoptosis,	   a	   variety	   of	   pathways	   have	   been	   found	   to	   interact	  with	   gemcitabine	   activity.	   	   Examples	   include	   p53	   mutations	   reducing	  increasing	  resistance94,	  the	  cytotoxic	  effect	  of	  gemcitabine	  being	  mediated	  by	  p38	  and	   leading	   to	  MAPK-­‐‑caspase	  dependent	  apoptosis129,	  and	  gemcitabine	  resistance	  being	  associated	  with	  over	  activation	  of	  the	  PI3K/Akt	  pathway130.	  	  	  
1.2.3.5  Stroma	  
One	  of	  the	  important	  factors	  in	  gemcitabine	  resistance	  in	  pancreatic	  cancer	  is	  the	  tumour	  environment	  characterised	  by	  the	  dense	  surrounding	  stroma	  and	  subsequent	  poor	  vascularisation	  due	  to	  high	  pressures.	  	  Among	  all	  epithelial	  tumours,	   pancreatic	   cancer	   possesses	   the	   most	   extensive	   desmoplastic	  reaction	  which	  can	  account	  for	  up	  to	  90%	  of	  tumour	  volume131.	   	  This	   limits	  both	  drug	  delivery	  to	  the	  tumour	  cells	  and	  also	  the	  immune	  system95.	  
A	   vital	   pathway	   for	   the	   development	   of	   the	   stroma	   is	   hedgehog	   (Hh)	  signalling.	   	   This	   is	   known	   to	   promote	   tumorigenesis	   and	   the	   characteristic	  desmoplastic	  reaction	  seen	  in	  pancreatic	  cancer,	  by	  affecting	  the	  motility	  and	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differentiation	  of	  stromal	  cells,	  causing	  the	  extracellular	  matrix	  composition	  to	  be	  modified132.	  	  	  
It	   has	   also	   been	   shown	   that	   inhibiting	   the	   Hh	   signalling	   pathway,	   stroma	  related	   gemcitabine	   resistance	   could	   be	   partially	   overcome,	   by	   increasing	  vascularity	  and	  drug	  delivery	  to	  the	  tumour	  by	  up	  to	  60%133.	  
Further	  studies	  have	  also	  shown	  a	  synergistic	  effect	  between	  inhibition	  of	  the	  Hh	   pathway	   and	   gemcitabine	   in	   pancreatic	   cancer	   cell	   lines	   and	   mouse	  xenograft	  models134–136.	  
1.2.3.6  EMT	  phenotype	  
Epithelial	  to	  mesenchymal	  transition	  (EMT)	  plays	  an	  important	  role	  in	  many	  solid	  tumours,	  including	  pancreatic	  cancer.	   	  gemcitabine	  resistant	  cells	  have	  been	   shown	   to	   have	   lower	   expression	   of	   epithelial	   markers	   such	   as	   E-­‐‑cadherin	  and	  higher	  expression	  of	  mesenchymal	  markers	  such	  as	  vimentin137.	  	  	  
It	   has	   also	   been	   demonstrated	   that	   repressors	   of	   E-­‐‑cadherin	   such	   as	   ZEB1	  and	   slug	   can	   cause	   gemcitabine	   resistance	   in	   pancreatic	   cancer	   and	  conversely	   that	   downregulation	   of	   ZEB1	   induced	   reversal	   of	   EMT	  characteristics	  of	  Gemcitabine	  resistant	  cells138,139.	  
However,	  although	  it	  is	  now	  well	  known	  that	  the	  EMT	  phenotype	  is	  linked	  to	  resistance,	   the	   diversity	   of	   EMT	   causing	   transcriptional	   factors	  may	   enable	  cancer	  cells	   to	  adapt	  and	  survive	  a	   single	   targeted	   therapy.	   	  Therefore,	   this	  remains	  an	  emerging	  area	  of	  research140.	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1.3  PDAC	  immortal	  cell	  lines	  
The	  laboratory	  cell	  work	  utilised	  immortalised	  pancreatic	  cancer	  cell	  lines	  in	  regular	  use	  within	  the	  department	  of	  molecular	  and	  clinical	  cancer	  medicine	  at	  the	  University	  of	  Liverpool.	  	  The	  origins	  and	  characteristics	  of	  the	  various	  cell	  lines	  are	  described	  below.	  
  Suit-­‐2	  
These	  cells	  have	  the	  following	  mutations:	  
K-­‐‑RAS	  alteration	  	   P53	  alteration	  	   P16	  alteration	  	   SMAD4	  alteration	  	  p.G12D	   p.R273H	   69	  GAG-­‐‑TAG	  Product	   Glu	   –	  stop	   None	  Wild	  type	  
	  
Table	  4:   Mutations	  in	  SUIT-­‐‑2	  cell	  line	  
	  SUIT-­‐‑2	  cells	  are	  derived	  from	  a	  metastatic	  liver	  tumour	  of	  human	  pancreatic	  carcinoma.	  	  These	  cells	  grow	  in	  monolayered	  sheets	  and	  histologically	  closely	  resemble	   the	   original	   moderately	   differentiated	   pancreatic	   tubular	  adenocarcinoma.	   	   The	   cells	   produce	   both	   carcinoembryonic	   antigen	   (CEA)	  and	  carbohydrate	  antigen	  19-­‐‑9	  (CA19-­‐‑9),	  and	  propagate	  even	  in	  serum	  free	  medium141.	  	  Parental	  SUIT-­‐‑2	  cells	  were	  given	  the	  abbreviation	  AS.	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  BxPC3	  
These	  cells	  have	  the	  following	  mutations:	  
K-­‐‑RAS	  alteration	  	   P53	  alteration	  	   P16	  alteration	  	   SMAD4	  alteration	  	  None	  Wild	  type	   p.Y220C	   Homozygous	  deletion	   Homozygous	  deletion	  
Table	  5:   Mutations	  in	  BxPC3	  cell	  line	  BxPC3	   are	   derived	   from	   an	   adenocarcinoma	   of	   the	   pancreatic	   body	   from	   a	  61-­‐‑year-­‐‑old	  female.	  They	  express	  CA	  19-­‐‑9	  and	  CEA.	  
  Panc1	  
These	  cells	  have	  the	  following	  mutations:	  
K-­‐‑RAS	  alteration	  	   P53	  alteration	  	   P16	  alteration	  	   SMAD4	  alteration	  	  p.G12D	   p.R273H	   Homozygous	  deletion	   None	  Wild	  type	  
Table	  6:   Mutations	  in	  the	  Panc1	  cell	  line	  Panc1	  are	  derived	  from	  an	  adenocarcinoma	  of	  the	  head	  of	  the	  pancreas	  of	  a	  56-­‐‑year-­‐‑old	  male.	  They	  do	  not	  express	  CA19-­‐‑9	  or	  CEA.	  
  MiaPaCa	  
These	  cells	  have	  the	  following	  mutations:	  
K-­‐‑RAS	  alteration	  	   P53	  alteration	  	   P16	  alteration	  	   SMAD4	  alteration	  	  p.G12C	   p.R248W	   Homozygous	  deletion	   None	  Wild	  type	  
Table	  7:   Mutations	  in	  the	  MiaPaCa	  cell	  line	  MiaPaCa	  are	  derived	  from	  an	  adenocarcinoma	  of	  the	  pancreatic	  body	  and	  tail	  of	  a	  65-­‐‑year-­‐‑old	  male.	  They	  do	  not	  express	  either	  CA19-­‐‑9	  or	  CEA.	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1.4  Previous	  work	  
  Development	  of	  resistant	  cell	  lines	  
The	   wild-­‐‑type	   SUIT-­‐‑2	   cell	   line	   was	   grown	   in	   increasing	   concentrations	   of	  gemcitabine	  and	  5-­‐‑FU	  to	  create	  resistant	  cell	   lines.	   	   Initial	  MTS	  assays	  were	  performed	  on	  the	  original	  line	  and	  from	  this,	  IC50	  values	  were	  obtained.	  	  This	  value	  was	  used	  to	  give	  an	  initial	  concentration	  of	  chemotherapy	  to	  use.	  
For	   gemcitabine,	   the	   initial	   concentration	   was	   5nM	   of	   gemcitabine	   in	   the	  20mls	  of	  full	  media	  used	  with	  T-­‐‑75	  flasks.	  	  The	  cells	  were	  passaged	  3	  times	  in	  the	   initial	   concentration	   and	   the	   concentration	   was	   then	   doubled	   up	   to	   a	  maximum	  of	  1000nM.	  
For	  5-­‐‑FU,	  the	  initial	  concentration	  was	  1µM	  and	  increased	  up	  to	  a	  maximum	  of	  50µM.	  
Both	   gemcitabine	   and	   5-­‐‑FU	   were	   diluted	   in	   fresh	   full	   media	   and	   were	  produced	  from	  master	  stock	  frozen	  at	  -­‐‑80°C.	  
This	  process	  produced	  a	  cell	  line	  which	  could	  be	  cultured	  in	  1µM	  gemcitabine	  but	   lost	   this	   resistance	   when	   cultured	   without	   gemcitabine	   for	   multiple	  passages.	   	   These	   cells	   were	   named	   KR	   and	   were	   used	   for	   the	   microarray	  experiments.	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From	   this	   population	   of	   transiently	   resistant	   cells,	   a	   clonal	   population	  was	  created	   by	   initially	   growing	   KR	   cells	   in	   5µM	   gemcitabine	   and	   then	   serially	  diluting	   the	   cells	   to	  a	   concentration	  of	  1-­‐‑2	   cells	  per	  well	   in	  a	  96-­‐‑well	  plate.	  	  After	   incubation	  until	   the	  well	  was	   confluent,	   the	  well	  was	   trypsinised	   and	  the	  cells	  once	  again	  serially	  diluted	  to	  seed	  at	  1-­‐‑2	  cells	  per	  well	  in	  a	  96-­‐‑well	  plate.	   	  This	  was	  repeated	  for	  a	  third	  time	  and	  the	  cells	  allowed	  to	  grow	  to	  a	  larger	  population	  in	  culture	  medium	  with	  5µM	  gemcitabine.	  	  This	  produced	  a	  cell	   line	  which	   tolerates	   higher	   levels	   of	   gemcitabine	   (5µM)	   and	  maintains	  resistance	   to	   gemcitabine	   even	   when	   cultured	   without	   gemcitabine	   for	   6	  months.	  	  This	  cell	  line	  was	  termed	  GR.	  	  	  
Unfortunately,	  it	  was	  not	  possible	  for	  me	  to	  use	  this	  KR	  cell	  line	  fully	  during	  my	   experiments.	   	   I	  was	   provided	  with	   cell	   lysate	   to	   perform	  western	   blots	  upon,	   but	   when	   the	   frozen	   stores	   of	   the	   cells	   were	   defrosted	   and	   culture	  attempted,	   it	   became	   apparent	   that	   they	   had	   developed	   a	   mycoplasma	  infection	  and	  could	  not	  be	  used.	  	  
Therefore,	   my	   experiments	   used	   cell	   lysate	   for	   the	   KR	   Suit-­‐‑2	   cell	   line	  provided	   to	  me	   only.	   	   Thankfully	   the	   GR	   Suit-­‐‑2	   cell	   line	  was	   unaffected	   by	  these	  problems	  and	  could	  be	  used	  freely.	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  Determination	  of	  gemcitabine	  sensitivity	  
An	  MTS	  assay	  was	  performed	  to	  confirm	  the	  resistance	  of	  the	  clonal	  resistant	  cell	  line	  (GR)	  cell	  line	  relative	  to	  the	  parental	  SUIT-­‐‑2	  cell	  line	  (AS).	  
	  
	  
Figure	  8:   Cytotoxicity	   curves	   for	   AS	   and	   GR	   cell	   lines	   treated	   with	  
gemcitabine.	   Percentage	   of	   cells	   alive	   vs	   control	   are	   plotted	   against	  
concentration	  of	  gemcitabine	  (Dajani,	  unpublished)	  	  


















IC50	  curves	  for	  suit-­‐‑2	  parent	  and	  
clone	  4,	  48hrs	  after	  treatment.	  
suit-­‐‑2	  parentBlue	  line	  =	  AS	  Red	  line	  =	  GR	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represent	  the	  concentration	  of	  gemcitabine	  which	  kills	  half	  the	  cells	  and	  the	  IC50	  values	  in	  this	  experiment	  are	  ~0.025µM	  for	  AS	  and	  >100µM	  for	  GR.	  
This	   cytotoxicity	   study	   for	   the	   transiently	   resistant	   cell	   line	  KR	   vs	   parental	  Suit-­‐‑2	  (AS)	  shows	  an	  increase	  in	  the	  level	  of	  resistance	  to	  gemcitabine	  but	  not	  to	  the	  level	  of	  the	  GR	  resistant	  cell	  line	  in	  the	  previous	  figure.	  The	  IC50	  values	  for	   gemcitabine	   determined	   from	   the	   curves	   are	   35nM	   for	   AS	   cells	   and	  400nM	  for	  KR	  cells.	  
	  
Figure	  9:   Cytotoxicity	   curves	   for	   AS	   and	   KR	   cell	   lines	   treated	   with	  
gemcitabine.	   	  In	  this	  graph,	  the	  percentage	  of	  cells	  alive	  is	  plotted	  as	  
relative	   to	   1=100%,	   against	   concentration	   of	   gemcitabine.	   Suit-­‐‑2	  
(blue	   line)	   represents	   the	   parental	   Suit-­‐‑2	   cell	   line	   called	   AS	   in	   my	  
work,	  and	  Suit-­‐‑2	  KR	  (red	  line),	  the	  resistant	  cell	  line	  termed	  KR	  in	  this	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   Microarray	  
The	   sensitive	   cell	   line	   AS	   and	   the	   first	   resistant	   cell	   line	   KR	  were	   used	   for	  microarray	   experiments.	   	   Total	   protein	   was	   extracted	   from	   cultured	   cell	  lysate	  and	  hybridised	  to	  810	  Protein	  Antibody	  Arrays	  to	  compare	  differential	  protein	  expression142.	  	  RNA	  was	  extracted	  from	  cultured	  cells	  and	  hybridised	  to	  Illumina	  Human	  v3	  Bead	  Arrays	  to	  compare	  gene	  expression.	  
	   	  
  Bioinformatics	  	  
The	  microarray	  results	  were	  examined	  by	  the	  resident	  bioinformatics	  expert	  in	  the	  Department	  of	  Molecular	  and	  Clinical	  Cancer	  Medicine	  in	  Liverpool,	  Dr	  Brian	  Lane.	  	  The	  following	  genes	  and	  proteins	  were	  found	  to	  be	  significantly	  differentially	  expressed:	  
Genes/RNA	   Proteins	  BEX4	   Glutathione	  S-­‐‑transferase	  P	  LOC439949	   Zinc	  finger	  protein	  593	  SERPIN	  A1	   Occludin	  SNAR-­‐‑A1	   Folate	  receptor	  alpha	  	   Ribonucleotide	  reductase	  subunit	  M2	  (RRM2)	  
Table	  8:   Differentially	   expressed	   genes	   and	   proteins	   in	  
microarrays	  	  
	   	  
	   	   	  	   66	  
1.5  Genes	  and	  proteins	  of	  interest	  
  Genes	  of	  interest	  
1.5.1.1  SERPIN	  A1	  
The	   serpins	   are	   a	   super-­‐‑family	   of	   proteins	  whose	  membership	   is	   based	   on	  the	   presence	   of	   a	   common	   core	   comprising	   of	   three	   b-­‐‑sheets	   and	   8-­‐‑9	   a-­‐‑helices.	  	  Despite	  the	  common	  core,	  they	  have	  a	  wide	  variety	  of	  functions	  and	  properties.	  	  The	  family	  is	  subdivided	  into	  16	  ‘clades’	  which	  are	  each	  assigned	  a	  letter.	  	  SERPIN	  A1	  is	  the	  first	  such	  member	  of	  the	  A	  clade	  which	  represents	  a	  group	  of	  proteinase	  inhibitor143.	  	  	  
The	   gene	   termed	   SERPIN	  A1	   codes	   for	   the	   protein	  a-­‐‑1-­‐‑antitrypsin	   (A1AT),	  which	  is	  also	  sometimes	  referred	  to	  as	  a-­‐‑1-­‐‑proteinase	  inhibitor.	  	  It	  is	  a	  52kDa	  acute	   phase	   protein	   which	   inhibits	   serine	   proteases	   and	   is	   released	   from	  human	  neutrophils	  during	  the	   inflammatory	  process.	   	  Deficiency	  of	  A1AT	  is	  associated	   with	   both	   chronic	   liver	   disease	   and	   pulmonary	   emphysema144.	  	  Although	  the	  main	  site	  of	  production	  is	  in	  the	  liver,	  it	  has	  been	  shown	  to	  be	  produced	  by	  pancreatic	  islet	  cells145.	  
A1AT	  has	   long	  been	  suspected	  as	  being	  a	  potential	  biomarker	  of	  pancreatic	  cancer146,	  however	  others	  have	  argued	  that	  the	  fact	  it	  is	  involved	  in	  the	  acute	  phase	   response	   makes	   its	   usefulness	   as	   a	   specific	   marker	   of	   the	   disease	  unlikely147.	  	  	  	  Conversely,	  it	  has	  also	  been	  shown	  to	  inhibit	  angiogenesis	  in	  the	  corneas	  of	  rats	  and	  to	  reduce	  subcutaneous	  tumour	  growth	  in	  mice148.	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More	  specific	  to	  pancreatic	  cancer	  and	  gemcitabine,	  high	  levels	  of	  A1AT	  were	  shown	  to	  predict	  short	  overall	  survival	  in	  patients	  with	  advanced	  pancreatic	  cancer	  receiving	  gemcitabine	  monotherapy149.	  	  SERPINA1	  was	  also	  shown	  to	  have	  high	  expression	  in	  pancreatic	  cancer	  cell	  lines	  with	  intrinsic	  sensitivity	  to	   gemcitabine	   and	   also	   have	   low	   expression	   in	   cell	   lines	   with	   acquired	  gemcitabine	   resistance150.	   	   Although	   these	   two	   results	   seem	   contradictory,	  they	   do	   suggest	   some	   association	   between	   SERPINA1	   and	   gemcitabine	  resistance.	  
More	   recently,	   A1AT	   has	   been	   suggested	   as	   an	   immunohistochemistry	  staining	   marker	   (along	   with	   three	   others	   as	   a	   panel	   of	   four)	   for	   serous	  cystadenoma	  of	  the	  pancreas151,	  and	  the	  ratio	  of	  serum	  trypsin	  to	  A1AT	  has	  been	  shown	  to	  be	  higher	  in	  pancreatic	  cancer	  patients	  with	  PRSS1	  mutations	  compared	  to	  healthy	  controls152.	  
Combining	  all	  the	  evidence	  available	  as	  well	  as	  the	  ingenuity	  pathway	  above,	  SERPIN	  A1	  and	  A1AT	  were	  felt	  to	  represent	  a	  good	  avenue	  of	  investigation.	  
	  
1.5.1.2  Other	  genes	  
Three	   other	   RNAs	   were	   identified	   by	   the	   arrays	   as	   being	   differentially	  expressed.	   	   First	   the	   small	   ILF3/NF90-­‐‑associated	   RNA	   A1	   (SNAR-­‐‑A1)	   is	   a	  small	  non-­‐‑coding	  RNA	  which	  binds	  to	  NF90.	  	  There	  is	  no	  literature	  available	  on	  the	  function	  of	  this	  RNA.	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Secondly,	  brain	  expressed	  X-­‐‑linked	  4	  (BEX4)	  is	  a	  member	  of	  a	  group	  of	  pro-­‐‑apoptotic	  genes.	  	  At	  the	  time	  of	  reporting	  of	  the	  arrays,	  there	  was	  no	  available	  literature	  on	  the	  BEX4.	  	  Very	  recently,	  decreased	  expression	  has	  been	  linked	  with	  growth	  of	  oral	  squamous	  cell	  cancers	  and	  neuroblastomas153,154.	  	  	  
The	  final	  RNA	  has	  the	  name	  LOC439949	  and	  codes	  for	  a	  hypothetical	  protein	  only.	  
Given	   the	   lack	  of	   literature	  noted	  and	   the	   limited	  resources	  available,	   these	  three	  differentially	  expressed	  RNAs	  were	  not	  investigated.	  
  Proteins	  of	  interest	  
1.5.2.1  Glutathione	  S-­‐transferase	  P	  
Glutathione	   S-­‐‑transferases	   (GSTs)	   are	   a	   family	   of	   enzymes	   which	   play	   an	  important	   role	   in	   detoxification	   of	   carcinogens.	   	   Carcinogen	   metabolism	  involves	  phase	  I	  metabolic	  activation	  and	  phase	  II	  detoxification	  involving	  a	  variety	  of	  enzymes.	  	  GSTs	  are	  the	  principal	  phase	  II	  enzymes	  which	  catalyse	  the	   conjugation	   of	   toxic	   and	   carcinogenic	   electrophilic	  molecules155.	   	   There	  are	   four	   main	   classes	   of	   which	   glutathione	   S-­‐‑transferase	   P	   (or	   Pi)	   is	   one	  (GSTP).	  	  It	  is	  a	  23kDa	  protein.	  
Given	   the	   link	   with	   carcinogen	   metabolism,	   GSTP	   is	   an	   obvious	   source	   of	  interest	  for	  oncological	  research.	  	  However,	  although	  one	  study	  looking	  at	  the	  gene	   expression	   from	   five	   human	   pancreatic	   cancer	   patients	   showed	  upregulation	   of	   GSTP146,	   subsequent	   studies	   looking	   at	   much	   larger	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populations	   have	   shown	   no	   such	   differential	   expression	   when	   compared	  with	  healthy	  controls156,157.	  	  GSTP	  was	  selected	  to	  be	  investigated	  further.	  
1.5.2.2  Occludin	  
Occludin	  is	  a	  59	  kDa	  protein	  which	  is	  an	  integral	  plasma	  membrane	  protein	  located	  at	  the	  tight	  junctions	  between	  cells.	  	  It	  has	  therefore	  been	  implicated	  in	   as	   playing	   a	   vital	   role	   in	   the	   cell	   dissociation	   which	   leads	   to	   tumour	  invasion	  and	  metastases	  in	  pancreatic	  cancer158.	   	   It	  has	  also	  been	  suggested	  that	  occluding	  plays	  a	  role	  in	  the	  development	  of	  the	  EMT	  phenotype	  noted	  in	  pancreatic	  cancer159–162.	  
Occludin	  was	  therefore	  considered	  a	  suitable	  candidate	  for	  further	  study.	  
1.5.2.3  Folate	  receptor	  a	  
Folate	   receptor	  a	   (FOLR)	   is	   a	  member	   of	   the	   folate	   receptor	   family	  which	  mediate	   delivery	   of	   5-­‐‑methyltetrahydrofolate	   into	   cells.	   	   This	   is	   the	  biologically	   active	   form	  of	   folate	  used	   for	  DNA	  production	  and	   the	   cysteine	  cycle.	  	  The	  	  a	  form	  is	  usually	  only	  expressed	  on	  luminal	  epithelial	  cells	  of	  the	  kidney,	  lung,	  choroid	  plexus	  and	  placenta,	  so	  is	  not	  in	  contact	  with	  circulating	  folate.	   	   It	   has	   been	   shown	   to	   be	   overexpressed	   in	   numerous	   solid	   organ	  tumours	   including	   kidney,	   brain,	   lung,	   endometrial,	   ovarian,	   colorectal,	  gastric,	  and	  pancreatic163.	  	  	  
The	  main	  area	  of	   interest	  at	  present	   for	  FOLR	  is	   in	  ovarian	  cancer,	  where	  a	  monoclonal	   antibody	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trials	   as	  part	  of	   combination	   therapy164,165.	   	   In	  pancreatic	   cancer,	   the	   folate	  receptor	   family	  has	  been	  developed	  as	  a	  potential	   target	   folate-­‐‑gemcitabine	  nanoparticle	   to	   target	   drug	   delivery,	   but	   this	   remains	   in	   early	   stages	   of	  development166.	  	  FOLR	  was	  also	  chosen	  as	  a	  candidate	  for	  further	  study.	  	  	  
1.5.2.4  Ribonucleotide	  reductase	  subunit	  molecule	  2	  (RRM2)	  
RRM2	   is	   the	  smaller	  of	   the	   two	  subunits	  which	  make	  up	   the	  ribonucleotide	  reductase	   enzyme.	   	   The	   function	   of	   this	  molecule	   as	   described	   above	   is	   to	  increase	  the	  pool	  of	  natural	  nucleotide	  triphosphates,	  for	  incorporation	  into	  DNA	  in	  competition	  with	  gemcitabine.	  	  	  
As	   early	   as	   1999,	   overexpression	   of	   RRM2	   was	   being	   described	   as	   a	  mechanism	   of	   resistance	   to	   gemcitabine	   in	   oropharyngeal	   epidermoid	  carcinoma116.	   	   In	  2004	   it	  was	  shown	  that	  siRNA	  knockdown	  of	  RRM2	  could	  both	  attenuate	  pancreatic	  cancer	  invasiveness	  and	  gemcitabine	  resistance	  in	  vitro167,	   as	   well	   as	   suppress	   tumour	   growth	   and	   inhibit	   metastases	   in	   an	  orthotopic	  xenograft	  model	  in	  vivo124.	  	  	  
In	  2007,	  Itoi	  et	  al168	  looked	  at	  EUS-­‐‑FNA	  biopsies	  taken	  from	  31	  patients	  with	  unresectable	   pancreatic	   cancer	   and	   assessed	   them	   for	   RRM2	   expression.	  	  They	  found	  that	  the	  median	  survival	  of	  patients	  with	  low	  levels	  of	  RRM2	  was	  8.8	   months	   vs	   5.0	   months	   for	   those	   patients	   with	   high	   levels	   of	   RRM2	  (p=0.01).	   	   The	   overall	   response	   rate	   to	   gemcitabine	   was	   also	   significantly	  higher	  in	  low	  vs	  high	  expression	  of	  RRM2	  (50.0%	  vs	  7.7%,	  p=0.013).	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Around	  the	  same	  time,	  a	  number	  of	  groups	  were	  assessing	  RRM2,	  along	  with	  other	  well-­‐‑known	  proteins	  associated	  with	  gemcitabine	  metabolism.	   	  RRM2	  was	   consistently	   shown	   to	   be	   related	   to	   gemcitabine	   sensitivity93,115,169.	   	   A	  subsequent	   meta-­‐‑analysis	   of	   this	   collection	   of	   studies	   showed	   that	   RRM2	  levels	   were	   associated	   with	   overall	   survival	   (HR=2.13	   (1.00-­‐‑4.52),	   p=0.05)	  but	   not	   disease	   or	   progression	   free	   survival	   (p=0.227	   and	   0.19	  respectively)170.	  	  	  
Meanwhile	   another	   group	   again	   showed	   that	   siRNA	   knockdown	   could	  decrease	  resistance	  to	  gemcitabine113.	  	  	  
Xie	  et	  al171	   examined	   resected	   tumours	   of	   117	   patients	   for	   levels	   of	   RRM2,	  they	  showed	  no	  prognostic	  benefit	  of	  low	  levels.	   	  However,	  only	  44	  patients	  received	   adjuvant	   gemcitabine,	   but	   even	   in	   this	   subset	   neither	   progression	  free	   nor	   overall	   survival	   were	   significantly	   different	   whether	   high	   or	   low	  levels	  of	  RRM2	  were	  seen.	  	  This	  study	  may	  have	  been	  underpowered	  to	  show	  a	  result,	  given	  there	  were	  only	  8	  patients	  in	  the	  high	  expression	  group	  given	  adjuvant	  gemcitabine.	  
In	  comparison	  to	  these	  relatively	  low	  patient	  numbers,	  Farrell	  et	  al172	  looked	  at	   229	   patients	   from	   the	   Radiation	   Therapy	   Oncology	   Group	   (RTOG)	   trial	  who	   received	   gemcitabine.	   	   They	   claim	   that	   RRM2	   was	   associated	   with	  survival	  in	  these	  patients	  and	  tentatively	  suggest	  that	  RRM2	  should	  ‘possibly’	  be	  pursued	  further	  as	  a	  biomarker	  of	  gemcitabine	  resistance.	   	  However,	  the	  data	  in	  the	  actual	  paper	  could	  be	  viewed	  as	  equivocal.	  	  It	  should	  be	  noted	  that	  the	  patients	  in	  this	  trial	  received	  combination	  chemo-­‐‑radiotherapy	  both	  pre-­‐‑	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and	  post-­‐‑operatively	  which	  may	  have	  an	  effect	  on	  the	  biology	  of	  tumours	  not	  seen	   outside	   the	  US	  where	   radiotherapy	   is	   not	   standard	   practice,	   and	  may	  also	  have	  affected	  the	  tumour	  biology	  prior	  to	  the	  samples	  being	  taken	  due	  to	  neo-­‐‑adjuvant	  treatment.	  	  	  
Given	  all	  the	  interest,	  RRM2	  was	  an	  obvious	  candidate	  for	  further	  study.	  	  Also,	  to	  date	  no	  study	  has	  shown	  a	  survival	  difference	  in	  RRM2	  levels	   in	  patients	  with	   resected	   tumours	   prior	   to	   treatment	   with	   gemcitabine,	   i.e.	   prior	   to	  adjuvant	   therapy	   without	   any	   neoadjuvant	   therapy	   pre-­‐‑operatively.	   	   This	  could	  be	  a	  viable	  route	  of	  enquiry	  with	  the	  facilities	  and	  bio-­‐‑bank	  available	  at	  Liverpool	  university.	  	  	  
1.5.2.5  Interleukin	  1β	  
Interleukin	  1-­‐‑b	  (IL1b)	  is	  a	  member	  of	  the	  interleukin	  1	  family	  of	  cytokines.	  	  It	  is	  produced	  by	  macrophages	  and	  is	  a	  mediator	  of	  the	  inflammatory	  response	  which	   is	   involved	   in	  a	  wide	  variety	  of	   cellular	  activities.	   	   Its	   role	   in	  chronic	  inflammation,	   carcinogenesis	   and	   angiogenesis,	   plus	   the	   availability	   of	   IL1	  blocking	  drugs	  and	  evidence	   from	  animal	  models,	  have	   led	  some	  to	  suggest	  using	   reducing	   IL1	   activity	   in	   human	   malignancies,	   particularly	   metastatic	  disease173.	  	  	  
In	   pancreatic	   cancer,	   interleukin	   1	   receptor	   antagonist	   levels	   have	   been	  associated	  with	  disease	   severity174,175,	   and	   increased	   levels	   can	  activate	   the	  hedgehog	  pathway,	  affecting	  tumour	  development	  and	  stroma	  formation176.	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Given	  the	  prominent	  function	  of	  IL1b	  in	  various	  cellular	  processes	  including	  the	   inflammatory	  response,	  a	  specific	   role	  within	  a	  pathway	  of	  gemcitabine	  resistance	  may	  be	  difficult	  to	  identify.	  	  However,	  the	  initial	  ingenuity	  pathway	  showed	  an	  interaction	  with	  SERPIN	  A1,	  and	  so	  IL1b	  was	  selected	  for	  further	  study.	  
1.5.2.6  Zinc	  finger	  protein	  593	  
Although	   the	   phrase	   zinc	   finger	   protein	   is	   now	   used	   to	   describe	   a	   wide	  variety	   of	   protein	   structures,	   when	   a	   literature	   search	   was	   performed	  specifically	   looking	   for	   zinc	   finger	   protein	   593,	   no	   results	   were	   found.	  	  Therefore,	   in	   view	   of	   limited	   resources,	   this	   protein	   was	   not	   investigated	  further.	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1.6  Summary	  
Pancreatic	  cancer	  is	  a	  devastating	  disease	  with	  an	  extremely	  poor	  prognosis,	  due	   to	   a	   combination	   of	   late	   presentation	   in	   approximately	   80%	   and	   high	  levels	  of	  recurrence	  for	  the	  few	  deemed	  suitable	  for	  curative	  resection.	  	  	  
Gemcitabine	   based	   chemotherapies	   remain	   the	   current	   gold	   standard,	   but	  many	  tumours	  have	  innate	  resistance	  or	  progress	  despite	  treatment.	  	  	  
The	  previous	  work	  done	  within	  the	  department	  at	  the	  university	  of	  Liverpool	  identified	   SERPIN	  A1	   and	   a	   number	   of	   proteins	   of	   interest	  which	   required	  further	  investigation,	  which	  was	  the	  aim	  in	  this	  research.	  
	  
2   Aims	  and	  Objectives	  
The	  aim	  of	  this	  study	  is	  to	  examine	  the	  results	  of	  the	  microarray	  and	  identify	  a	   novel	   pathway	   for	   gemcitabine	   resistance.	   	   Once	   candidate	   genes	   and	  proteins	  have	  been	  validated,	  they	  will	  be	  manipulated	  to	  assess	  their	  effect	  on	  resistance	  to	  gemcitabine.	  	  If	  a	  link	  with	  resistance	  can	  be	  confirmed,	  the	  candidate	   genes	   and	  proteins	   could,	   in	   the	   future,	   be	   interrogated	   for	   their	  potential	   effect	   on	   patients	   treated	   with	   gemcitabine	   from	   the	   bank	   of	  pancreatic	  cancer	  tissue	  microarrays	  available	  within	  the	  department.	   	   If	  an	  effect	   on	   recurrence	   or	   survival	   could	   be	   established	   this	   could	   lead	   to	  personalised	  chemotherapy	  or	  potential	  targets	  for	  novel	  treatments.	  
Objectives:	  
	   1	   To	   establish	   levels	   of	   gemcitabine	   resistance	   and	   levels	   of	  proteins	  previously	  associated	  with	  gemcitabine	  metabolism	  and	  resistance.	  
	   2	   To	  validate	  the	  results	  of	  the	  RNA	  and	  protein	  microarrays.	  
	   3	   To	  knockdown	  the	  differentially	  expressed	  genes	  and	  proteins	  of	  interest	  to	  assess	  an	  effect	  on	  resistance.	  
	   4	   To	  optimise	  immunocytochemistry	  and	  immunohistochemistry	  of	   any	   genes	   or	   proteins	   affecting	   resistance	   to	   allow	   further	   studies	   on	  human	  tissue	  to	  assess	  any	  effect	  on	  recurrence	  or	  survival.	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3   Materials	  and	  Methods	  
3.1  Materials	  
   Chemical	  or	  Reagent	  
Chemical	  or	  reagent	   Supplier	  
Acrylamide-­‐‑bis	   ready-­‐‑to-­‐‑use	  
solution	  30%	  for	  electrophoresis	  
VWR	  international,	  Lutterworth	  	  
Albumin	  from	  Bovine	  Serum	   Sigma	  Chemical	  Co,	  Poole	  
Ammonium	  persulfate	   Sigma	  Chemical	  Co,	  Poole	  
Blotting	  paper	  Whatman	  GB004	   	   VWR	  international,	  Lutterworth	  
β-­‐‑actin	  Primary	  Antibody	  	   Cell	  Signalling,	  Hitchin	  
Bradford	  dye	  reagent	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   BioRad,	  Hemel	  Hempstead	  
Coomassie	  Blue	   Sigma	  Chemical	  Co,	  Poole	  
Dimethyl	  Sulfoxide	  (DMSO)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Fisher	  Scientific,	  Loughborough	  
Distilled	  water	   University	  of	  Liverpool	  stores	  
DL-­‐‑Dithiothreitol	  (DTT)	   Sigma	  Chemical	  Co,	  Poole	  
dNTP	  mix	   Life	  technologies,	  Paisley	  
Ethanol	   University	  of	  Liverpool	  stores	  
EZ4U	  Assay	   	   Biomedica,	  Austria	  
Foetal	  Bovine	  Serum	  (FBS)	   Life	  technologies,	  Paisley	  
Gemcitabine	  	   Eli-­‐‑Lilly,	  Basingstoke	  
Glycine	   Fisher	  Scientific,	  Loughborough	  
Hydrochloric	  acid	   University	  of	  Liverpool	  stores	  
L-­‐‑glutamine	   	   Life	  technologies,	  Paisley	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Chemical	  or	  reagent	   Supplier	  
LightCycler®	   480	   SYBR	   Green	   I	  
Master	  mix	  
Sigma	  Chemical	  Co,	  Poole	  
Lipofectamine	  2000	   Invitrogen,	  Renfrew,	  UK	  
Non-­‐‑fat	  Dry	  Milk,	  Blotting	  Grade	  	  	  	  	  	  	   BioRad,	  Hemel	  Hempstead	  
OPTIMEM®	   I	   Reduced	   Serum	  
Medium	   (1X),	   liquid	   -­‐‑	   with	   L-­‐‑
Glutamine	  
GE	  Healthcare,	  Amersham	  
Restore™	   Western	   Blot	   Stripping	  
Buffer	  
Thermo	  Scientific,	  Loughborough	  
PCR	  buffer	  10X	   Life	  technologies,	  Paisley	  
Phosphatase	   Inhibitor	   Cocktail	  
Tablets	  
Roche	  Applied	  Sciences,	  Burgess	  Hill	  
Phosphate	   Buffered	   Saline	   (PBS)	  
Tablets	  
Fisher	  Scientific,	  Loughborough	  
Penicillin-­‐‑streptomycin	   Sigma	  Chemical	  Co,	  Poole	  
Protease	   inhibitor	   tablets,	   EDTA-­‐‑
free	  
Roche,	  Welwyn	  Garden	  City	  
Protein	  ladder	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Life	  technologies,	  Paisley	  
Random	  primer	  for	  PCR	   Life	  technologies,	  Paisley	  
RNAse	  A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Thermo	  Scientific,	  Loughborough	  
RNAse	  free	  water	   Life	  technologies,	  Paisley	  
RNase	  inhibitor	   Life	  technologies,	  Paisley	  
RPMI-­‐‑1640	  Media	   Sigma	  Chemical	  Co,	  Poole	  
SMARTpool	  SiRNA	  GSTP	   Dharmacon	  Inc.,	  Chicago	  
SMARTpool	  SiRNA	  RRM2	   Dharmacon	  Inc.,	  Chicago	  
SMARTpool	  SiRNA	  SERPIN	  A1	   Dharmacon	  Inc.,	  Chicago	  
Sodium	  chloride	   Sigma	  Chemical	  Co,	  Poole	  
Sodium	  Dodecyl	  Sulfate	  (SDS)	  
	  
Fisher	  Scientific,	  Loughborough	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Chemical	  or	  reagent	   Supplier	  
SuperScript®	   II	   Reverse	  
Transcriptase	  
Life	  technologies,	  Paisley	  
Taq	  DNA	  polymerase	   Life	  technologies,	  Paisley	  
TEMED(N,N,N′,N′-­‐‑
Tetramethylethylenediamine)	  
Sigma	  Chemical	  Co,	  Poole	  
Tris	  Base	   EMD	  Chemicals,	  San	  Diego	  
Tris	  HCL	   Sigma	  Chemical	  Co,	  Poole	  
Tween®	  20	   	   Sigma	  Chemical	  Co,	  Poole	  
Trypsin	   Sigma	  Chemical	  Co,	  Poole	  
Virkon	   	   	   Antec	  International,	  Sudbury	  
Western	  Lightning	  Plus	  ECL	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   PerkinElmer,	  Cambridge	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  Equipment	  
Equipment	   Supplier	  
Cell	  Counting	  Slides	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   BioRad,	  Hemel	  Hempstead	  
Centrifuge	  (Heraeus)	   Thermo	  Scientific,	  Loughborough	  
Dako	  EnVision+	  System	   DAKO,	  Cambridge	  
Falcon	  Tubes	  -­‐‑	  15	  and	  50ml	   	   Corning	  Inc.,	  New	  York	  
GBX	  Developer	  and	  Fixer	   Kodak	  
High	  Pure	  RNA	  Isolation	  Kit	   Roche	  Applied	  Sciences,	  Burgess	  Hill	  
LightCycler	  480	   Sigma	  Chemical	  Co,	  Poole	  
LightCycler	   480	   96	   	   Multiwell	  
Plate	  and	  sealing	  foil	  
Sigma	  Chemical	  Co,	  Poole	  
Microcentrifuge	   tubes	  
(0.5ml/1ml)	  
Eppendorf,	  Stevenage	  
Multiskan	  EX	  spectrophotometer	  	   Thermo	  electron	  corporation	  	  
PageRuler	   Prestained	   Protein	  
Ladder	  
Fermentas,	  York	  
pH	  Meter	  Seven	  Compact	   Mettler-­‐‑Toledo,	  Beaumont	  Leys	  
X-­‐‑Ray	  Kodak	  Film	  18x24	  cm	   	   Thermo	  Scientific,	  Loughborough	  
Pipettes	  -­‐‑	  5,	  10,	  25ml	   	   	   Corning	  Inc.,	  New	  York	  
Pipette	  tips	   	   	   	   	   Starlab,	  Milton	  Keynes	  
Plates	  (96-­‐‑well)	   Corning	  Inc.,	  New	  York	  
Procell	  Incubator	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   JenconsScientificLtd,Leighton	  Buzzard	  
Sonicade	   Branson	  Ultrasonics,	  Connecticut	  
Trans-­‐‑Blot®	   Turbo™	   Transfer	  
System	  
BioRad,	  Hemel	  Hempstead	  
T25	  and	  T75	  Flasks	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Thermo	  Scientific,	  Loughborough	  
Vortex	  Genie	  2	   Scientific	  Industries,	  New	  York	  
Water	  Bath	  JB	  Aqua	  26	  Plus	   	   Grant,	  Shepreth,	  Cambridgeshire	  
Weighing	  Scales	   VWR,	  Lutterworth	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  Preparation	  of	  Solutions	  
1M	  DL-­‐Dithiothreitol	  (DTT)	  
0.154g	  DTT,	  1ml	  distilled	  water.	  	  Storage:	  Aliquoted	  and	  stored	  at	  -­‐‑20°c	  
1M	  Tris	  
30.29g	   Tris	   HCl,	   200ml	   distilled	   water,	   pH	   as	   required.	   	   Storage:	   Room	  temperature	  
Running	  Buffer	  x10	  
50ml	  20%	  Sodium	  dodecyl	  sulphate	  (SDS),	  144g	  Glycine,	  30g	  Tris	  Base,	  Make	  up	  to	  1L	  with	  distilled	  water.	  	  Storage:	  Room	  temperature	  
PBST	  x1	  
10	  phosphate	  buffered	  saline	  (PBS)	  tablets,	  1L	  distilled	  water,	  1ml	  Tween	  per	  0.1%	  concentration	  desired.	  	  Storage:	  Room	  temperature	  
TBST	  x10	  
87.66g	   Sodium	   chloride,	   121g	   Tris	   Base,	   1L	   distilled	  water,	   pH	   to	   7.5	  with	  sodium	  chloride	  and/or	  sodium	  hydroxide,	  titrate	  to	  x1	  with	  distilled	  water,	  then	   add	   1ml	   Tween	   per	   0.1%	   concentration	   desired.	   	   Storage:	   Room	  temperature	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Reducing	  Sample	  Buffer	  x5	  
1g	   Sodium	   dodecyl	   sulphate	   (SDS)	   powder,	   3ml	   1M	   Tris	   HCl	   pH	   6.8,	   5ml	  Glycerol,	   2ml	   distilled	   water,	   0.05g	   bromophenol	   blue.	   	   Storage:	   Aliquoted	  and	  stored	  at	  -­‐‑20°c	  
RIPA	  Buffer	  
50nM	  Tris	  HCL	  pH	  8,	   150mM	  NaCl,	   1%	  NP-­‐‑40,	   0.5%	  Sodium	  deoxycholate,	  0.1%	   SDS.	   	   Storage:	   Stored	   at	   4°c.	   10ml	   aliquoted	   when	   required	   with	   a	  protease	  inhibitor	  tablet	  added	  
Freezing	  Media	  
90%	   Foetal	   bovine	   serum,	   10%	  DMSO.	   	   Storage:	   Aliquoted	   and	   stored	   at	   -­‐‑20°c	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3.2  Methods	  
  Cell	  culture	  methods	  
3.2.1.1  Culturing	  and	  Sub-­‐Culturing	  
All	   cell	   culture	   work	   was	   performed	   under	   a	   class	   2	   laminar	   flow	   tissue	  culture	   cabinet	   using	   standard	   aseptic	   technique.	   	   All	   liquids	   used	   in	   cell	  culture	  were	  pre-­‐‑warmed	  to	  37°C.	  
All	   cell	   lines	  were	  cultured	   in	  75cm2	   filter	   capped	   flasks	   (T-­‐‑75)	  with	  RPMI-­‐‑1640	   media	   with	   10%	   Foetal	   Bovine	   Serum	   (FBS),	   5mls	   of	   2500iu	  penicillin/5µg	  per	  ml	  streptomycin	  solution,	  and	  5mls	  of	  2mM	  L-­‐‑glutamine,	  and	   incubated	   at	   37°C	   in	   5%	  CO2.	   	   Once	   the	   cells	   had	   formed	   a	  monolayer	  which	  was	  about	  80%	  confluent	  they	  were	  split.	  	  
Splitting	   involved	   removing	   the	   media	   with	   a	   pipette	   and	   replacing	   with	  10mls	   Phosphate	   Buffered	   Saline	   (PBS).	   	   The	   flask	   was	   agitated	   for	   a	   few	  seconds	   to	  wash	   the	   remaining	  media	   from	   the	   cells	   and	   the	  PBS	   removed	  with	  a	  pipette.	   	   2mls	  of	  Trypsin	  was	   then	  added	   to	   the	   flask	  with	  a	  pipette	  and	  the	  cells	  were	  then	  incubated	  at	  37°C/5%	  CO2	  for	  between	  two	  and	  five	  minutes,	   until	   all	   the	   cells	   had	  detached	   from	   the	  bottom	  of	   the	   flask.	   	   The	  Trypsin	  and	  cells	  were	  made	  up	  to	  10mls	  with	  fresh	  media	  with	  a	  pipette	  to	  inactivate	   the	  Trypsin	  and	   the	  mixture	   removed	   from	   the	   flask	   in	   a	  pipette	  and	   a	   proportion	   of	   the	   total	   cells	   either	   replaced	   in	   the	   same	   flask	   or	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transferred	  to	  further	  flasks.	   	  Media	  was	  then	  added	  up	  to	  a	  total	  volume	  of	  20mls	  (for	  T-­‐‑75	  flasks)	  and	  the	  flasks	  replaced	  in	  the	  incubator.	  	  	  
Cells	  were	   usually	   split	   1:10	   approximately	   twice	   per	  week	   (i.e.	   1ml	   of	   the	  10ml	  mixture	  of	  media,	  Trypsin	  and	  cells	  returned	  to	  the	  flask).	  	  Flasks	  were	  changed	  every	  2-­‐‑3	  weeks.	  
Mycoplasma	   testing	   was	   performed	   routinely	   throughout	   the	   work	   by	  laboratory	   technicians	  within	   the	  department	  at	  approximately	  six	  monthly	  intervals.	  	  Similarly,	  genotyping	  on	  all	  cell	  lines	  was	  performed	  by	  laboratory	  technicians	  at	  the	  commencement	  and	  end	  of	  the	  work.	  
	  
3.2.1.2  	   Long	  term	  Cryostorage	  of	  Cells	  
When	   fully	   confluent,	   cells	  were	  washed	  with	   PBS	   and	   trypsinised	   as	  with	  standard	   culture	   and	   then	   the	   10mls	   of	   cells,	   Trypsin	   and	  media	   placed	   in	  15ml	   flacon	   tubes	  and	  centrifuged	   for	  5	  minutes	  at	  1000rpm	  to	   form	  a	  cell	  pellet.	   	   This	   pellet	   was	   resuspended	   in	   10mls	   of	   PBS	   to	   wash	   the	   Trypsin	  from	  the	  cells	  and	  re-­‐‑pelleted	  by	  further	  centrifuge	  in	  a	  15ml	  falcon	  tube	  for	  5minutes	  at	  1000rpm.	   	  The	  FBS	  was	   then	  removed	  and	   the	  cells	  were	   then	  resuspended	  using	  a	  5ml	  pipette	   in	  1-­‐‑10mls	  of	   full	  media	  depending	  on	  the	  size	  of	  the	  pellet.	  	  The	  suspension	  was	  split	  between	  NUNC	  cryotubes	  placing	  1ml	   in	   each	   tube	  with	   a	   1000µl	   pipette	   and	   placed	   on	   ice	   for	   10	  minutes.	  	  0.25mls	  of	   freezing	  media	  was	  added	  and	   the	  cells	  placed	  back	  on	   ice	   for	  5	  minutes.	  	  A	  further	  0.25mls	  of	  freezing	  media	  was	  added	  and	  the	  cells	  placed	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on	  ice	  for	  a	  final	  20	  minutes.	   	  They	  were	  then	  transferred	  to	  a	  -­‐‑80°C	  freezer	  for	   at	   least	   3	   days	   prior	   to	   being	   stored	   long	   term	   in	   liquid	   nitrogen	   at	  ~-­‐‑200°C.	  	  	  
	  
3.2.1.3  	   Recovery	  of	  cells	  from	  cryostorage	  
Cells	  were	  thawed	  in	  a	  water	  bath	  at	  37°C	  and,	  once	  warmed,	  were	  pipetted	  into	   a	   25cm2	   filter	   capped	   flask	   (T-­‐‑25)	   and	   supplemented	   with	   10mls	   of	  media.	   	  The	  cells	  were	  then	  incubated	  at	  37°C	  and	  5%	  CO2.	  	  The	  media	  was	  removed	  with	  a	  25ml	  pipette	  and	  replaced	  with	   fresh	  media	  at	  24	  hours	   to	  remove	   any	   remnant	   of	   DMSO	   (from	   the	   freezing	   media)	   and	   the	   cells	  transferred	   to	   T-­‐‑75	   flasks	   after	   72	   hours.	   	   Once	   established,	   all	   cells	   were	  passaged	  (split)	  at	  least	  3	  times	  prior	  to	  being	  used	  for	  experiments.	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  Cytotoxicity	  studies	  using	  MTS	  assay	  methods	  
Cytotoxicity	   studies	   with	   MTS	   (3-­‐‑(4,5-­‐‑dimethylthiazol-­‐‑2-­‐‑yl)-­‐‑5-­‐‑(3-­‐‑carboxymethoxyphenyl)-­‐‑2-­‐‑(4-­‐‑sulfophenyl)-­‐‑2H-­‐‑tetrazolium)	  utilise	  the	  ability	  of	  mitochondrial	   dehydrogenase	   to	   convert	   the	   tetrazolium	   ring	   of	  MTT	   (a	  yellow	  liquid)	  to	  a	  formazan	  product	  which	  is	  a	  darker	  orange	  colour	  with	  an	  absorbance	  wavelength	  or	  490nm.	   	  The	  number	  of	  surviving,	  respiring	  cells	  is	  therefore	  proportional	  to	  the	  colour	  of	  the	  solution	  which	  is	  measured	  with	  a	  spectrophotometer.	  	  	  
Cell	  were	  grown	  to	  confluence	  in	  T75	  flasks	  and	  then	  a	  cell	  pellet	  produced	  as	  above	  (3.2.2).	  	  The	  pellet	  was	  resuspended	  in	  10mls	  of	  media	  and	  10µl	  placed	  in	  the	  BIO-­‐‑RAD	  TC10	  Automated	  Cell	  Counted	  to	  find	  out	  the	  concentration	  of	  the	  cells.	   	  The	  cells	  were	   then	  diluted	  by	   the	  required	  amount	   to	  produce	  a	  concentration	  of	  1.5x104	  cells	  per	  ml.	  	  200µl	  of	  this	  solution	  was	  then	  seeded	  into	   each	  well	   of	   a	   96-­‐‑well	   plate	   (i.e.	   3x103	   cells	   per	  well).	   	   The	   cells	  were	  then	  incubated	  overnight	  at	  37°C	  and	  5%	  CO2.	  	  	  
After	   24	   hours,	   solutions	   of	   varying	   concentrations	   of	   chemotherapy	   were	  prepared.	  	  The	  concentrations	  were	  prepared	  by	  diluting	  the	  premade	  stock	  in	   full	  media.	   	   The	  media	   in	   the	   96-­‐‑well	   plate	  was	   removed	  with	   a	   suction	  device.	   	   The	   96-­‐‑well	   plate	   was	   divided	   into	   12	   lanes	   of	   8	   and	   the	   varying	  concentrations	  of	  chemotherapy	  and	  media	  each	  added	  to	  a	  lane	  of	  8	  wells,	  as	  well	   as	   a	   control	   lane	   of	   cells	   with	   no	   chemotherapy	   and	   a	   lane	   of	   media	  without	  any	  cells	  as	  a	  negative	  control.	  The	  cells	  were	  incubated	  at	  37°C	  and	  5%	  CO2	  for	  72	  hours.	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The	  MTS	  assay	  was	  performed	  at	  72	  hours	  using	  a	  kit	  from	  Biomedica	  (EZ4U).	  	  The	  kit	  was	  used	  as	  per	  the	  manufacturer’s	  instructions	  and	  involved	  mixing	  the	  2.5mls	  of	  the	  activator	  liquid	  with	  the	  substrate	  powder.	  	  This	  produces	  a	  yellow	  liquid	  and	  20µl	  of	   this	  was	  added	  by	  pipette	  to	  each	  of	   the	  96	  wells.	  	  Readings	  were	   then	   taken	   at	   0,	   1,	   2,	   3	   and	  4	  hours	  using	   the	  Multiskan	  EX	  spectrophotometer	  (Thermo	  electron	  corporation).	   	  The	  Multiskan	  Ex	  takes	  readings	  of	  absorbance	  at	  wavelengths	  of	  450nm	  and	  620	  nm.	   	  The	  620nm	  reading	   is	   a	   control	   for	   light	   outside	   the	   range	   produced	   by	   the	   purple	  formazan	   and	   can	   therefore	   be	   subtracted	   from	   the	   450nm	   reading	   to	  produce	  a	  reading	  specific	  to	  the	  formazan.	  
The	   readings	  were	   then	   standardised	   relevant	   to	   the	   positive	   and	   negative	  controls	   to	   produce	   values	   between	   0-­‐‑100%	   of	   cells	   viable	   and	   plotted	  against	   concentration.	   	   This	   produced	   ‘so-­‐‑called’	   IC50	   curves	   showing	  decreasing	   viability	  with	   increasing	   concentrations	   of	   gemcitabine.	   	   	   These	  curves	  could	  in	  turn	  be	  used	  to	  find	  IC50	  values,	  which	  is	  the	  concentration	  of	  gemcitabine	  needed	  to	  kill	  50%	  of	  the	  cells.	  
	   	   	  	   87	  
	  
Figure	  10:   An	  example	  of	  a	  96-­‐‑well	  plate	   following	  MTS	  assay.	  The	  12	  
columns	   are	   treated	   similarly,	   allowing	   8	   repeats	   of	   each	   condition	  
and	  statistical	  analysis	  if	  required.	  The	  concentration	  of	  gemcitabine	  
increases	   from	   left	   to	   right,	   with	   no	   gemcitabine	   in	   the	   left-­‐‑hand	  
column	   and	   no	   cells	   seeded	   in	   the	   right-­‐‑hand	   column.	   This	   allows	  
comparison	  between	  a	  presumed	  100%	  of	  cells	  alive	  (respiring)	  vs	  0%	  
cells	  alive.	  	  The	  depth	  of	  colour	  is	  greater	  the	  more	  cells	  are	  respiring.	  
The	  colour	  can	  be	  seen	  to	  decrease	  from	  left	  to	  right	  as	  concentration	  
of	  gemcitabine	  increases.	  This	  colour	  change	  can	  be	  measured	  with	  a	  
spectrophotometer	   and	   converted	   to	   numerical	   values	   and	   then	  
survival	  curves.	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  Western	  Blot	  methods	  
3.2.3.1  Antibodies	  and	  controls	  used	  
Target	   Company	  and	  code	   Size	  in	  kDa	   %	  Gel	   Dilution	  for	  primary	  antibody	  
2O	  antibody	  and	  dilution	  
Dilution/	  blocking	  agent	   Control	  
IL-­‐‑1β	   Abcam	  Ab45692	   17	   15	   1:5000	   Rabbit	  1:2000	   5%	  milk/	  PBS	   Abcam	  (ab9617)	  
α-­‐‑1-­‐‑anti-­‐‑trypsin	   Abcam	  Ab9399	   52	   12	   1:5000	   Mouse	  1:3000	   5%	  milk/	  TBS	   Pooled	  human	  serum	  
hENT1	   Mackay	  antibody	   40	   12	   1:500	   Mouse	  1:2000	   3%	   BSA/	  PBS	   None	  CNT1	   Santacruz	  SC49284	   72	   12	   1:1000	   Mouse	  1:2000	   3%	  BSA/PBS	   None	  DCK	   Abcam	   30	   12	   1:500	   Rabbit	  1:2000	   3%	  BSA/PBS	   None	  CDA	   Abcam	  82346	   -­‐‑	   -­‐‑	   -­‐‑	   -­‐‑	   -­‐‑	   Abcam	  Ab99441	  
DCTD	   Abcam	  Ab103988	   20-­‐‑22	   15	   1:5000	   Rabbit	  1:2000	   5%	  BSA/PBS	   Abcam	  Ab96766	  
RRM1	   Abcam	  Ab81085	   80	   12	   1:2000	   Rabbit	  1:2000	   5%	  milk/PBS	   None	  RRM2	   Abcam	  Ab57653	   45	   12	   1:5000	   Mouse	  1:3000	   5%	  milk/TBS	   Abcam	  Ab99137	  
Il-­‐‑15	   Abcam	  Ab40668	   31	   12	   1:1000	   Rabbit	  1:3000	   5%	  BSA/PBS	   Abcam	  Ab73500	  
GSTP	   Abcam	  Ab47709	   23	   15	   1:2000	   Mouse	  1:3000	   5%	  Milk/PBS	   Cell	  lysate	  Occludin	   Abcam	  Ab31721	   59	   12	   1:250	   Rabbit	  1:3000	   5%BSA/PBS	   Cell	  lysate	  	  	  
Table	  9:   Antibodies,	   controls	  and	  conditions	  used	   for	  western	  
blot	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The	   table	   above	   shows	   the	   antibodies	   and	   conditions	   used	   in	   Western	  Blotting	   along	   with	   order	   numbers	   where	   these	   were	   purchased	  commercially.	  
3.2.3.2  	   Production	  of	  protein	  from	  whole	  cells	  
Cells	  were	  grown	  to	  full	  confluence,	  the	  media	  removed	  and	  the	  cells	  washed	  with	  PBS.	  	  	   They	   were	   then	   incubated	   with	   Trypsin	   until	   the	   cells	   were	  detached	  from	  the	  base	  of	  the	  flask.	  	  The	  cells	  were	  then	  drawn	  up	  in	  media	  and	   centrifuged	   (5	  minutes	   at	  1000	   rpm)	   to	  produce	  a	   cell	   pellet.	   	  The	   cell	  pellet	  was	   then	   resuspended	   in	   1ml	   of	   PBS,	   centrifuged	   again	   and	   the	   PBS	  removed.	   	   Lysis	   buffer	  was	   then	   added	   (50-­‐‑100µl	  depending	  on	   the	   size	   of	  the	  cell	  pellet)	  and	  the	  solution	  was	  sonified	  for	  10	  seconds	  to	  disrupt	  the	  cell	  membranes	  (Sound	  Enclosed	  Sonifier,	  Branson	  Ultrasonics,	  Shanghai,	  China).	  	  The	   resulting	   solution	  was	   then	   centrifuged	   for	   10	  minutes	   at	   10,000	   rpm	  and	   the	   lysate	   removed	   by	   pipetting	   from	   the	   cell	   pellet.	   	   The	   lysate	   was	  stored	  at	  -­‐‑80°C	  and	  the	  cell	  pellet	  discarded.	  
Cell	   lysate	   was	   produced	   as	   above	   and	   the	   amount	   of	   total	   protein	   in	   the	  lysate	  then	  determined	  by	  Bradford	  assay	  prior	  to	  Western	  blotting	  to	  ensure	  consistent	  loading	  between	  samples	  (described	  below).	  
3.2.3.3  Production	  of	  supernatant	  from	  cultured	  cells	  
Cells	  were	   initially	   grown	   until	   confluent	   in	   full	  media	   including	   FBS.	   	   The	  media	  was	   then	   removed	   and	   the	   cells	  washed	  with	   PBS	   before	   placing	   in	  serum	  free	  media	  for	  24	  hours.	  	  The	  media	  was	  again	  removed	  and	  the	  cells	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washed	   with	   PBS	   before	   placing	   in	   small	   amounts	   of	   serum	   free	   media	  overnight	  (5mls	  of	  media	  for	  one	  T75	  plate).	  
The	   supernatant	   was	   then	   removed	   and	   filtered	   through	   a	   Spin-­‐‑XUF	   20ml	  (Corning,	   order	   no.431491)	   for	   10	   minutes	   at	   3000rpm.	   	   This	   filter	   is	  designed	  to	  only	  allow	  substances	  less	  than	  100kDa	  to	  pass	  through	  it.	  
The	   cells	  were	   then	   harvested	   and	   counted	   to	   allow	   standardisation	   of	   the	  amount	  of	  supernatant	  to	  be	  loaded	  in	  further	  experiments	  per	  cell	  line.	  
3.2.3.4  Protein	  quantification	  with	  Bradford	  assay	  
The	  Bradford	  assay	  is	  a	  colorimetric	  protein	  assay	  which	  uses	  the	  change	  in	  colour	  of	  Coomassie	  blue	  dye	  from	  its	  red	  form	  to	  its	  blue	  form	  when	  it	  binds	  to	  protein.	  	  The	  blue	  form	  of	  the	  dye	  has	  an	  absorbance	  spectrum	  of	  595nm	  which	   increases	  proportionally	   to	   the	   amount	   of	   dye	  bound	   to	   protein	   and	  therefore	  the	  amount	  of	  protein.	  	  	  
Solutions	  of	  standard	  protein	  concentration	  were	  made	  up	  by	  diluting	  Bovine	  Serum	  Albumin	  (BSA)	  in	  distilled	  water	  (dH2O).	  	  An	  initial	  stock	  was	  made	  of	  5mg/ml	  by	  diluting	  0.05g	  BSA	  in	  10mls	  dH2O.	  	  This	  stock	  was	  further	  diluted	  as	  shown	  on	  the	  next	  page.	  
2µl	   of	   the	   standards	   and	   the	   lysate	   samples	   (in	   triplicate)	   were	   added	   to	  798µl	   dH2O	   and	   200µl	   of	   Coomassie	   blue	   solution	   and	   assayed	   by	  spectrophotometry	  at	  595nm.	  	  The	  standards	  were	  used	  to	  produce	  standard	  curves	  and	  the	  protein	  concentration	  in	  the	  lysate	  estimated.	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Volume	  of	  5mg/ml	  BSA	  standard	  in	  µl	   Volume	  of	  dH2O	  in	  µl	   Final	  concentration	  of	  BSA	  in	  mg/ml	  100	   0	   5	  70	   30	   3.5	  50	   50	   2.5	  20	   80	   1	  10	   90	   0.5	  
Table	  10:   Making	  up	  standards	  for	  Coomassie	  blue	  staining	  	  
	  
3.2.3.5  	   Polyacrylamide	  Gel	  Production	  
Different	   percentage	   gels	  were	  used	  depending	   on	   the	  molecular	  weight	   of	  the	  protein	  being	  tested	  for	  according	  to	  the	  following	  table:	  
Molecular	  weight	  of	  protein	   %	  gel	  >150	  kDa	   6%	  90-­‐‑150	  kDa	   8%	  60-­‐‑90	  kDa	   10%	  30-­‐‑60	  kDa	   12%	  <30	  kDa	   15%	  
Table	  11:   Percentage	   gels	   used	   for	   western	   blot	   depending	   on	  
molecular	  weight	  of	  protein	  	  
The	   gels	   consist	   of	   a	   resolving	   section	   for	   the	   separation	   of	   proteins	   and	   a	  stacking	  gel	  for	  the	  alignment	  of	  proteins	  prior	  to	  entering	  the	  resolving	  gel.	  	  The	   different	   gels	   were	   produced	   using	   varying	   amounts	   of	   dH2O,	   30%	  acrylamide,	   Tris	   solution,	   10%	   sodium	   dodecyl-­‐‑sulphate	   (SDS),	   10%	  ammonium	   persulphate	   (APS)	   and	  N,	   N,	   N',	   N'-­‐‑tetramethylethylenediamine	  (TEMED)	   according	   to	   the	   table	   below	   depending	   on	   the	   protein	   being	  blotted	  for.	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%	  gel	   6	   8	   10	   12	   15	  H2O	   2.6	   2.3	   1.9	   1.6	   1.1	  30%	  acrylamide	  mix	   1.0	   1.3	   1.7	   2.0	   2.5	  1.5M	  Tris	  (pH	  8.8)	   1.3	   1.3	   1.3	   1.3	   1.3	  10%	  SDS	   0.05	   0.05	   0.05	   0.05	   0.05	  10%	  APS	   0.05	   0.05	   0.05	   0.05	   0.05	  TEMED	   0.004	   0.003	   0.002	   0.002	   0.002	  
Table	  12:   Ingredients	   (in	   mls)	   per	   percentage	   for	   one	  
resolving	  gel	  (5mls	  total)	  	  
H2O	   1.4	  30%	  acrylamide	  mix	   0.33	  1.0M	  Tris	  (pH6.8)	   0.25	  10%	  SDS	   0.02	  10%	  APS	   0.02	  TEMED	   0.002	  
Table	  13:   Ingredients	  (in	  mls)	  for	  one	  stacking	  gel	  (2mls	  total)	  	  
Bio-­‐‑Rad	  mini	  gel	  apparatus	  was	  used	  for	  gel	  production,	  electrophoresis	  and	  transfer.	   	   The	   resolving	   gel	  mixture	  was	  made,	   vortexed	  and	  4mls	  pipetted	  between	  two	  glass	  plates	  to	  produce	  a	  0.75mm	  flat	  gel.	  	  The	  glass	  plates	  were	  sealed	   below	   and	   at	   the	   sides	   and	   placed	   vertical	   leaving	   room	   for	   the	  subsequent	   stacking	   gel.	   	   Once	   this	   had	   set	   (20	   minutes	   at	   room	  temperature)	   the	   stacking	   gel	   mixture	   was	   made,	   vortexed	   and	   1.5mls	  pipetted	   into	   the	   space	   left	   on	   top	   of	   the	   resolving	   gel.	   	   A	   comb	  was	   then	  placed	   into	   the	   stacking	  gel	   to	   create	   lanes	   into	  which	   the	  protein	  could	  be	  loaded.	   	  Once	  set,	  the	  comb	  was	  removed	  and	  the	  gel	  used	  that	  day,	  or	  kept	  hydrated	  in	  the	  fridge	  overnight.	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3.2.3.6  	   Electrophoresis	  
Protein	  samples	  were	  prepared	  for	  electrophoresis	  in	  the	  following	  manner.	  	  3µl	  loading	  buffer	  was	  added	  to	  the	  volume	  of	  lysate	  required	  depending	  on	  the	  Bradford	  assay	  and	   the	   amount	  made	  up	   to	  15µl	  with	  1x	  RBB	   in	  0.5ml	  epindorfs.	  	  	  
These	  samples	  were	  warmed	  at	  96°C	  for	  15	  minutes	  to	  denature	  the	  proteins	  and	   centrifuged	   at	   13,000	   rpm	   for	   a	   few	   seconds.	   	   While	   warming	   the	  samples,	   a	   Mini	   Protean	   III	   electrophoresis	   chamber	   (Bio-­‐‑Rad)	   was	   set	   up	  and	   the	   glass	   plates	   containing	   the	   gels	   placed	   vertically	   within	   it	   and	  running	   buffer	   poured	   in	   to	   completely	   cover	   the	   gels.	   	   Any	   air	   bubbles	  within	   the	   lanes	   of	   the	   gels	   were	   removed	   with	   a	   needle	   and	   syringe	  containing	  running	  buffer.	  
A	   commercial	   pre-­‐‑made	   protein	   ladder	   (New	   England	   Biolabs)	   stored	   at	   -­‐‑20°C	  was	   then	   thawed	   and	   5µl	   loaded	   by	   pipetting	   into	   the	   end	   lane.	   	   The	  protein	  samples	  were	  then	  loaded	  into	  the	  remaining	  lanes.	  	  	  
The	  electrical	   input	  was	  then	  attached	  to	  run	  through	  the	  gel	  top	  to	  bottom	  and	  a	  current	  of	  25-­‐‑55	  mA	  applied	  until	   the	   lightest	  proteins	  of	   the	  protein	  ladder	  had	  reached	  the	  bottom	  of	  the	  gel	  (~one	  hour).	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3.2.3.7  Transfer	  
Proteins	   were	   then	   transferred	   from	   the	   polyacrylamide	   gels	   to	   Hybond	  Enhanced	   Chemo-­‐‑Luminescence	   nitrocellulose	   membranes.	   	   The	   gels	   were	  removed	  from	  the	  glass	  plates	  and	  trimmed	  to	  size.	  	  They	  were	  then	  placed	  in	  transfer	   cassettes	   adjacent	   to	   the	   membranes	   and	   flanked	   by	   Whattman	  chromatography	   paper	   and	   sponge.	   	   The	   cassettes	   were	   then	   placed	   into	  transfer	  chambers	  and	  immersed	  in	  transfer	  buffer.	   	  A	  magnetic	  stirrer	  was	  placed	  in	  the	  bottom	  of	  the	  chamber	  and	  the	  chamber	  sat	  on	  the	  base	  unit	  of	  the	   magnetic	   stirrer,	   and	   an	   ice	   block	   placed	   in	   the	   chamber	   to	   prevent	  overheating	  when	  a	  voltage	  was	  applied.	  	  A	  potential	  difference	  of	  100V	  was	  then	  applied	  for	  between	  30minutes	  depending	  on	  the	  size	  of	  the	  cassette.	  
	  
3.2.3.8  Immunoblot	  
The	  membranes	  were	  removed	  from	  the	  chamber	  after	  transfer	  and	  blocked	  as	   per	   the	   above	   protocols	   prior	   to	   applying	   the	   primary	   antibody.	   	   The	  choice	  of	  blocking	  agent	  was	  dependent	  on	  preliminary	  trials	  of	  the	  antibody	  and	  its	  optimum	  experimental	  design,	  and	  involved	  rocking	  the	  membrane	  at	  25rpm	  in	  the	  chosen	  solution	  for	  at	  least	  one	  hour.	  
	  
The	  primary	  antibody	  was	  diluted	  in	  the	  same	  solution	  used	  for	  blocking	  to	  a	  concentration	   determined	   by	   the	   optimisation	   experiments	   and	   rocked	   at	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25rpm	   for	   either	   1-­‐‑2	   hours	   at	   room	   temperature	   or	   in	   a	   cold	   room	   at	   4°C	  overnight.	  
After	  removal	  of	  the	  primary	  antibody,	  the	  membranes	  were	  washed	  in	  plain	  TBS	   or	   PBS	   dependent	   on	   the	   above	   solutions.	   	   At	   least	   4	   washes	   of	   15	  minutes	  each,	  rocking	  at	  25rpm	  were	  used.	  
The	   secondary	   antibody	   was	   chosen	   dependent	   on	   the	   primary	   (rabbit	   or	  mouse)	  and	  was	  then	  diluted	  in	  the	  blocking	  solution	  as	  above.	  	  The	  solution	  again	   depended	   on	   the	   optimisation	   experiments.	   	   This	   was	   added	   to	   the	  membrane	  which	  was	  then	  rocked	  at	  25rpm	  for	  90	  minutes.	  	  	  
A	  further	  4	  washes	  of	  15	  minutes	  each	  were	  performed	  as	  above.	  
Following	  the	  final	  wash,	  the	  solution	  was	  removed	  and	  Amersham	  ‘Western	  Lightning’	   Enhanced	   Chemo-­‐‑Luminescence	   (ECL)	  was	   used	   to	   visualise	   the	  blot.	   	  2.5mls	  of	  the	  two	  separate	  ECL	  components	  were	  mixed	  separately	  in	  falcon	   tubes	  and	  added	   to	   the	  membrane	   for	  5	  minutes.	   	  Following	   this	   the	  ECL	  was	  removed	  and	  the	  membrane	  placed	  in	  a	  light	  proof	  cassette	  between	  2	  pieces	  of	  transparent	  acetate.	   	  Tracking	  tape	  was	  placed	  alongside	  the	  gel	  and	  the	  protein	   ladder	   levels	  marked	  onto	  the	  tape	  with	  a	  permanent	  black	  marker	  to	  allow	  them	  to	  be	  seen	  on	  the	  developed	  film.	  
The	  light	  proof	  cassette	  was	  then	  moved	  to	  a	  dark	  room	  and	  Kodak	  Biomax	  light	   film	  placed	  onto	   the	  membrane	   for	  various	  exposure	   times	  dependent	  on	   the	   strength	   of	   the	   luminescence.	   	   The	   film	   was	   then	   developed	   for	   1	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minute	   and	   fixed	   for	   the	   same	   length	   of	   time	   before	   being	   washed	   in	   tap	  water	  and	  dried.	  	  	  
3.2.3.9  Quantification	  of	  protein	  loading	  
β	  Actin	  is	  a	  relatively	  stable	  cytoskeletal	  protein	  present	  in	  constant	  levels	  in	  all	  mammalian	   cells.	   	   Therefore,	   it	   can	   be	   used	   as	   a	   control	   to	   ensure	   that	  there	  was	  consistent	  loading	  of	  protein	  from	  well	  to	  well	  in	  the	  Western	  Blot.	  
Following	   the	   above	   immunoblot,	   the	   membranes	   were	   stripped	   of	   the	  antibodies	  by	  placing	  in	  an	  oven	  with	  stripping	  buffer	  for	  30-­‐‑60	  minutes.	  	  The	  stripping	  buffer	  was	   then	  washed	  off	  with	   at	   least	   4	  washes	   of	   15	  minutes	  rocking	  at	  25rpm.	  
The	  β	  Actin	   immunoblot	  was	  then	  performed	  in	  the	  same	  way	  as	  the	   initial	  experiment	  above	  using	  the	  same	  blocking/dilution	  agent	  and	  the	  following	  concentrations;	  block,	  primary	  antibody	  (β	  Actin	  at	  1:10,000	  dilution),	  wash,	  secondary	  antibody	  (Mouse	  at	  1:2,000	  dilution),	  wash,	  develop.	  
Even	   loading	   was	   seen	   as	   equal	   size	   and	   densities	   of	   bands	   at	   42kDa	  (molecular	  weight	  of	  β	  Actin).	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  Polymerase	  chain	  reaction	  
To	  allow	  quantification	  of	  levels	  of	  RNA,	  RNA	  was	  first	  extracted	  and	  purified	  from	  cells,	  from	  which	  cDNA	  could	  be	  produced.	  	  Primers	  to	  be	  used	  for	  PCR	  were	   then	   tested	   and	   conditions	   optimised	  with	   reverse	   transcription	   PCR	  (RT-­‐‑PCR).	   Following	   this,	   quantitative	   real-­‐‑time	   RT-­‐‑PCR	   was	   performed,	  using	  GAPDH	  as	  a	  loading	  control.	  
3.2.4.1  Extraction	  of	  RNA	  from	  animal	  cells	  
RNA	   was	   purified	   from	   cells	   using	   the	   RNeasy	   Mini	   Kit	   equipment	   from	  QUIAGEN.	   	  This	  contained	  Buffer	  RLT,	  QIA	  shredder,	  RNeasy	  column,	  Buffer	  RW1,	  Buffer	  RPE,	  RNase	  free	  water	  and	  1.5ml	  and	  2ml	  collection	  tubes.	  	  	  
Cells	   from	  a	   fully	   confluent	  T-­‐‑75	   flask	  were	   trypsinised	   as	  per	   the	   splitting	  procedure	  (section	  3.2.1).	  	  Instead	  of	  replacing	  a	  certain	  amount	  of	  the	  10mls	  of	  cells,	  media	  and	  Trypsin	  back	  to	  the	  flask,	  it	  was	  placed	  into	  a	  15ml	  falcon	  tube	  and	  centrifuged	  at	  500rpm	  for	  5	  minutes	  to	  produce	  a	  cell	  pellet.	   	  The	  media	  was	  removed	  by	  pipetting	  and	  the	  cells	  resuspended	  in	  10mls	  of	  PBS	  to	  wash	  them	  before	  being	  centrifuged	  again	  to	  produce	  a	  cell	  pellet	  and	  the	  PBS	  removed.	  	  	  
The	   cells	   were	   then	   disrupted/lysed	   by	   adding	   600	   µl	   of	   Buffer	   RLT.	   	   The	  lysate	   was	   then	   homogenised	   by	   adding	   it	   to	   a	   QIA	   shredder	   in	   a	   2ml	  collection	   tube	   and	   centrifuging	   at	   10,000rpm	   for	   15	   seconds.	   	   The	   QIA	  shredder	   was	   discarded	   and	   600µl	   of	   70%	   ethanol	   was	   added	   to	   the	   flow	  through	   and	  mixed	   by	   pipetting.	   	   The	   solution	  was	   then	   transferred	   to	   an	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RNeasy	  column	  and	  centrifuged	  for	  15	  seconds	  at	  10,000rpm.	  	  This	  time	  the	  flow	  through	  was	  discarded	  and	  the	  RNeasy	  column	  transferred	  to	  a	  new	  2ml	  collection	  tube.	  
700µl	   of	   Buffer	   RW1	   solution	   was	   added	   to	   the	   RNeasy	   column	   and	  centrifuged	   at	   10,000rpm	   for	  15	   seconds	   to	  wash	   the	   column	  and	   the	   flow	  through	   discarded.	   	   Following	   this	   500µl	   of	   Buffer	   RPE	   was	   added	   to	   the	  column	  and	  the	  column	  centrifuged	  (15	  seconds	  at	  10,000rpm)	  and	  the	  flow	  through	  again	  discarded.	  	  A	  further	  500µl	  of	  Buffer	  RPE	  was	  then	  added	  and	  the	  column	  centrifuged	  at	  10,000rpm	  but	  for	  2	  minutes.	  
The	  flow	  through	  was	  again	  discarded	  and	  the	  column	  transferred	  to	  another	  new	  2ml	   collection	   tube	   and	   centrifuged	   at	   10,000rpm	   for	  1	  minute	   to	  dry	  the	  column.	  	  Finally,	  the	  RNeasy	  column	  was	  placed	  in	  a	  new	  1.5ml	  collection	  tube	  and	  50µl	  of	  RNase	  free	  water	  added	  prior	  to	  centrifuging	  for	  1	  minute	  at	  10,000rpm	   to	   elute	   the	  RNA	   from	   the	   column.	   	   The	   flow	   through	  was	   then	  retained	   as	   the	   purified	  RNA.	   	   A	   second	   eluting	   step	   could	   be	   performed	   if	  necessary.	  
The	  quality	   of	   the	  RNA	  produced	  was	   then	   tested	  using	   the	  Nanodrop	  ND-­‐‑1000	  spectrophotometer.	  	  This	  allowed	  quantification	  of	  the	  amount	  of	  RNA	  using	  the	  optical	  density	  at	  260nm	  wavelength	  and	  the	  purity	  assessed	  using	  the	  260/280nm	  optical	  density	  ration	  (greater	  than	  2	  considered	  acceptable).	  
Purified	  RNA	  was	  stored	  at	  -­‐‑80°C.	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3.2.4.2  Producing	  cDNA	  from	  RNA	  
2µl	   of	   the	   purified	   RNA	   was	   added	   to	   1µl	   of	   random	   primers,	   2µl	   of	  deoxynucleotide	  triphosphates	  (dNTP)	  mixture	  (5mM)	  and	  8µl	  of	  RNase	  free	  water	   in	   0.1ml	   Eppendorfs.	   	   This	   mixture	   was	   incubated	   at	   65°C	   for	   5	  minutes	  and	  immediately	  chilled	  on	  ice	  before	  being	  briefly	  microcentrifuged	  (i.e.	  a	  few	  seconds)	  to	  collect	  all	  the	  condensation.	  	  	  
Then	  4µl	  of	  First	   Strand	  buffer	  was	  added	  along	  with	  2µl	  of	  DTT	   (0.1M)	   to	  each	   Eppendorf.	   	   The	   mixture	   was	   vortexed	   and	   incubated	   at	   42°C	   for	   2	  minutes.	   	   1µl	   of	   Reverse	   Transcriptase	   was	   then	   added	   before	   mixing	   by	  vortex,	   spinning	   briefly	   in	   a	  microcentrifuge	   and	   incubating	   at	   25°C	   for	   10	  minutes.	   	   This	   was	   further	   incubated	   at	   42°C	   for	   2	   hours	   and	   then	   heat	  inactivated	  at	  70°C	  for	  15	  minutes.	  
This	   process	   produced	   20µμl	   of	   concentrated	  DNA	  which	  were	   diluted	  with	  RNase/DNase	  free	  water	  to	  produce	  a	  200µl	  of	  a	  1:10	  master	  solution.	  	  These	  were	  further	  diluted	  as	  required	  below.	  
As	   a	   negative	   control,	   the	   above	   steps	   were	   also	   performed	   using	   2µl	   of	  RNase	  free	  water	  instead	  of	  purified	  RNA	  at	  the	  initial	  step.	  
The	  cDNA	  was	  stored	  at	  -­‐‑20°C.	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3.2.4.3  Reverse	  Transcription	  PCR	  (RT-­‐PCR)	  
Non-­‐‑quantitative	  RT-­‐‑PCR	  was	  used	  to	   test	   the	  primers	  produced	  a	  constant	  DNA	  segment	  of	  the	  anticipated	  length,	  and	  to	  create	  the	  optimal	  protocol	  for	  PCR	  prior	  to	  Quantitative	  RT-­‐‑PCR.	  	  	  
Samples	  were	  made	  up	  as	  follows:	  
2.5µl	   Buffer,	   1.56µl	   MgCl,	   0.52µl	   dNTP,	   0.52µl	   Primer	   5’,	   0.52µl	   Primer	   3’,	  0.129µl	  Taq	  polymerase,	  16.151µl	  DNase	  free	  water,	  and	  2µl	  of	  1:10	  cDNA.	  
These	   samples	   were	   mixed	   by	   vortex	   and	   then	   run	   on	   the	   G	   Storm	   GS1	  Thermal	  Cycler	  (GRI	  thermal	  cyclers).	  	  The	  protocol	  varied	  depending	  on	  the	  primers	   (section	   3.6.1)	   but	   the	   temperatures	   used	   for	   the	   housekeeping	  control	   gene	   GAPDH	   is	   shown	   below	   as	   an	   example	   (GAPDH	   is	   used	   as	   a	  control	   to	   ensure	   even	   loading	   of	   samples	   as	   it	   is	   uniformly	   present	   in	   all	  cells):	  
Initialisation	  step:	  95°C	  for	  12	  minutes	  
Denaturation	  step:	  95°C	  for	  30	  seconds	  	   (this	   step	   disrupts	   the	   hydrogen	  bonds	  between	  complimentary	  DNA	  strands	  producing	  single	  DNA	  strands)	  
Annealing	  step:	  67°C	  for	  30	  seconds	  (this	  allows	  binding	  (annealing)	  of	  the	  primers	  to	  their	  complimentary	  bases	  on	  the	  single	  stranded	  DNA)	  
Elongation	  step:	  72°C	  for	  1	  minute	  (this	  step	  allows	  the	  DNA	  polymerase	  to	  synthesise	  a	  new	  complimentary	  DNA	  strand	  to	  the	  primer-­‐‑DNA	  complex)	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The	   denaturation,	   annealing	   and	   elongation	   steps	   are	   repeated	   through	  multiple	  cycles	  (e.g.	  40	  times	  for	  GAPDH/SERPIN	  A1)	  
Final	  elongation:	  72°C	  for	  10	  minutes	  
	  
After	  performing	  RT-­‐‑PCR,	   loading	  dye	  (to	  allow	  visualisation)	  was	  added	  to	  the	   DNA	   and	   the	   combination	   was	   electrophoresed	   through	   agarose	   gels.	  	  This	  allowed	  comparison	  of	  the	  size	  of	  the	  DNA	  produced	  against	  a	  standard	  100	  base	  pair	  DNA	  ladder.	  	  
Gels	  were	  made	  as	   follows.	   	  60mls	  of	  TAE	  buffer	  and	  either	  0.6g	  of	  agarose	  were	   mixed	   together	   to	   form	   1%	   agarose	   gels.	   	   The	   solution	   was	   then	  microwaved	  on	  full	  power	  for	  2	  minutes,	  stopping	  to	  stir	  the	  mixture	  after	  1	  minute.	  After	  microwaving,	   6µl	   of	  Gel	  Red	  Nucleic	  Acid	   Stain	  was	   added	   to	  the	   mixture	   which	   was	   stirred	   and	   poured	   into	   a	   rectangular	   plastic	  electrophoresing	  tray	  containing	  a	  comb	  to	  provide	  wells.	   	  This	  was	   left	   for	  30	  minutes	  to	  set.	  
The	   gel	   was	   covered	   with	   running	   buffer	   and	   the	   wells	   were	   loaded	   with	  mixtures	  of	  13µl	  of	  the	  PCR	  samples	  with	  2µl	  of	  loading	  dye.	   	  A	  further	  well	  was	  also	  filled	  with	  2µl	  of	  loading	  dye	  with	  3µl	  of	  100	  base	  pair	  DNA	  ladder	  to	  allow	  identification	  of	  the	  size	  of	  the	  DNA	  segments	  produced	  by	  the	  PCR.	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A	  potential	  difference	  of	  120V	  was	   set	  up	  across	   the	  gel	   and	   run	   for	  30-­‐‑40	  minutes.	   	  When	  the	  run	  had	   finished,	   the	  buffer	  was	  poured	  off	  and	  the	  gel	  viewed	  under	  UV	  light.	  
	  
3.2.4.4  Quantitative	  Reverse	  Transcription	  PCR	  (qRT-­‐PCR)	  
qRT-­‐‑PCR	  experiments	  were	  run	  on	  the	  ‘Lightcycler®	  480	  Instrument’	  (Roche).	  	  For	  this,	  samples	  of	  20µl	  were	  made	  up	  as	  follows:	  
7µl	  DNase	  free	  water,	  10µl	  of	  LightCycler®	  480	  SYBR	  Green	  I	  Master	  (Roche),	  0.5µl	   each	  of	   forward	  and	   reverse	  primer	   (1:10	  dilution),	   and	  2µl	   of	   cDNA.	  	  PCR	   controls	   were	   also	   made	   up	   with	   2µl	   of	   DNase	   free	   water	   instead	   of	  cDNA.	  	  	  
The	  samples	  were	  loaded	  into	  LightCycler®	  480	  Multi-­‐‑96-­‐‑well	  Plate	  (Roche)	  in	   triplicate	   at	   least.	   	   Once	   the	   samples	   had	   been	   loaded,	   the	   wells	   were	  covered	   with	   sealing	   foil	   (provided	   with	   the	   Plates)	   and	   the	   plates	   were	  centrifuged	  at	  1000rpm	  for	  30	  seconds	  to	  ensure	  the	  samples	  settled	  at	  the	  bottom	   of	   the	   wells.	   	   The	   plates	   were	   then	   loaded	   into	   the	   Lightcycler	  Instrument	  and	  run	  according	  to	  the	  protocols	  below:	  
qRT-­‐‑PCR	  protocol	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3.2.4.5  Quantification	  of	  total	  RNA/DNA	  
To	  ensure	  that	  the	  correct	  amount	  of	  cDNA	  was	  loaded	  into	  each	  well	  of	  the	  qRT-­‐‑PCR	   experiments,	   quantification	   of	   the	   cDNA	   samples	   had	   to	   be	  performed.	  
This	  was	  performed	  by	  creating	  GAPDH	  curves	  with	  the	  qRT-­‐‑PCR	  Lightcycler	  480	  machine.	  	  To	  do	  this,	  the	  master	  samples	  of	  cDNA	  were	  further	  diluted	  to	  produce	   1:100,	   1:500,	   1:1000,	   1:10,000,	   1:50,000	   samples.	   20µl	   qRT-­‐‑PCR	  samples	   (using	   GAPDH	   primers)	   were	   made	   up	   for	   each	   dilution	   of	   each	  cDNA	  sample	  in	  triplicate	  and	  these	  were	  loaded	  into	  the	  Multi-­‐‑96-­‐‑well	  Plate.	  	  The	  plate	  was	  then	  run	  on	  the	  GAPDH	  primer	  protocol.	  	  Using	  the	  computer	  software,	  this	  allowed	  the	  creation	  of	  GAPDH	  curves	  plotting	  dilution	  against	  the	  Crossing	  Point	  (CP)	  of	  the	  sample.	  
The	  CP	  represents	  the	  point	  (in	  cycles	  of	  PCR)	  of	  the	  exponential	  increase	  in	  the	  cDNA	  per	  sample.	  	  For	  2	  samples	  of	  equal	  quantities	  of	  starting	  DNA,	  the	  CP	  will	  be	  identical.	  	  	  
Therefore,	  using	   the	  above	  curves,	   the	  dilution	  required	   for	  each	  sample	   to	  produce	  an	  identical	  CP	  was	  worked	  out.	  	  The	  experiment	  was	  then	  repeated	  using	  each	  sample	  at	  its	  own	  dilution	  as	  found	  above	  loaded	  in	  triplicate	  with	  GAPDH	  primers	  once	  again	  and	  identical	  CPs	  confirmed.	  
The	  experiment	  with	  the	  primer	  of	  choice	  could	  then	  be	  performed	  using	  the	  same	   dilutions	   of	   the	   cDNA	   master	   samples	   in	   the	   knowledge	   that	   the	  samples	  contained	  equal	  amounts	  of	  cDNA.	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  Gene	  Knockdown	  
siRNA	  was	  purchased	  from	  Dharmacon	  RNAi	  technologies.	  
Knockdown	  was	  performed	  in	  three	  6-­‐‑well	  plates.	  	  One	  6-­‐‑well	  plate	  was	  used	  for	   knockdown	  with	   the	   siRNA	  of	   interest	  while	   the	   other	   two	  plates	  were	  used	   for	   two	   different	   negative	   controls.	   	   The	   6-­‐‑wells	  meant	   one	   could	   be	  used	  for	  post-­‐‑knockdown	  RNA	  isolation/cDNA	  production/PCR	  experiments,	  two	  used	   for	  cytotoxicity	  experiments	  and	   three	  used	   to	  extract	  protein	   for	  Western	  Blot	  experiments.	  	  	  
Cells	  were	  grown	  to	  confluence	  in	  a	  T-­‐‑75	  flask	  and	  subsequently	  trypsinised	  and	   made	   up	   to	   10mls	   with	   media	   to	   inactivate	   the	   trypsin.	   	   This	   10mls	  mixture	  was	  then	  centrifuged	  in	  a	  15ml	  falcon	  tube	  at	  1000rpm	  for	  5	  minutes	  to	  produce	  a	  cell	  pellet.	  	  The	  media	  and	  Trypsin	  was	  removed	  with	  a	  pipette	  and	  the	  cells	  resuspended	  in	  10mls	  of	  PBS	  to	  wash	  the	  cells.	  	  A	  cell	  pellet	  was	  again	   formed	  by	  centrifuge	   for	  5	  minutes	  at	  1000rpm.	   	  The	  cells	  were	   then	  resuspended	   in	   10mls	   of	   media	   and	   10µl	   of	   this	   placed	   in	   the	   BIORAD	  automated	  cell	  counter	  to	  give	  the	  density	  of	  cells	  per	  ml.	  	  The	  cells	  were	  then	  seeded	  in	  three	  6-­‐‑well	  plates	  at	  a	  density	  of	  1x105	  cells	  per	  well	  in	  3mls	  of	  full	  media.	  	  These	  were	  then	  incubated	  overnight	  at	  37°C,	  5%	  CO2.	  	  This	  resulted	  in	  approximately	  40%	  confluence	  at	  48	  hours.	  	  	  
At	   48	   hours,	   the	   full	  media	  was	   initially	   replaced	  with	   2.6mls	   of	   antibiotic	  free	  media	  per	  well.	   	  Then	  for	  each	  well	  the	  following	  were	  made	  up	  in	  two	  separate	   tubes:	  200µl	  of	  OptimemI	  was	  added	   to	  4µl	  of	   lipofectamine	  2000	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(tube	  1)	  and	  a	  further	  200µl	  of	  OptimemI	  was	  added	  to	  10nM	  of	  siRNA	  (tube	  2).	  	  The	  siRNA	  used	  was	  SERPIN	  A1	  for	  6	  wells	  and	  the	  two	  negative	  control	  siRNA	  for	  6	  wells	  each	  (off-­‐‑target	  and	  RISC	  free	  controls).	  
These	  tubes	  were	  incubated	  at	  room	  temperature	  for	  five	  minutes	  and	  then	  combined	  and	  mixed	  by	  flicking	  the	  tube	  to	  make	  a	  total	  of	  ~400µl	  per	  well.	  	  This	  mixture	  was	   incubated	   for	   a	   further	   30	  minutes	   at	   room	   temperature	  before	  being	  added	  in	  a	  drop	  wise	  fashion	  to	  each	  well.	  
Transfection	  occurred	  while	  the	  6-­‐‑well	  plates	  were	  incubated	  at	  37°C	  and	  5%	  CO2	  for	  the	  next	  24	  hours.	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  Immunocytochemistry	  
Immunocytochemistry	  (ICC)	  was	  used	  to	  demonstrate	  levels	  and	  position	  of	  protein	  within	  cultured	  cells.	  
1   Cells	  were	  grown	  to	  confluence	  in	  2	  T75	  flasks,	  washed	  with	  PBS	  and	  trypsinised	  as	  per	  cell	  culture.	   	  Media	  was	  then	  added	  to	   the	  trypsin	   and	   centrifuged	   in	   a	   50ml	   Falcon	   tube	   for	   5	   minutes	   at	  500rpm.	   	   The	   media/Trypsin	   was	   removed	   and	   the	   cell	   pellet	  resuspended	   in	   5mls	   of	   PBS	   to	   wash	   the	   cells,	   followed	   by	  centrifuging	  again	  at	  500rpm	  for	  5	  minutes.	  	  	  2   The	  pellet	  was	  resuspended	  in	  4%	  formaldehyde	  (pH7)	  and	  left	  to	  sediment.	  	  After	  2	  hours,	  the	  formaldehyde	  was	  carefully	  pipetted	  off	   leaving	  the	  sedimented	  cells	  and	   fresh	  PBS	  used	  to	  resuspend	  the	  cells	  once	  more.	  	  	  3   Following	  this	  the	  cells	  were	  applied	  to	  slides.	  4   Primary	   antibody	   solutions	   (RRM2	   1:1000)	  were	  made	   up	   using	  the	   diluent	   buffer	   (Dako)	   and	   the	   cells	   left	   in	   these	   solutions	  overnight	  at	  4OC.	  	  	  5   The	   following	   morning,	   the	   cells	   were	   washed	   with	   PBS	   and	  covered	  with	  HRP-­‐‑labelled	  anti-­‐‑mouse	  secondary	  antibody	  (Dako)	  and	  left	  on	  a	  shaker	  at	  100rpm	  for	  1	  hour	  at	  room	  temperature.	  	  	  6   The	   slides	   were	   then	   stained	   by	   covering	   in	   AEC+	   chromagen	  substrate	   (Dako)	  and	   left	  on	  shaker	  at	  100rpm	  for	  10	  minutes	  at	  room	  temperature.	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7   The	  slides	  were	  washed	  with	  PBS	  and	  placed	  in	  Haematoxylin	  for	  10	  seconds.	  	  Slides	  were	  placed	  in	  2%	  ammonium	  hydroxide	  for	  5	  seconds.	  8   Slides	   were	   placed	   in	   30%	   ethanol	   followed	   by	   70%,	   90%	   and	  100%	  ethanol,	  all	  for	  3	  minutes	  each.	  9   Slides	  were	  placed	  in	  Xylene	  for	  5	  minutes,	  3	  successive	  times.	  10  Slides	  were	  then	  mounted	  on	  a	  coverslip	  to	  allow	  viewing.	  
	  
  Immunohistochemistry	  
Immunohistochemistry	  (IHC)	  was	  performed	  to	  show	  levels	  and	  position	  of	  protein	  within	  human	  tissue	  sections.	   	  The	  conditions	  were	  optimised	  using	  fresh	  frozen	  paraffin	  embedded	  (FFPE)	  blocks	  of	  human	  PDAC	  cut	  into	  5μM	  sections	  on	  superfrost	  plus	  slides	  dried	  overnight	  at	  37OC.	   	  Sections	   from	  3	  patients	  were	  used	  from	  a	  store	  available	  in	  the	  department.	  	  	  
Optimisation	  experiments	  used	  varying	  concentrations	  of	  antibody	  based	  on	  the	   company	   recommendations,	   as	   well	   as	   positive	   and	   negative	   control	  (cytokeratin	   antibody	   and	   without	   primary	   antibody	   respectively).	   	   The	  RRM2	   antibody	   concentration	   providing	   the	   best	   results	  was	   1:1000.	  Dako	  EnVisionTM+	  kits	  were	  used.	  	  The	  protocol	  was	  as	  follows:	  
1   Slides	  placed	  in	  Xylene	  for	  5	  minutes,	  3	  successive	  times	  to	  remove	  the	  paraffin.	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2   Slides	   placed	   in	   100%	   ethanol	   followed	   by	   90%,	   70%	   and	   30%	  ethanol,	  all	  for	  3	  minutes	  each.	  	  	  3   Slides	  placed	  in	  distilled	  water.	  4   Slides	  put	  in	  metal	  rack	  and	  placed	  in	  pressure	  cooker	  containing	  2	  litres	   of	   boiling	   citrate	   buffer	   (4.2g	   citric	   acid	   in	   2	   litres	   distilled	  water,	  pH6)	  for	  3	  minutes.	  5   Slides	  cooled	  with	  gentle	  stream	  of	  cold	  water	  for	  5	  minutes.	  6   Slides	  placed	   in	  PBS	  and	   rocked	  at	  20rpm	   for	  3	   x	  2	  minutes	   and	  subsequently	  dried	  using	  blue	  roll	  taking	  care	  not	  to	  wipe	  around	  rather	  than	  on	  the	  section.	  7   A	   ‘Dako	   Pen’	   (Dako)	   was	   used	   to	   create	   a	   water	   repellent	   circle	  around	   the	   tissue	   sections	   and	   this	   circle	   filled	   with	   peroxidise	  blocking	   solution	   (Dako),	   covering	   the	   tissue	   sections	  and	   left	  on	  shaker	  at	  100rpm	  for	  10	  minutes.	  8   Slides	  were	  then	  washed	  and	  dried	  as	  in	  step	  6.	  9   Tissue	   sections	  were	   then	   covered	   in	  primary	  antibody	   solutions	  (RRM2	  1:1000)	  and	  left	  overnight	  at	  4OC.	  	  Antibody	  solutions	  were	  created	  using	  diluent	  buffer	  (Dako).	  10   The	   following	  morning,	   slides	  were	   then	  washed	   and	  dried	   as	   in	  step	  6.	  11   Tissue	   sections	   were	   covered	   with	   HRP-­‐‑labelled	   anti-­‐‑mouse	  secondary	   antibody	   (Dako)	   and	   left	   on	   a	   shaker	   at	  100rpm	   for	  1	  hour	  at	  room	  temperature.	  12   Slides	  were	  then	  washed	  and	  dried	  as	  in	  step	  6.	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13   Tissue	  sections	  were	  then	  stained	  by	  covering	  in	  AEC+	  chromagen	  substrate	   (Dako)	  and	   left	  on	  shaker	  at	  100rpm	  for	  10	  minutes	  at	  room	  temperature.	  	  	  14   Slides	  were	  then	  washed	  and	  dried	  as	  in	  step	  6.	  15   Slides	  were	  placed	  in	  Haematoxylin	  for	  10	  seconds.	  16   Slides	  were	  placed	  in	  2%	  ammonium	  hydroxide	  for	  5	  seconds.	  17   Slides	   placed	   in	   30%	   ethanol	   followed	   by	   70%,	   90%	   and	   100%	  ethanol,	  all	  for	  3	  minutes	  each.	  18   Slides	  placed	  in	  Xylene	  for	  5	  minutes,	  3	  successive	  times.	  19   Slides	  were	  then	  mounted	  on	  a	  coverslip	  to	  allow	  viewing.	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4   Results	  
4.1  Confirmation	  of	  resistance	  and	  establishment	  of	  
levels	   of	   proteins	   previously	   associated	   with	  
gemcitabine	  metabolism	  and	  resistance	  
  Overview	  
Cells	   from	   the	   various	   cell	   lines	   were	   first	   established	   using	   culture	  techniques.	  	  The	  cell	  lines	  were	  then	  treated	  with	  gemcitabine	  and	  subjected	  to	  MTS	  analysis	  to	  establish	  levels	  of	  resistance	  to	  gemcitabine.	  	  Western	  blot	  analysis	  was	  then	  performed	  on	  the	  cell	  lines	  to	  assess	  levels	  of	  the	  proteins	  described	   in	   the	   introduction	   already	   known	   to	   be	   associated	   with	  gemcitabine	  metabolism	  and	  resistance.	  
The	   aims	  were	   to	   confirm	   the	   resistance	   of	   the	   cell	   lines	   used	   and	   then	   to	  identify	   any	   significant	   differences	   in	   the	   levels	   of	   established	   proteins	   of	  interest	  which	  may	  be	  the	  cause	  of	  this	  resistance.	  
	  
  Gemcitabine	  resistance	  in	  cell	  lines	  
The	   cell	   lines	   were	   subjected	   to	   MTS	   analysis	   to	   assess	   their	  resistance/sensitivity	  to	  gemcitabine.	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4.1.2.1  Suit2	  (AS)	  
	  
Figure 11:   IC50	  curve	  for	  Suit2	  cells	  treated	  with	  gemcitabine.	   	  Curves	  
produced	   after	   48	   hours,	   showing	   concentration	   gemcitabine	   (nM)	  
against	  %	  cells	  viable.	  IC50	  value	  is	  0.1	  nM.	  	   
4.1.2.2  BxPC3	  (Bx)	  
	  
Figure	  12:   IC50	   curve	   for	   BxPc3	   cells	   treated	   with	   gemcitabine.	  
Showing	   concentration	   (nM)	   against	   %	   cells	   viable	   compared	   to	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4.1.2.3  Panc1	  (P1)	  
	  
Figure 13:   IC50	  curve	   for	  Panc1	  cells	   treated	  with	  gemcitabine.	  Curve	  
produced	  after	  48	  hours	  showing	  concentration	  of	  gemcitabine	  (nM)	  
against	  %	  cells	  viable.	  IC50	  value	  is	  103nM.   
4.1.2.4  MiaPaCa	  (MP)	  
	  
Figure 14:   IC50	   curve	   for	   MiaPaCa	   cells	   treated	   with	   gemcitabine.	  
Curve	  produced	  after	  48	  hours	  showing	  concentration	  of	  gemcitabine	  












































IC50	  curves	  for	  MiaPaCa	  cells	  treated	  
with	  Gemcitabine
MiaPaCa
	   	   	  	   113	  
4.1.2.5  KR	  Suit2	  (KR)	  
As	   discussed	   in	   the	   introduction,	   I	   was	   unable	   to	   perform	   any	   culture	  experiments	  with	  the	  transiently	  resistant	  cell	  line	  KR,	  due	  to	  a	  mycoplasma	  infection	   with	   the	   frozen	   supply.	   	   I	   did	   have	   a	   supply	   of	   cell	   lysate	   which	  could	  be	  used	   for	   the	  western	  blots	   shown	   further	   into	   the	   results	   section.	  	  Below	   is	   the	   cytotoxicity	   graph	   provided	   by	  my	   predecessor	  which	   is	   also	  shown	   in	   the	   previous	   work	   section	   of	   the	   introduction.	   	   Hence	   it	   is	   in	   a	  different	   format	   to	   the	  others	   and	  does	  not	   appear	   in	   the	   combined	   curves	  figure	  below.	  
	  
Figure	  15:   (provided	  by	  Dajani	  et	  al)	  Cytotoxicity	  curves	  for	  AS	  and	  KR	  
cell	   lines	   treated	  with	  gemcitabine.	   	   In	   this	  graph,	   the	  percentage	  of	  
cells	  alive	   is	  plotted	  as	   relative	   to	  1=100%,	  against	   concentration	  of	  
gemcitabine.	  Suit-­‐‑2	  (blue	  line)	  	  represents	  the	  parental	  Suit-­‐‑2	  cell	  line	  
called	  AS	   in	  my	  work,	  and	  Suit-­‐‑2	  KR	  (red	   line),	   the	  resistant	  cell	   line	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4.1.2.6  GR	  Suit2	  (GR)	  
	  
Figure 16:   IC50	  curve	  for	  clonal	  resistant	  Suit2	  cells	  (GR)	  treated	  with	  
gemcitabine.	  Curve	  produced	  after	  48	  hours	  showing	  concentration	  of	  
gemcitabine	  (nM)	  against	  %	  cells	  viable	  compared	  to	  control	  treated	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4.1.2.7  Combined	  IC50	  curves	  and	  values	  
	  
Figure	  17:   IC50	  curves	  for	  all	  the	  cell	  lines	  combined	  when	  treated	  with	  
gemcitabine.	  X-­‐‑axis	  shows	  the	  concentration	  of	  gemcitabine	  (nM)	  used	  
and	   the	   y-­‐‑axis	   shows	   %	   viable	   cells	   after	   48	   hours	   compared	   with	  
control	  cells	  of	  that	  type	  treated	  with	  standard	  media.	  	  	  
Cell	  line	   IC50	  value	  for	  Gemcitabine/nM	  
Suit2	   0.1	  
MiaPaCa	   0.8	  
BxPc3	   33.6	  
Panc1	   103	  
GR	  Suit2	   >300,000	  
Table	  14:   Summary	   of	   IC50	   values	   for	   all	   cell	   lines	   used,	  
treated	   with	   gemcitabine.	   	   This	   value	   represents	   the	  
concentration	   of	   gemcitabine	  which	   renders	   50%	   of	   the	   cells	  
non-­‐‑viable	   after	   48	   hours	   compared	   with	   minimum	   numbers	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As	   can	  be	   seen	   from	   the	   figures	   and	   tables	   above,	   Suit2	   cells	   are	   relatively	  sensitive	   to	  gemcitabine	  compared	  to	   the	  other	  original	  cell	   lines	  used	  by	  a	  factor	  of	  at	  least	  10	  (IC50	  value	  of	  3.42	  compared	  with	  33.6,	  41.2	  and	  103).	  
However,	   the	   clonal	   resistant	   cell	   line	   GR	   Suit2	   is	   far	   more	   resistant	   by	   a	  factor	  of	  100,000	  compared	  with	  the	  original	  cell	  line.	  
I	   have	   not	   added	   the	   transiently	   resistant	   cell	   line	   to	   this	   table	   as	   the	  experiment	   by	   my	   predecessor	   found	   a	   slightly	   higher	   IC50	   value	   for	   the	  sensitive	  Suit-­‐‑2	  (35nM	  vs	  3.42nM)	  which	  would	  be	  misleading	  when	  quoting	  the	   KR	   IC50	   of	   400nM	   gemcitabine.	   	   However,	   it	   is	   clear	   from	   my	  predecessor’s	  curves	  that	  the	  KR	  cell	   line	  was	  relatively	  resistant	  compared	  to	  the	  parental	  cell	  line,	  probably	  in	  the	  region	  of	  10	  times	  more	  resistant.	  
Having	  shown	  that	  the	  developed	  cell	  line	  was	  indeed	  relatively	  resistant	  to	  gemcitabine,	  I	  then	  went	  on	  to	  explore	  the	  potential	  mechanism	  of	  resistance	  by	  looking	  at	  expression	  of	  various	  proteins	  and	  genes	  of	  interest.	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  Proteins	   previously	   associated	   with	   gemcitabine	  
metabolism	  and	  resistance	  
As	   described	   in	   the	   introduction,	   there	   are	   a	   number	   of	   proteins	   already	  known	  to	  be	  relevant	  to	  gemcitabine	  metabolism	  and	  resistance.	  	  I	  therefore	  performed	  western	  blots	  to	  show	  baseline	  levels	  of	  some	  of	  these	  proteins	  in	  the	  various	  cell	  lines,	  which	  may	  be	  related	  to	  the	  levels	  of	  resistance	  shown	  above.	  
The	  blots	  were	  performed	  using	  the	  conditions	  described	  in	  the	  methods	  for	  each	  particular	  antibody.	   	  The	  protein	   ladder	  was	  always	  placed	  on	   the	   left	  followed	   by	   3	   different	   lines	   of	   Suit2	   cells	   which	   were;	   parental	   Suit2,	  clonally	   resistant	   Suit2	   (GR),	   transiently	   resistant	   suit2	   KR.	   	   In	   addition,	  further	  lanes	  were	  used	  for	  the	  immortal	  pancreatic	  cancer	  cell	  lines	  BxPc3,	  Panc1,	  and	  MiaPaCa.	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4.1.3.1  hENT-­‐1	  
	  
Figure	  18:   Western	   blot	   for	   hENT1.	   	   Bands	   demonstrated	   at	  
approximately	   40	   kDa	   and	   the	   actin	   blot	   shown	   underneath.	   	   A	  
blocking	   agent	   of	   3%	   BSA	   diluted	   in	   PBS	   was	   used	   with	   a	   primary	  
antibody	   concentration	   of	   1:500	   and	   a	   mouse	   secondary	   antibody	  
concentration	   of	   1:2000.	   No	   control	   lane	  was	   used	   as	   the	   bands	   are	  
well	   expressed	   in	   the	   cell	   lines.	   	   The	   first	   lane	   is	   the	   control	   protein	  
ladder	   and	   names	   of	   cell	   lines	   are	   shown	   underneath	   the	   relevant	  
lanes.	  	  	  The	   figure	   above	   is	   an	   example	   of	   a	   western	   blot	   for	   hENT1.	   This	   shows	  similar	   levels	   in	   the	   first	   2	   lanes	   representing	   AS	   and	   GR	   cell	   lines	   but	   a	  markedly	   lighter	   band	   in	   the	   third	   lane	   representing	   KR.	   	   The	   BxPc3	   and	  MiaPaCa	  lanes	  show	  similar	  expression	  to	  AS	  and	  GR	  with	  a	  denser	  band	  in	  the	  Panc1	  lane.	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The	  actin	  shows	  slightly	  less	  overall	  protein	  in	  the	  last	  4	  lanes	  but	  not	  enough	  to	  account	  for	  the	  described	  differences.	  
4.1.3.1.1   CNT-­‐1	  
	  
Figure	  19:   Western	   blot	   for	   CNT-­‐‑1.	   	   Bands	   demonstrated	   at	  
approximately	  60	  kDa	  and	  the	  actin	  blot	  shown	  underneath.	  The	  first	  
lane	   is	   the	   control	   protein	   ladder	  and	  names	  of	   cell	   lines	  are	   shown	  
underneath	  the	  relevant	  lanes.	  	  
The	   figure	   above	   is	   an	   example	   of	   a	   western	   blot	   for	   CNT1,	   which	   is	  represented	  by	   the	  bolder	  bands	   above	   at	   approximately	  60kDa.	   	   This	  was	  repeated	  on	  3	  occasions	  but	   this	  was	   the	   ‘cleanest’	   blot	   obtained.	   	  There	   is	  some	  variation	  in	  the	  loading	  of	  total	  protein	  making	  it	  difficult	  to	  show	  any	  definite	  difference	  in	  the	  first	  5	  lanes	  but	  there	  is	  far	  less	  expression	  of	  CNT1	  in	  MiaPaCa	  than	  the	  other	  cell	  lines.	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4.1.3.2  DCK	  
	  
Figure	  20:   Western	   blot	   for	   DCK.	   Bands	   demonstrated	   at	  
approximately	   30	   kDa	   and	   the	   actin	   blot	   shown	   underneath.	   	   A	  
blocking/dilution	   agent	   of	   3%	   BSA/PBS	   was	   used	   with	   a	   primary	  
antibody	  dilution	  of	  1:500	  and	  a	  secondary	  rabbit	  antibody	  at	  1:2000	  
dilution.	   No	   control	  was	   required	   for	   this	   blot.	   	   The	   first	   lane	   is	   the	  
protein	   ladder	   and	   names	   of	   cell	   lines	   are	   shown	   underneath	   the	  
relevant	   lanes	   (AS=parenteral	   Suit2,	   GR=clonally	   resistant	   SUIt2,	  
KR=transiently	  resistant	  Suit2).	  	  	  	  
The	   figure	   above	   is	   an	   example	   of	   a	  western	   blot	   for	   DCK.	   Optimising	   this	  commercial	   antibody	  was	   very	   difficult	   and	   it	   is	   not	   a	   very	   clean	   antibody.	  	  There	  are	  multiple	  bands	  in	  all	  lanes	  but	  the	  protein	  DCK	  should	  be	  30.5kDa	  which	  the	  band	  marked	  corresponds	  to.	  	  If	  this	  band	  is	  taken	  as	  being	  specific	  to	  DCK,	  then	  KR,	  BxPc3	  and	  especially	  Panc1	  cell	  lines	  show	  decreased	  levels	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of	   DCK	   but	   it	   is	   difficult	   to	   draw	   any	   meaningful	   conclusions	   with	   this	  antibody.	  
4.1.3.3  CDA	  
Attempts	  were	  made	  to	  optimise	  an	  antibody	  from	  Abcam	  (ab82346)	  for	  CDA	  due	   to	   its	   known	   role	   in	   the	   metabolism	   of	   gemcitabine.	   	   However,	   these	  were	  unsuccessful	  and	  no	  further	  work	  was	  performed	  on	  this	  protein.	  
4.1.3.4  DCTD	  
	  
Figure	  21:   Western	   blot	   for	   DCTD.	   Bands	   demonstrated	   at	  
approximately	  20	  and	  22	  kDa	  and	  the	  actin	  blot	  shown	  underneath.	  	  A	  
blocking/dilution	   agent	   of	   5%	   BSA/PBS	   was	   used	   with	   a	   primary	  
antibody	   dilution	   of	   1:5000	   and	   a	   secondary	   rabbit	   antibody	   at	  
1:2000	  dilution.	  A	  commercial	  protein	  control	  (ab96766)	  was	  used	  for	  
this	  blot	  (not	  shown).	  	  The	  first	  lane	  is	  the	  protein	  ladder	  and	  names	  of	  
cell	  lines	  are	  shown	  underneath	  the	  relevant	  lanes.	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The	  DCTD	  antibody	  also	  proved	  difficult	  to	  optimise.	  	  The	  expected	  weight	  of	  the	  protein	  is	  20-­‐‑22kDa	  but	  there	  are	  2	  bands	  at	  these	  levels	  and	  the	  bands	  higher	  up	  on	  the	  blots	  were	  always	  heavier.	  	  The	  blot	  above	  is	  an	  example	  of	  one	  of	  the	  cleanest	  obtained.	  	  Based	  on	  this,	  no	  meaningful	  conclusions	  were	  possible	  for	  the	  relative	  expression	  of	  DCTD	  between	  the	  cell	  lines.	  
4.1.3.5  RRM1	  
	  
Figure	  22:   Western	   blot	   for	   RRM1.	   Bands	   demonstrated	   at	  
approximately	   80	   kDa	   and	   the	   actin	   blot	   shown	   underneath.	   	   A	  
blocking/dilution	   agent	   of	   5%	   milk/PBS	   was	   used	   with	   a	   primary	  
antibody	   dilution	   of	   1:2000	   and	   a	   secondary	   rabbit	   antibody	   at	  
1:2000	  dilution.	  No	  control	  was	  required	  for	  this	  blot.	  	  The	  first	  lane	  is	  
the	  protein	  ladder	  and	  names	  of	  cell	   lines	  are	  shown	  underneath	  the	  
relevant	  lanes.	  	  	  The	  blot	  above	  shows	  a	  double	  band	  in	  some	  of	  the	  cell	  lines	  (namely	  BxPc3,	  Panc1	   and	   MiaPaCa	   with	   a	   very	   faint	   second	   band	   in	   GR)	   which	   was	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consistent	   throughout	   all	   repeats	   with	   this	   antibody.	   	   However,	   the	   lower	  band	  at	  80	  kDa	  was	  felt	  to	  represent	  the	  protein	  in	  question.	  	  	  
The	  blot	   shows	  a	  possible	   increase	   in	   expression	   in	  AS	  vs	  KR	   cell	   lines	  but	  this	  may	  be	  due	  to	  slightly	  uneven	  loading	  shown	  in	  the	  actin	  blot.	  	  The	  only	  consistent	   finding	   in	  repeated	  blots	  was	  relatively	  high	  expression	  in	  Panc1	  and	  MiaPaCa	   and	   relatively	   low	   expression	   in	   BxPc3	   compared	  with	   the	   3	  Suit	  two	  cell	  lines.	  	  	  
   Conclusions	  
	   hENT-­‐1	   CNT-­‐1	   DcK	   DCTD	   RRM1	  
AS	   «	   «	   «	   -­‐‑	   ­	  
GR	   «	   «	   «	   -­‐‑	   «	  
KR	   ¯	   «	   ¯	   -­‐‑	   ­	  
BxPC3	   «	   «	   ¯	   -­‐‑	   ¯	  
Panc-­‐1	   ­	   «	   ¯¯	   -­‐‑	   ­	  
MiaPaCa	   «	   ¯	   «	   -­‐‑	   ­	  
Table	  15:   Table	   summarising	   the	   findings	   in	   this	   section;	  
relative	   levels	   of	   proteins	   previously	   associated	   with	  
gemcitabine	   metabolism	   and	   resistance	   in	   a	   variety	   of	  
different	  immortal	  pancreatic	  cancer	  cell	  lines.	  	  
Looking	  specifically	  at	  the	  Suit-­‐‑2	  cell	  lines	  which	  form	  the	  basis	  of	  this	  thesis	  (AS,	  GR,	  KR),	   the	   results	   above	   show	  decreased	  expression	  of	  hENT-­‐‑1,	  DCK	  and	  possibly	  RRM1	  in	  the	  KR	  cell	   line	  compared	  to	  the	  AS	  and	  GR	  cell	   lines.	  While	   these	   differences	   could	   potentially	   be	   linked	   to	   the	   differences	   in	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resistance,	   these	   differences	   are	   not	   consistent	   in	   the	   2	   resistant	   cell	   lines	  (KR	  and	  GR).	  
Therefore,	   there	   seems	  no	   reason	   to	  discount	   the	   results	  of	   the	  microarray	  and	  the	  work	  proceeded	  to	  the	  validation	  stage.	  
Equally,	  while	  the	  levels	  of	  the	  proteins	  in	  the	  other	  PDAC	  cell	  lines	  did	  vary,	  this	  body	  of	  work	  concentrated	  on	  the	  Suit-­‐‑2	  cell	  line	  and	  continued	  as	  such,	  while	  also	  checking	  levels,	  where	  possible,	  in	  the	  other	  cell	  lines	  as	  a	  possible	  source	  of	  variations	  in	  innate	  resistance.	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4.2  Validation	  of	  microarray	  results	  
  Overview	  
As	   described	   in	   the	   previous	   work	   section,	   the	   bioinformatics	   analysis	  comparing	   the	   sensitive	   and	   resistant	   Suit2	   cell	   lines	   showed	   differential	  expression	  in	  the	  following	  genes	  and	  proteins:	  
Genes/RNA	   Proteins	  BEX4	   Glutathione	  S-­‐‑transferase	  P	  LOC439949	   Zinc	  finger	  protein	  593	  SERPIN	  A1	   Occludin	  SNAR-­‐‑A1	   Folate	  receptor	  alpha	  	   Ribonucleotide	  reductase	  subunit	  M2	  (RRM2)	  
Table	  5:	  Differentially	  expressed	  genes	  and	  proteins	  
Following	  a	  literature	  search	  for	  all	  these	  genes	  and	  proteins,	  it	  was	  decided	  to	  concentrate	  on	  the	  following	  as	  potentially	  affecting	  resistance:	  SERPINA1,	  glutathione	   S-­‐‑transferase	   P	   (GSTP),	   occludin,	   folate	   receptor	   alpha	   (FOLR)	  and	  ribonucleotide	  reductase	  subunit	  M2	  (RRM2).	  	  	  
I	  therefore	  went	  on	  to	  validate	  these	  findings	  by	  quantifying	  either	  protein	  or	  RNA	  expression	  with	  western	  blot	  or	  PCR	  respectively.	  
It	   was	   also	   decided	   to	   examine	   levels	   of	   Inerleukin-­‐‑1β	   (IL-­‐‑1β),	   as	   this	   had	  been	  implicated	  in	  a	  possible	  pathway	  between	  SERPIN	  A1	  and	  RRM2	  in	  the	  pathways	  shown	  in	  the	  introduction	  (previous	  work).	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  SERPINA1/α-­‐1-­‐antitrypsin	  (A1AT)	  
4.2.2.1  Western	  blot	  with	  cell	  lysate	  
The	  microarray	  suggested	  that	  the	  gene	  SERPIN	  A1	  was	  under	  expressed	  in	  resistant	   cells.	   	  This	  gene	  codes	   for	   the	  protein	  alpha-­‐‑1-­‐‑antitrypsin	   (A1AT).	  	  Therefore,	  western	  blots	  were	  performed	  as	  per	  section	  3.2.4.	  
	  
Figure	  23:   Western	   blot	   for	   A1AT.	   Original	   blot	   shown	   above	   on	   and	  
actin	  blot	  shown	  below.	  	  A	  blocking/dilution	  agent	  of	  5%	  milk/TBS,	  a	  
primary	   antibody	   concentration	   of	   1:5000	   and	   a	   secondary	   mouse	  
antibody	  at	  1:3000.	  The	  control	  was	  human	  serum.	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The	  Western	   blot	   above	   was	   done	   with	   the	   cell	   lines	   AS	   and	   GR	   only	   but	  shows	  no	  detectable	  A1AT	  in	  either	   lane.	   	  The	  left-­‐‑hand	  film	  shows	  a	  dense	  band	  at	  ~52kDa	  in	  the	  control	  lane	  as	  expected	  but	  no	  other	  bands.	   	  The	  β-­‐‑actin	   film	   shows	  adequate	   loading	  between	   the	  2	   experimental	   lanes	   and	  a	  small	   amount	   of	   overspill	   only	   in	   the	   control.	   	   The	   lack	   of	   β-­‐‑actin	   band	   is	  expected	  in	  the	  control	  as	  the	  control	  was	  human	  serum,	  whereas	  β-­‐‑actin	  is	  a	  cellular	  protein.	  	  Note	  the	  marks	  on	  the	  left	  of	  the	  films	  are	  made	  by	  hand	  to	  represent	  the	  protein	  ladder	  visible	  on	  the	  membrane,	  with	  their	  associated	  weights	  in	  kDa.	  
This	  experiment	  was	  repeated	  with	   the	  AS,	  GR	  and	  KR	  cell	   lines	   to	  confirm	  the	  findings	  of	  no	  protein	  traceable	  on	  western	  blot:	  
	  
Figure	  24:   Repeat	  western	  blot	  for	  A1AT.	  	  A	  blocking/dilution	  agent	  of	  
5%	   milk/TBS,	   a	   primary	   antibody	   concentration	   of	   1:5000	   and	   a	  
secondary	  mouse	  antibody	  at	  1:3000.	  The	  control	  was	  human	  serum.	  
Actin	  blot	  not	  shown.	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The	  repeat	  once	  again	  shows	  no	  detectable	  protein	  in	  any	  of	  the	  cell	  lines	  but	  a	  good	  clean	  band	  at	  ~52kDa	  in	  the	  control	  (actin	  not	  shown).	  	  	  
4.2.2.2  Western	  blot	  with	  supernatant	  
Having	   failed	   to	   show	   any	   level	   of	   A1AT	   protein	   within	   the	   cells	   of	   the	  various	   cell	   lines,	   I	   next	   collected	   samples	   of	   the	   supernatant	   in	  which	   the	  cells	  were	  cultured	  as	  per	  the	  methods,	  looking	  for	  a	  demonstrable	  secreted	  level	  of	  A1AT.	  
	  
Figure	  25:   Western	   blot	   for	   A1AT	   using	   supernatant	   collected	   from	  
cultured	  cells.	   	  A	  blocking/dilution	  agent	  of	  5%	  milk/TBS,	  a	  primary	  
antibody	  concentration	  of	  1:5000	  and	  a	  secondary	  mouse	  antibody	  at	  
1:3000.	  The	  control	  was	  human	  serum.	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However,	  this	  blot	  again	  shows	  no	  level	  of	  A1AT	  which	  could	  be	  picked	  up	  via	  this	  method.	  	  This	  suggests	  that	  the	  level	  of	  A1AT	  at	  the	  protein	  level,	  either	  within	   or	   secreted	  by	   the	   cells	  was	   too	   low	   for	  western	  blot	   analysis.	   	   The	  reason	  the	  control	  lane	  is	  so	  ‘dirty’	  is	  that	  I	  used	  relatively	  long	  exposures	  of	  the	   film	   to	   the	  membrane	   in	   an	   attempt	   to	   show	  up	   even	  very	   light	   bands.	  Because	   the	   control	   provides	   a	   very	   strong	   band,	   however,	   there	   has	   been	  some	  spill	  over	  into	  the	  rest	  of	  the	  lane.	  
As	  expected	   there	  was	  no	  β-­‐‑actin	  demonstrated	   in	   any	  of	   the	   lanes	  as	   they	  were	   all	   secreted	   samples	   and	   the	   control	   was	   serum.	   	   Standardisation	   of	  samples	  was	  by	  volume	  of	  supernatant.	  
	  
4.2.2.3  qRT-­‐PCR	  for	  SERPINA1	  
The	  decision	  was	  therefore	  made	  to	  confirm	  the	  microarray	  data	  with	  qRT-­‐‑PCR	  for	  SERPIN	  A1	  RNA	  as	  its	  protein	  (A1AT)	  was	  not	  detectable	  in	  the	  cells	  or	   their	   supernatant.	   	  This	   required	  a	  number	  of	   steps.	   	  First	  primers	  were	  designed	   for	   SERPINA1	   using	   a	   computer	   programme	   as	   described	   in	   the	  methods.	  	  cDNA	  was	  then	  produced	  for	  the	  various	  cell	  lines,	  again	  as	  per	  the	  methods.	  	  The	  purity	  of	  the	  cDNA	  was	  assessed,	  following	  which	  the	  primers	  were	   tested.	   	   Finally,	   qRT-­‐‑PCR	   could	   be	   performed	   to	   quantify	   levels	   of	  SERPINA1	  RNA	  in	  the	  cell	  lines.	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4.2.2.3.1   Design	  of	  Primers	  
GAPDH	   primers	   (housekeeping	   gene	   used	   as	   control)	   were	   purchased	  commercially	  and	  PCR	  primers	  for	  SERPIN	  A1	  were	  designed	  using	  the	  Clone	  MFC	   application	   (Scientific	   and	   Educational	   Software).	   	   Protocols	   for	   PCR	  were	  developed	  using	  non-­‐‑quantitative	  RT-­‐‑PCR	  (see	  below).	  	  	  
GAPDH:	  
Forward:	  5’	  –	  GCA	  TGG	  ACT	  GTG	  GTC	  –	  3’	  
Reverse:	  5’	  –	  AGG	  TGA	  AGG	  TCG	  GAG	  –	  3’	  
The	  PCR	  Protocol	  for	  GAPDH	  was	  as	  follows:	  	  95°C	  for	  12	  minutes,	  40	  cycles	  of	  (95°C	  for	  30	  seconds,	  67°C	  for	  30	  seconds,	  72°C	  for	  1	  minute),	  72°C	  for	  10	  minutes.	  
SERPIN	  A1	  (expected	  fragment	  length=492	  base	  pairs):	  
Forward:	  5’	  –CACTC	  AGAAG	  CCTTC	  ACTGT-­‐‑	  3’	  
Reverse:	  	  5’	  –GGACG	  CTCTT	  CAGAT	  CATAG-­‐‑	  3’	  
The	   PCR	   Protocol	   for	   SERPIN	  A1	  was	   as	   follows:	   	   95°C	   for	   12	  minutes,	   40	  cycles	  of	  (95°C	  for	  30	  seconds,	  55°C	  for	  30	  seconds,	  72°C	  for	  1	  minute),	  72°C	  for	  10	  minutes.	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4.2.2.3.2   Confirmation	  of	  successful	  RNA	  extraction	  and	  cDNA	  production	  for	  
use	  in	  PCR	  
RT-­‐‑PCR	  was	  performed	  with	  GAPDH	  primers	  (GAPDH	  is	  a	  housekeeping	  gene,	  consistently	   expressed	   among	   all	   animal	   cells	   and	   therefore	   used	   as	   a	  control)	  to	  confirm	  that	  RNA	  had	  been	  extracted	  properly	  from	  the	  cells	  and	  cDNA	  produced.	  
	  
Figure	  26:   RT-­‐‑PCR	  for	  GAPDH.	  Performed	  to	  assess	  production	  of	  cDNA	  
from	  the	  different	  cell	  lines.	  	  The	  control	  was	  a	  sample	  undergoing	  the	  
same	  steps	  of	   the	  RT-­‐‑PCR	  process	  but	   loaded	  with	  water	  rather	  than	  
RNA.	  	  The	  lanes	  are	  left	  to	  right:	  control	  protein	  ladder	  (multiple	  faint	  
bands),	   parental	   Suit2	   (AS),	   parental	   Suit2	   (AS),	   clonally	   resistant	  
Suit2	  (GR),	  transiently	  resistant	  Suit2	  (KR)	  and	  control.	  
	  AS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  AS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  KR	  	  	  	  	  	  	  	  	  	  	  	  	  	  Control 
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The	  picture	  of	  the	  PCR	  gel	  shows	  4	  bands	  relating	  to	  the	  cell	  line	  lanes	  and	  no	  band	   in	   the	  control	   lane.	   	  The	  protein	   ladder	  can	  be	  seen	   faintly	   to	   the	   left.	  	  This	  confirms	  the	  production	  of	  cDNA	  with	  no	  contaminant	  in	  the	  control.	  
	  
4.2.2.3.3   Trial	  of	  SERPINA1	  primers	  for	  use	  with	  qRT-­‐PCR	  
Once	   the	  production	  of	   cDNA	  was	   confirmed,	   the	  primers	  designed	   against	  SERPIN	  A1,	  which	  codes	   for	  A1AT,	  were	  tested.	   	  The	  expected	   length	  of	   the	  cDNA	   segments	   produced	   was	   492	   base	   pairs	   according	   to	   the	   clone	  computer	  programme.	  	  2	  lanes	  of	  AS	  cell	  line	  cDNA	  were	  used	  for	  the	  test.	  
	  
Figure	  27:   RT-­‐‑PCR	   for	   SERPIN	   A1.	   	   Lanes	   are	   left	   to	   right:	   protein	  
ladder	  with	   strong	  band	  at	   500	  base	   pairs,	   Suit2,	   Suit2	   and	   control.	  	  
The	   control	  was	   a	   sample	   undergoing	   the	   same	   steps	   of	   the	  RT-­‐‑PCR	  
process	  but	  loaded	  with	  water	  rather	  than	  RNA.	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The	  picture	  of	  the	  PCR	  gel	  shows	  2	  bright	  bands	  in	  the	  2	  cell	  line	  cDNA	  lanes	  just	  below	  the	  bright	  lane	  in	  the	  DNA	  ladder	  representing	  DNA	  of	  length	  500	  base	  pairs.	  	  This	  corresponds	  to	  the	  492	  base	  pairs	  expected.	  	  Therefore,	  the	  primers	  were	  suitable	  to	  continue	  using	  for	  further	  experiments.	  	  	  
	  
4.2.2.3.4   qRT-­‐PCR	  for	  SERPINA1	  
The	  microarray	  suggested	  SERPIN	  A1	  was	  under	  expressed	   in	   the	  resistant	  cell	  lines.	  
GAPDH	  is	  a	  housekeeping	  gene,	  consistently	  expressed	  among	  all	  animal	  cells	  and	  was	   therefore	  used	  as	  a	   control	   to	  ensure	  equal	   loading.	   	  First,	  GAPDH	  curves	  were	  produced	  as	  described	  in	  section	  3	  for	  the	  different	  cell	  lines	  to	  allow	   quantification	   of	   the	   amount	   of	   total	   cDNA	   in	   each	   sample.	   	   The	  samples	  were	  then	  diluted	  to	  what	  was	  thought	  to	  be	  equal	  concentrations	  of	  total	  cDNA.	  	  qRT-­‐‑PCR	  was	  then	  performed	  in	  duplicate	  for	  the	  3	  cell	  lines	  for	  GAPDH	  once	  more	  to	  confirm	  equal	  loading:	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Figure	  28:   qRT-­‐‑PCR	   for	   GAPDH.	   Performed	   in	   duplicate	   for	   AS,GR,KR.	  	  
The	   graph	   shows	   amplification	   curves	   which	   represent	   number	   of	  
cycles	  plotted	  against	  fluorescence.	  	  	  	  
Cell	  line	   Crossing	  point	  AS	   24.68	  AS	   24.62	  GR	   24.88	  GR	   24.85	  KR	   25.04	  KR	   25.04	  
Table	  16:   Crossing	   points	   for	   qRT-­‐‑PCR	   for	   GAPDH.	   These	  
provide	   a	   number	   for	   the	   curves	   in	   the	   above	   figure.	   Which	  
represents	   the	   number	   of	   cycles	   at	  which	   increase	   in	   cDNA	   is	  
truly	  exponential.	  	  
	  Overlying	  curves	  would	  represent	  equal	  amounts	  of	  cDNA	  within	  the	  sample.	  	  The	  Lightcycler	  machine	  also	  provides	  a	  crossing	  point	  which	  represents	  the	  point	   at	   which	   increase	   in	   cDNA	   fluorescence	   is	   truly	   exponential.	   	   These	  numbers	  are	  lower	  the	  more	  cDNA	  is	  present	  as	  the	  exponential	  phase	  takes	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less	  cycles	  of	  PCR	  to	  occur.	  	  As	  PCR	  involves	  doubling	  of	  the	  DNA	  per	  cycle,	  a	  number	  one	  higher	  than	  another	  represents	  half	  as	  much	  DNA	  present,	  and	  a	  number	  2	  higher	  represents	  a	  quarter	  as	  much	  DNA,	  etc.	  
The	   above	   figure	   and	   table	   show	   that	   there	   were	   very	   similar	   amounts	   of	  cDNA	  loaded	  between	  the	  samples	  as	  expected.	  
Following	  confirmation	  of	  equal	  amounts	  of	  cDNA	  in	  each	  sample,	  qRT-­‐‑PCR	  was	  performed	  looking	  at	  the	  levels	  of	  SERPIN	  A1	  using	  the	  primers	  designed	  above.	  
	  
Figure	  29:   qRT-­‐‑PCR	   for	   SERPIN	   A1	   in	   AS,GR	   and	   KR	   cell	   lines.	   	   There	  
were	  6	  wells	  for	  each	  cell	   line.	  The	  graph	  shows	  amplification	  curves	  
which	  represent	  number	  of	  cycles	  plotted	  against	  fluorescence.	  	  	  	  
Cell	  line	   Cycles	   Mean	  AS	   38.93	   	   	  AS	   39.54	   	   	  AS	   39.56	   40.00	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AS	   41.83	   	  AS	   40.42	   	  AS	   39.73	   	  GR	   42.94	   	   	  GR	   42.44	   	   	  GR	   42.44	   42.33	  GR	   41.84	   	  GR	   42.02	   	   	  GR	   42.28	   	  KR	   42.11	   	  KR	   44.02	   	  KR	   41.63	   42.03	  KR	   41.20	   	   	  KR	   42.05	   	   	  KR	   41.15	   	  
Table	  17:   Crossing	   points	   for	   qRT-­‐‑PCR	   for	   SERPIN	   A1.	   The	   6	  
wells	  of	  each	  cell	  line	  have	  been	  averaged	  in	  the	  right	  column.	  The	  figure	  and	  table	  above	  show	  differing	  amounts	  of	  SERPIN	  A1	  in	  each	  of	  the	  cell	  lines.	  	  The	  experiment	  was	  performed	  with	  6	  wells	  of	  each	  cell	  line	  to	  allow	   averaging	   and	   statistical	   analysis	   to	   be	   performed	   to	   confirm	  differential	  expression.	  
Specifically,	  comparing	  levels	  of	  SERPIN	  A1	  in	  the	  resistant	  cell	  lines	  GR	  and	  KR	  verses	  the	  parental	  cell	  line	  AS	  showed	  statistically	  significant	  differences	  (GR	   vs	   AS,	   T-­‐‑test,	   p=0.002;	   KR	   vs	   AS,	   T-­‐‑test,	   p=0.007).	   	   When	   using	   the	  average	   for	   each	   cell	   line,	   expression	   of	   SERPIN	   A1	   was	   decreased	   in	   the	  resistant	   cell	   lines	   (AS	   vs	   GR	   =	   80.04%	   decreased	   expression,	   AS	   vs	   KR	   =	  75.43%	  decreased	  expression).	  
Given	  the	  definite	  decrease	  in	  the	  amount	  of	  SERPIN	  A1	  RNA	  present	  in	  both	  the	   GR	   and	   the	   KR	   resistant	   cell	   line,	   it	   was	   decided	   to	   continue	   to	   a	  knockdown	  experiment	  for	  SERPIN	  A1	  to	  look	  for	  an	  effect	  on	  resistance.	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  Glutathione	  S-­‐transferase	  P	  (GSTP)	  
Glutathione-­‐‑S-­‐‑Transferase-­‐‑P	   (GSTP)	   was	   investigated	   by	  means	   of	   western	  blotting.	   The	   experiments	   were	   performed	   in	   triplicate	   following	  optimisation	   of	   the	   antibody	   conditions	   as	   usual.	   In	   this	   case,	   it	   was	   not	  immediately	   obvious	   to	   the	   naked	   eye	   if	   there	  was	   a	   significant	   difference	  between	  the	  sensitive	  and	  resistant	  cell	  lines	  (AS	  vs	  GR	  and	  KR),	  so	  the	  blots	  were	  then	  analysed	  to	  measure	  the	  density	  of	  the	  bands	  created	  and	  this	  was	  adjusted	   according	   to	   the	   consistency	   of	   the	   loading,	   as	   subsequently	  measured	  by	  the	  actin	  blots.	  	  An	  example	  blot	  is	  shown	  below	  and	  the	  density	  analysis	  shown	  below	  that	  in	  both	  graphical	  and	  numerical	  form.	  
	  
Figure	  30:   Example	   western	   blot	   for	   Glutathione	   S	   Transferase	   P	  
(GSTP).	  Upper	  figure	  shows	  original	  blot	  for	  GSTP	  and	  lower	  blot	  is	  for	  
Actin.	  Lanes	  are	  shown	  corresponding	  to	  the	  various	  cell	  lines.	  
!!!!AS!!!!!!!GR!!!!!!!!KR!!!!!!!Bx!!!!!!!!P1!!!!!!!!!MP!!!!!!!!!
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Figure	  31:   Bar	  chart	  representing	  the	  results	  of	  western	  blots	  for	  GSTP.	  
The	   blots	   were	   repeated	   in	   triplicate,	   the	   density	   of	   the	   bands	  
measured,	  with	   the	  GSTP	  bands	  adjusted	   for	   the	  density	  of	   the	  Actin	  
bands,	  averaged,	  then	  compared	  with	  the	  AS	  (original	  Suit-­‐‑2)	  cell	  line	  
which	  was	  given	  an	  arbitrary	  value	  of	  1.	  Error	  bars	  represent	  95%	  CI.	  
This	  allowed	  variations	  to	  be	  more	  easily	  appreciated.	  The	  numerical	  
values	  are	  shown	  in	  the	  table	  below.	  
AS	   1	  
GR	   0.88	  
KR	   0.85	  
Bx	   1.04	  
P1	   0.56	  
MP	   0.2	  









AS GR KR Bx P1 MP
	   	   	  	   139	  
It	  was	  also	  noted	  that	  P1	  and	  MP	  cell	  lines	  produced	  far	  lower	  levels	  of	  GSTP	  than	  other	  cell	  lines.	  
  Occludin	  
	  
Figure	  32:   Example	   western	   blot	   for	   Occludin.	   Upper	   figure	   shows	  
original	  blot	  for	  Occludin	  and	  lower	  blot	  is	  for	  actin.	  Lanes	  are	  shown	  
corresponding	  to	  the	  various	  cell	  lines.	  Occludin	   was	   also	   investigated	   by	   means	   of	   western	   blotting.	   Despite	  repeated	  attempts	  to	  optimise	  the	  conditions,	  the	  best	  that	  could	  be	  achieved	  is	   shown	   above.	   	   This	   demonstrates	   a	   relatively	   dirty	   blot	   with	   numerous	  bands	  at	  different	  levels	  for	  all	  the	  cell	  lines.	  There	  is	  a	  potential	  increase	  in	  expression	  in	  the	  resistant	  cell	  lines	  (GR	  and	  KR)	  compared	  to	  the	  parent	  cell	  line	   (AS),	   however	   the	   relative	   densities	   of	   the	   different	   bands	   also	   varied	  from	  cell	  line	  to	  cell	  line	  (for	  instance	  a	  large	  band	  in	  P1	  at	  a	  smaller	  protein	  
!!!!AS!!!GR!!!KR!!!!!Bx!!!!!P1!!!!!MP!!!!!!!!!
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size	  (lower	  on	  the	  figure)	  which	  is	  not	  present	  in	  any	  other	  cell	  line).	  It	  was	  therefore	   felt	   that	   meaningful	   comparisons	   and	   conclusions	   could	   not	   be	  drawn	   from	   these	   westerns,	   and	   given	   more	   success	   was	   had	   with	   other	  proteins,	  it	  was	  decided	  not	  to	  further	  investigate	  the	  protein	  Occludin.	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   Folate	  receptor	  alpha	  (FOLR) 
	  
Figure	  33:   Example	   western	   blot	   for	   Folate	   receptor	   alpha	   (FOLR).	  
Upper	  figure	  shows	  original	  blot	  for	  FOLR	  and	  lower	  blot	  is	  for	  actin.	  
Lanes	  are	  shown	  corresponding	  to	  the	  various	  cell	  lines.	  FOLR	   was	   similarly	   investigated	   by	   means	   of	   western	   blot.	   	   The	   antibody	  used	  provided	  2	  bands	   in	  each	  cell	   line	  but	  despite	  this,	   it	  can	  be	  seen	  that,	  despite	   equal	   loading	   of	   protein	   as	   shown	   by	   similar	   densities	   in	   the	   actin	  blot,	   there	   does	   not	   appear	   to	   be	   a	   significant	   difference	   in	   the	   amount	   of	  FOLR	  present	  in	  the	  different	  cell	  lines.	  In	  particular,	  the	  AS	  and	  GR	  cell	  lines	  of	   most	   interest	   are	   very	   similar.	   This	   finding	   held	   true	   throughout	  optimisation	  of	  the	  antibody	  and	  repeated	  experiments.	  
It	  was	  therefore	  decided	  not	  to	  proceed	  to	  the	  next	  stage	  if	  investigation	  with	  FOLR.	  
!!AS!!!!!!!GR!!!!!!KR!!!!!!!Bx!!!!!P1!!!!!MP!!!!!!!!!
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  Ribonucleotide	  reductase	  subunit	  2	  (RRM2)	  
4.2.6.1  Western	  blot	  
The	  microarray	   suggested	   that	  RRM2	  was	  under	  expressed	   in	   the	   resistant	  cell	  line	  KR	  compared	  to	  the	  AS	  cell	  line.	  
	  
Figure	  34:   Example	   western	   blot	   for	   RRM2.	   Upper	   figure	   shows	  
original	   blot	   for	   RRM2	   and	   lower	   blot	   is	   for	   actin.	   Lanes	   are	   shown	  
corresponding	   to	   the	   various	   cell	   lines.	   In	   this	   experiment,	   a	   control	  
lane	  of	  RRM2	  protein	   is	  shown	  the	  right-­‐‑hand	  side	  of	   the	  blot,	  at	   the	  
same	  protein	  size	  as	  those	  shown	  in	  the	  cell	  lines	  (45kDa)	  The	  upper	  film	  shows	  a	  lower	  amount	  of	  protein	  in	  the	  3rd	   lane	  at	  ~45	  kDa	  which	   is	   the	   expected	   weight	   of	   RRM2.	   	   The	   control	   is	   a	   commercially	  available	  RRM2	  protein.	   	  The	  lower	  film	  shows	  relatively	  consistent	   loading	  between	  the	  lanes	  with	  a	  small	  amount	  of	  overspill	  into	  the	  control	  lane.	  
!!!!AS!!!!!!!!!GR!!!!!!!!!!!!KR!!!!!!!!!!Control!!!
	   	   	  	   143	  
When	  these	  bands	  were	  quantified	  using	  the	  Kodak	  machine	  and	  adjusted	  for	  the	  size	  of	  the	  β-­‐‑actin	  bands,	  there	  was	  found	  to	  be	  19.6%	  less	  RRM2	  in	  the	  KR	  cell	  line	  compared	  to	  the	  same	  amount	  in	  the	  AS	  and	  GR	  cell	  lines.	  
A	  repeat	  of	  this	  experiment	  was	  also	  performed:	  
	  
Figure	  35:   Repeat	  western	  blot	  for	  RRM2.	  Upper	  figure	  shows	  original	  
blot	   for	   RRM2	   and	   lower	   blot	   is	   for	   actin.	   Lanes	   are	   shown	  
corresponding	   to	   the	   various	   cell	   lines.	   In	   this	   experiment,	   a	   control	  
lane	  of	  RRM2	  protein	  is	  shown	  the	  right-­‐‑hand	  side	  of	  the	  blot.	  In	  this	  
experiment,	  2	  lanes	  of	  GR	  were	  used	  in	  lanes	  2	  and	  3.	  The	  repeat	  was	  performed	  with	  2	  lanes	  of	  GR	  protein.	  	  The	  film	  above	  shows	  3	  dense	  bands	  in	  the	  first	  3	  lanes	  (with	  double	  bands	  in	  lanes	  2	  and	  3),	  and	  a	  much	  lighter	  band	  in	  lane	  4	  corresponding	  to	  the	  KR	  cell	  line.	  	  The	  actin	  film	  below	   does	   show	   slightly	   lighter	   band	   representing	   less	   loading	   in	   lane	   4	  compared	  to	  the	  others,	  but	  not	  enough	  to	  explain	  the	  findings	  above.	  	  Due	  to	  
!!!!!!AS!!!!!!!!GR!!!!!!!!!GR!!!!!!!!KR!!!!!Control!!!
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the	  double	  bands	  in	  lanes	  2	  and	  3,	  quantification	  was	  not	  performed,	  but	  in	  combination	   with	   the	   first	   western	   for	   RRM2,	   there	   appears	   to	   decreased	  protein	  level	  in	  the	  KR	  cell	  line.	  	  
This	  film	  is	  taken	  at	  a	  longer	  exposure	  than	  the	  previous	  experiment	  which	  is	  why	  the	  control	  lane	  has	  more	  bands	  within	  it.	  The	  far	  denser	  band	  remains	  present	  at	  the	  45kDa	  mark,	  consistent	  with	  above.	  
Given	   the	   definite	   decrease	   in	   the	   amount	   of	   RRM2	   present	   in	   the	   KR	  resistant	  cell	  line,	  it	  was	  decided	  to	  continue	  to	  a	  knockdown	  experiment	  for	  RRM2	  to	  look	  for	  an	  effect	  on	  resistance.	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   Interleukin-­‐1β 
4.2.7.1  Western	  blot	  on	  cell	  lysate	  
Interleukin	  1-­‐‑β	  (Il-­‐‑1β)	  was	  investigated	  as	  it	  was	  identified	  on	  the	  Ingenuity	  pathway	  downstream	  of	  A1AT	  and	  upstream	  of	  RRM2.	  	  Initially	  Western	  blot	  on	  whole	  cell	  lysate	  was	  performed	  to	  assess	  intracellular	  levels	  of	  Il-­‐‑1β.	  
	  
Figure	  36:   Example	  western	  blot	   for	   Il-­‐‑1β.	  Upper	  part	  of	   figure	   shows	  
original	   blot	   for	   Il-­‐‑1β	   and	   lower	   blot	   is	   for	   actin.	   Lanes	   are	   shown	  
corresponding	  to	  the	  various	  cell	  lines.	  The	   above	   films	   again	   show	   no	   detectable	   bands,	   this	   time	   for	   Il-­‐‑1β.	   	   The	  band	  seen	  on	  the	  right	  of	  the	  upper	  film	  at	  17kDa	  (expected	  weight	  of	  Il-­‐‑1β)	  is	   the	  control	  protein.	   	  The	  β-­‐‑actin	   film	  below	  shows	  good	  amounts	  of	   total	  protein	  were	  loaded.	  	  
!!!!AS!!!!!!!!!!!!!!!!!!!!AS!!!!!!!!!!!!!!!!!!!!GR!!!!!!!!!!!!!!!KR!!!!!!!!!!Control!
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4.2.7.2  Western	  blot	  on	  supernatant	  
Given	   no	   Il-­‐‑1β was identified on Western blots using whole cell lysate, 
I decided to assess to see of the cells were producing Il-1β into the 
surrounding media.  Therefore, Western blot was performed on 
supernatant taken from the cell media for the different cell lines.	  
	  
Figure	  37:   Western	   blot	   probing	   for	   IL-­‐‑1β in	   supernatant.	   The	   band	  
seen	  to	  the	  right	  is	  the	  control	  protein.	  No	  actin	  blot	  is	  shown.	  However,	  as	  can	  be	  seen	  in	  the	  Western	  blot	  above,	  there	  was	  no	  measurable	  level	  of	  expression	  identified	  for	  Il-­‐‑1β. 
  
!!AS!!!!!!!!!!GR!!!!!!!!!KR!!!!!!!!!BxPc3!!!!!!!Panc1!!!!MiaPaCa!!!!!!!!Control!
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  Conclusions	  
These	  results	  have	  shown	  the	  following:	  
-­‐‑A	   decrease	   in	   SERPIN	   A1	   RNA	   in	   both	   the	   GR	   and	   KR	   cell	   lines	  compared	  to	  the	  AS	  cell	  line.	  
-­‐‑A	  decrease	  in	  GSTP	  protein	  in	  both	  the	  GR	  and	  KR	  cell	  lines	  compared	  to	  the	  AS	  cell	  line.	  
-­‐‑A	  decrease	  in	  the	  RRM2	  protein	  in	  the	  KR	  cell	  line	  compared	  to	  the	  GR	  and	  AS	  cell	  lines.	  
-­‐‑No	  difference	  in	  the	  protein	  levels	  of	  FOLR	  
-­‐‑Unable	  to	  accurately	  measure	  levels	  of	  Occludin	  or	  IL-­‐‑1β.	  
	   AS	   GR	   KR	  
SERPIN	  A1	   «	   ¯	   ¯	  
GSTP	   «	   ¯	   ¯	  
Occludin	   -­‐‑	   -­‐‑	   -­‐‑	  
FOLR	   «	   «	   «	  
RRM2	   «	   «	   ¯	  
IL-­‐1β	   -­‐‑	   -­‐‑	   -­‐‑	  
Table	  19:   Table	   summarising	   the	   findings	   in	   this	   section;	  
Relative	   levels	   of	   the	   proteins	   and	   genes	   of	   interest	   in	   the	  
different	  suit-­‐‑2	  cell	  lines	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4.3  Knockdown	  of	  differentially	  expressed	  genes	  and	  
proteins	  of	  interest	  
  Overview	  
I	  had	  confirmed	  SERPINA1,	  GSTP	  and	  RRM2	  as	  being	  differentially	  expressed	  between	   the	   resistant	   and	   sensitive	   Suit2	   cell	   lines.	   	   I	   went	   on	   to	   perform	  siRNA	   knockdown	   of	   these,	   confirmed	   at	   either	   RNA	   or	   protein	   level,	   and	  performed	  MTS	  experiments	  to	  assess	  any	  potential	  effect	  on	  resistance.	  	  
I	  also	  performed	  an	  experiment	  involving	  treating	  cells	  with	  exogenous	  A1AT	  to	  assess	  for	  any	  effect	  on	  resistance.	  
	  	  
	   	  




The	   first	   stage	   was	   to	   confirm	   consistent	   loading	   across	   the	   samples	   with	  qRT-­‐‑PCR	  for	  GAPDH	  as	  previously:	  
	  
Figure	  38:   qRT-­‐‑PCR	   for	   GAPDH	   in	   SERPINA1	   KD.	   	   2	   negative	   controls	  
were	  used	  (6	  wells	  used	  for	  each).	  The	   above	   shows	   qRT-­‐‑PCR	   for	   GAPDH	   for	   SERPINA1	   knockdown	   (termed	  KD),	  and	  2	  negative	  controls	  used	  (-­‐‑1	  representing	  an	  off-­‐‑target	  control	  and	  -­‐‑2	   representing	  a	  RISC	   free	   control).	   	  All	  3	   cell	   lines	  were	   loaded	  6	   times	   in	  separate	  wells	  to	  allow	  statistical	  analysis	  to	  be	  performed.	  	  However,	  due	  to	  problems	   with	   the	   designed	   primer	   (namely	   primer-­‐‑dimers,	   where	   the	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primers	  bind	  to	  each	  other	  rather	  than	  DNA	  as	  intended	  and	  therefore	  create	  negligible	  amounts	  of	  amplified	  DNA),	  some	  of	  the	  samples	  were	  unsuitable	  for	  analysis	  and	  therefore	  removed	  from	  the	  analysis.	  	  	  
	  The	   above	   figure	   shows	   fairly	   consistent	   amounts	   of	   cDNA	   loaded	  throughout	  the	  samples.	  
The	  experiment	  therefore	  continued	  with	  qRT-­‐‑PCR	  for	  SERPIN	  A1.	  
	  
Figure	  39:   qRT-­‐‑PCR	   amplification	   curves	   for	   SERPIN	   A1	   knockdown.	  
These	   curves	   represent	   multiple	   wells	   of	   the	   attempted	   knockdown	  
and	   2	   negative	   controls	   named	   -­‐‑1,	   -­‐‑2.	   Crossing	   points	   are	   shown	   in	  
following	  table.	  	  
In	  the	  figure	  above	  the	  lines	  for	  knockdown	  cells	  (KD)	  are	  grouped	  towards	  the	   right,	  which	   is	   represented	  numerically	   by	   the	   crossing	   point	   values	   in	  the	   table	   below.	   	  When	   analysed	   statistically	   using	   the	   students	   t-­‐‑test,	   the	  knockdown	  cells	   show	  a	   significantly	  different	   amount	  of	   SERPIN	  A1	   cDNA	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with	  p	  values	  of	  <0.001	  (KD	  vs	  -­‐‑1),	  0.027	  (KD	  vs	  -­‐‑2)	  and	  <0.001	  (KD	  vs	  both	  -­‐‑1	  and	  -­‐‑2).	  	  	  
Cell	  line	   Crossing	  Point	   Mean	  average	  KD	   39.46	   	  KD	   39.26	   	  KD	   39.31	   39.55	  KD	   40.18	   	  -­‐‑1	   36.99	   	  -­‐‑1	   36.43	   	  -­‐‑1	   36.65	   	  -­‐‑1	   36.07	   36.35	  -­‐‑1	   36.22	   	  -­‐‑1	   35.73	   	  -­‐‑2	   36.98	   	  -­‐‑2	   37.91	   	  -­‐‑2	   39.82	   37.67	  -­‐‑2	   36.75	   	  -­‐‑2	   36.89	   	  
Table	  20:   Crossing	   points	   for	   SERPIN	   A1	   knockdown.	   Multiple	  
wells	   of	   the	   attempted	   knockdown	   (KD)	   and	   2	   negative	  
controls	   (-­‐‑1,-­‐‑2)	   are	   shown,	   with	   averages	   across	   the	   number	  
of	  wells	  for	  each	  (max=6)	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4.3.2.2  MTS/IC50	  
The	  knockdown	  of	  SERPIN	  A1	  was	  repeated	  in	  order	  to	  assess	  the	  effect	  on	  gemcitabine	   sensitivity/resistance	   of	   the	   cells.	   	   This	   time	   the	   knockdown	  cells	  (KD)	  and	  negative	  controls	  (-­‐‑1	  representing	  an	  off-­‐‑target	  control	  and	  -­‐‑2	  representing	   a	   RISC	   free	   control)	  were	   also	   compared	  with	  AS	   and	  GR	   cell	  lines.	  
Firstly,	   the	   repeat	   knockdown	  was	   confirmed	   as	   above,	   beginning	  with	   the	  GAPDH	  to	  confirm	  consistent	  loading	  of	  the	  wells:	  
	  
Figure	  40:   qRT-­‐‑PCR	   for	   GAPDH	   in	   repeat	   SERPIN	   A1	   knockdown.	   All	  
wells	  show	  similar	  loading	  amounts	  of	  cDNA	  The	  GAPDH	  curves	  are	  again	  satisfactory.	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Figure	  41:   qRT-­‐‑PCR	   for	   SERPIN	   A1	   in	   repeat	   SERPIN	   A1	   knockdown.	  
Multiple	  wells	  of	  the	  attempted	  knockdown	  (KD),	  2	  negative	  controls	  (-­‐‑
1,-­‐‑2),	  plus	  the	  original	  cell	  lines	  AS	  and	  GR	  were	  used.	  	  
Cell	  line	   Crossing	  point	   Mean	  Average	  KD	   40.51	   	  KD	   40.82	   40.67	  -­‐‑1	   36.65	   	  -­‐‑1	   36.63	   36.81	  -­‐‑1	   37.16	   	  -­‐‑2	   37.47	   	  -­‐‑2	   36.72	   37.15	  -­‐‑2	   37.26	   	  AS	   36.46	   	  AS	   36.22	   36.	  08	  AS	   35.57	   	  GR	   39.53	   	  GR	   39.14	   39.34	  
Table	  21:   Crossing	   points	   for	   repeat	   SERPINA1	   knockdown.	  
This	  shows	  numerical	  values	  for	  the	  curves	  shown	  above.	  	  
This	  time	  the	  samples	  were	  performed	  in	  triplicate	  (as	  opposed	  to	  6	  times	  as	  above).	  	  Unfortunately,	  some	  of	  the	  samples	  had	  to	  be	  removed	  from	  analysis	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as	   insignificant	  amounts	  of	   cDNA	  were	  created	  as	   in	   the	  above	  experiment.	  	  This	  meant	  that	  2	  cell	  lines	  (KD	  and	  GR)	  only	  had	  two	  useable	  results.	  	  	  
The	   knockdown	   appears	   to	   have	   decreased	   the	   expression	   in	   the	   sensitive	  cell	   line	  used	  (AS)	   to	   less	   than	   that	  produced	  by	   the	  resistant	  cell	   line	  (GR)	  (Crossing	  points:	  AS=36.08	  vs	  GR=39.34	  vs	  Knockdown=40.67,	  where	  higher	  values	   represent	   lower	   amounts	   of	   RNA	   present).	   	   This	   also	   confirms	   the	  result	  above	  showing	  decreased	  expression	  of	  SERPINA1	  in	  the	  resistant	  cell	  line	  (GR)	  compared	  to	  the	  sensitive	  Suit2	  (AS).	  	  The	  result	  was	  felt	  successful	  to	  continue	  with	  the	  cytotoxicity	  experiment	  itself.	  
The	  following	  MTS	  assay	  was	  performed	  72	  hours	  after	  exposure	  to	  differing	  concentrations	   of	   gemcitabine	   but	   it	   is	   similar	   to	   that	   at	   24	   and	   48	   hours.	  	  The	   MTS	   was	   left	   for	   3	   hours	   before	   these	   readings	   were	   taken.	   	   On	   this	  graph	   C1	   represents	   the	   knockdown	   cells	   (KD),	   1	   represents	   the	   first	  negative	  control	  	  	  (-­‐‑1)	  and	  2	  the	  second	  negative	  control	  (-­‐‑2).	  
The	  curve	   for	   the	  knockdown	  cell	   line	  (C1)	   is	  very	  similar	   to	   those	  of	   the	  3	  sensitive	  cell	  lines	  (AS,-­‐‑1,-­‐‑2)	  but	  dramatically	  different	  to	  that	  of	  the	  resistant	  cell	  line	  GR.	  	  The	  IC50	  for	  KD,-­‐‑1,-­‐‑2and	  AS	  are	  all	  <0.01µM,	  whereas	  for	  the	  GR	  cell	  line	  has	  an	  IC50	  of	  between	  10-­‐‑100µM.	  
These	  data	  are	  extremely	  suggestive	   that	   the	  knockdown	  of	  SERPIN	  A1	  has	  no	  effect	  on	  the	  resistance	  to	  gemcitabine	  of	  the	  cells,	  and	  was	  accepted	  as	  a	  result.	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Figure	  42:   MTS	   assay	   following	   SERPIN	   A1	   knockdown.	   This	   shows	  
concentration	  of	  gemcitabine	  in	  µM	  against	  %	  cells	  alive	  at	  72	  hours.	  
The	   different	   curves	   represent	   the	   original	   cell	   lines	   AS	   and	   GR,	   the	  
knockdown	   cells	   (C1)	   and	   2	   negative	   controls	   (1	   and	   2).	   The	   curves	  
show	  no	   difference	   in	   comparing	   the	   knockdown	   to	   the	   original	   cell	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  GSTP	  
4.3.3.1  Knockdown	  of	  GSTP	  
The	   AS	   and	   GR	   cell	   lines	  were	  manipulated	   to	   reduce	   the	   amount	   of	   GSTP	  produced	   by	   the	   cells	   using	   siRNA	   knockdown	   as	   per	   the	   methods.	   	   This	  experiment	   was	   performed	   using	   20nM	   of	   the	   siRNA	   with	   the	   cell	   lysate	  harvested	  72	  hours	  after	   treatment	  with	   the	  siRNA.	   In	   the	   final	  experiment	  shown	   below,	   an	   off	   target	   negative	   control	   was	   used	   (AS-­‐‑OT	   or	   GR-­‐‑OT)	  which	   involved	   the	   cells	   being	   put	   through	   the	   same	   procedure	   except	   off	  target	  siRNA	  which	  did	  not	  affect	  expression	  was	  used.	  
	  
Figure	  43:   Knockdown	  of	  GSTP	  in	  AS	  and	  GR	  cell	  lines.	  Lanes	  include	  off	  
target	  negative	  controls	  (AS-­‐‑OT	  and	  GR-­‐‑OT)	  and	  the	  knockdown	  cells	  
(AS-­‐‑KD	  and	  GR-­‐‑KD).	  Original	  blot	  shown	  above	  and	  actin	  blot	  shown	  
below.	  
AS###AS$OT##AS$KD###GR####GR$OT##GR$KD#########
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The	   blot	   above	   shows	   a	   successful	   knockdown	   in	   both	  AS	   (AS-­‐‑KD)	   and	  GR	  (GR-­‐‑KD)	  cell	  lines.	  	  There	  is	  a	  very	  faint	  band	  remaining	  in	  the	  AS-­‐‑KD	  lane	  but	  none	  seen	  at	  all	   in	   the	  GR-­‐‑KD	   lane.	  Both	  off	   target	  controls	  (AS-­‐‑OT	  and	  GR-­‐‑OT)	   show	   no	   difference	   in	   levels	   of	   GSTP	   compared	  with	   the	   parental	   cell	  lane,	  and	  the	  actin	  blot	  below	  shows	  consistent	  loading	  throughout.	  	  
Having	  confirmed	  the	  knockdown,	  it	  was	  possible	  to	  assess	  for	  any	  effect	  on	  resistance.	  
4.3.3.2  MTS	  following	  knockdown	  of	  GSTP	  
The	   cell	   lines	   were	   subjected	   to	   MTS	   analysis	   with	   the	   cells	   treated	   with	  gemcitabine	  48	  hours	  after	  knockdown	  to	  allow	  the	  cytotoxicity	  assessment	  to	  be	  performed	  72	  hours	  after	  knockdown	  consistent	  with	  the	  western	  blots	  above.	   This	   meant	   the	   curves	   were	   produced	   after	   treatment	   with	  gemcitabine	  for	  24	  hours.	  
The	   figure	   below	   shows	   cytotoxicity	   curves	   for	   gemcitabine	   taken	   after	   24	  hours	  and	  the	  6	  different	  curves	  represent	  the	  original	  cell	  lines	  (AS/AS	  and	  GR/GR),	   2	   negative	   off	   target	   controls	   (AS/OT	   and	   GR/OT)	   and	   the	  knockdown	   cells	   (AS/KD	   and	   GR/KD).	   	   There	   is	   very	   little	   difference	   seen	  between	   the	   original	   cell	   lines,	   controls	   and	   knockdown	   cells	   in	   either	  parental	   cell	   line.	   This	   strongly	   suggests	   that	   the	   impressive	   knockdown	  achieved	  had	  no	   effect	   on	   resistance	   to	   gemcitabine.	   	   Therefore,	   no	   further	  experiments	  were	  performed	  on	  GSTP.	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Figure	  44:   IC50	  curves	  following	  knockdown	  of	  GSTP	  in	  AS	  and	  GR.	  This	  
plots	   percentage	   of	   cells	   alive	   against	   concentration	   of	   gemcitabine	  
and	  was	  performed	  24	  hours	  after	   treatment.	  The	  6	  different	   curves	  
represent	   the	   original	   cell	   lines	   (AS/AS	   and	   GR/GR),	   2	   negative	   off	  
target	   controls	   (AS/OT	  and	  GR/OT)	  and	   the	  knockdown	  cells	   (AS/KD	  
and	  GR/KD).	  	  













Concentration	  of	  Gemcitabine	  (nM)
AS/ASAS/OTAS/KDGR/GRGR/OTGR/KD
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  RRM2	  
4.3.4.1  Knockdown	  of	  RRM2	  
Both	   original	   Suit-­‐‑2	   cell	   lines	   (AS	   and	   GR)	   were	   manipulated	   to	   reduce	  expression	  of	  RRM2	  by	  siRNA	  knockdown	  as	  per	   the	  methods	  section.	   	  The	  concentration	   of	   siRNA	   used	  was	   20nM	   per	  well	   in	   a	   6-­‐‑well	   plate	   and	   the	  knockdown	  was	   optimum	   at	   24	   hours	   after	   treatment.	   	   Once	   again,	   an	   off	  target	  negative	  control	  (OT)	  was	  used	  by	  replacing	  with	  siRNA	  which	  did	  not	  code	  for	  the	  RRM2	  section	  of	  the	  gene.	   	  Following	  knockdown,	  western	  blot	  was	  performed	  on	  cell	  lysate	  to	  confirm	  reduced	  levels	  of	  RRM2.	  
	   	  
Figure	  45:   Western	  blot	  showing	  RRM2	  knockdown	  in	  AS	  cells.	  Left	  side	  
shows	  western	  blot	  for	  RRM2	  following	  knockdown	  of	  RRM2	  in	  AS	  cell	  
line	  with	  lanes	  representing	  original	  cell	  line	  (AS),	  off	  target	  negative	  
control	  (OT)	  and	  knockdown	  cell	  line	  (KD).	  Right	  side	  shows	  the	  actin	  
for	  same	  blot	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The	   figure	   above	   shows	   a	   western	   blot	   for	   RRM2	   (left)	   and	   a	   subsequent	  actin	  blot	  on	  the	  same	  blot	  (right).	   	  The	  lanes	  represent	  original	  Suit-­‐‑2	  cells	  (AS),	  off	   target	  siRNA	  negative	  control	   (OT),	  and	  the	  knockdown	  cells	   (KD).	  	  There	  has	  been	  a	  significant	  decrease	  in	  the	  expression	  of	  RRM2	  in	  the	  third	  lane,	  despite	  relatively	  equally	  loaded	  lanes	  as	  shown	  by	  the	  actin	  blot.	  This	  is	  consistent	  with	  successful	  knockdown	  of	  RRM2	  in	  the	  AS	  cell	  line.	  	  	  
	   	  
Figure	  46:   RRM2	   knockdown	   in	   GR	   cells.	   Left	   shows	   western	   blot	   for	  
RRM2	   following	  knockdown	  of	  RRM2	   in	  GR	  cell	   line.	   Lanes	   represent	  
parent	   resistant	   cell	   line	   (GR),	   off	   target	   negative	   control	   (OT)	   and	  
knockdown	  cells	  (KD).	  	  Right	  shows	  actin	  for	  same	  blot	  The	   figure	  above	   is	   similar	  but	   shows	  a	  western	  blot	   for	  RRM2	  (left)	  and	  a	  subsequent	  actin	  blot	  on	  the	  same	  blot	  (right)	  for	  the	  GR	  cell	  line.	  	  The	  lanes	  represent	   resistant	   GR	   Suit-­‐‑2	   cells	   (AS),	   off	   target	   siRNA	   negative	   control	  (OT),	  and	  the	  knockdown	  cells	  (KD).	  	  There	  is	  a	  subtle	  but	  definite	  decrease	  in	  the	  density	  of	  the	  band	  in	  the	  third	  lane	  corresponding	  to	  the	  knockdown	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cells.	  	  This	  is	  despite	  consistent	  loading	  of	  lanes	  shown	  on	  the	  actin	  blot.	  	  This	  confirms	  the	  knockdown	  was	  successful	  in	  reducing	  the	  expression	  of	  RRM2	  in	  the	  GR	  cell	  line.	  
4.3.4.2  MTS	  following	  knockdown	  of	  RRM2	  
The	  cell	  lines	  in	  the	  knockdown	  experiment	  were	  subjected	  to	  MTS	  analysis	  to	  show	  any	  effect	  on	  resistance	  to	  gemcitabine.	  	  The	  knockdown	  cells	  were	  treated	   with	   gemcitabine	   24	   hours	   after	   knockdown	   and	   the	   cytotoxicity	  experiment	   was	   performed	   a	   further	   24	   hours	   later	   (i.e.	   48	   hours	   after	  knockdown).	  
	  
Figure	  47:   MTS	  96-­‐‑well	   plates	   for	   knockdown	  of	  RRM2	   in	  GR	   cells.	   An	  
example	  of	  an	  experiment	  to	  demonstrate	  resistance	  to	  gemcitabine	  in	  
the	   resistant	   cell	   line	   GR	  with/without	   knockdown	   of	   RRM2	   (GR/KD	  
plate	   below	   is	   the	   knockdown).	   The	   depth	   of	   colour	   can	   be	   seen	   to	  
decrease	   more	   rapidly	   in	   the	   lower	   plate	   from	   left	   to	   right,	  
demonstrating	   a	   lower	   percentage	   of	   cells	   remaining	   alive.	   These	  
appearances	  are	  quantified	  below.	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The	   figure	   above	   shows	   an	   example	   of	   the	   96-­‐‑well	   plates	   after	   the	  cytotoxicity	  experiment.	   	  The	  upper	  plate	  is	  the	  original	  resistant	  Suit-­‐‑2	  cell	  ling	  (GR/GR)	  whereas	  the	  lower	  plate	  is	  the	  GR	  cell	  line	  after	  knockdown	  of	  RRM2	   (GR/KD).	   	   This	   shows	  a	  paler	   colour	  orange	   in	   the	  9th,	   10th	   and	  11th	  columns	   in	   the	  knockdown	  plate	  as	  compared	  to	   the	  original	  cells,	  which	   is	  visible	  to	  the	  naked	  eye,	  suggesting	  less	  cells	  have	  survived.	  
Gemcitabine	  concentration	  (nM)	   AS	   AS.KD	   GR	   GR.KD	  
0.001	   97.8	   90.0	   97.6	   99.7	  
0.01	   73.8	   34.9	   95.9	   97.5	  
0.1	   66.7	   31.6	   94.8	   96.8	  
1	   58.7	   26.1	   92.2	   95.1	  
10	   42.4	   17.9	   91.8	   95.3	  
100	   37.2	   16.2	   90.7	   92.7	  
1000	   34.7	   15.8	   90.9	   84.7	  
10000	   32.2	   15.0	   89.5	   45.5	  
100000	   31.4	   14.9	   77.3	   39.1	  
1000000	   29.8	   13.8	   23.9	   27.6	  
Table	  22:   Spectrophotometry	   of	   MTS	   96-­‐‑well	   plates	   for	  
knockdown	   of	   RRM2	   in	   GR	   cells.	   The	   results	   of	  
spectrophotometry	   of	   the	   above	   figure	   and	   a	   similar	  
experiment	   for	   knockdown	   in	   the	   AS	   cell	   line	   showing	   the	  
measured	   difference	   in	   depth	   of	   colour	   converted	   to	   a	  
percentage	   (compared	   to	   a	   control	   column	   of	   no	   cells	  
present)	   for	   the	   four	   cell	   lines	   (AS,	   AS	  with	  RRM2	  knockdown	  
(AS.KD),	   GR,	   GR	   with	   RRM2	   knockdown(GR.KD))	   for	   the	  
various	  concentrations	  of	  gemcitabine	  shown	   in	   the	   left-­‐‑hand	  
column.	  The	  table	  above	  shows	  the	  results	  of	  spectrophotometry	  of	  the	  96-­‐‑well	  plates	  shown.	   	  This	  allows	  a	  numerical	  value	   to	  be	  attributed	   to	   the	  visually	  paler	  colours.	   	   This	   depth	   of	   colour	   been	   plotted	   against	   concentration	   of	  gemcitabine	  used	  and	  the	  table	  shows	  the	  values	   for	  both	  original	  cell	   lines	  (AS	   and	   GR)	   and	   the	   2	   knockdown	   cell	   lines	   (AS.KD	   and	   GR.KD).	   	   This	  demonstrates	   a	  more	   rapid	   decrease	   in	   depth	   of	   colour	   (i.e.	   less	   surviving	  cells)	  in	  both	  the	  knockdown	  cells	  compared	  with	  their	  parent	  cell	  line.	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The	  values	  in	  this	  table	  re	  plotted	  as	  curves	  in	  the	  figure	  below.	  
	  
Figure	  48:   IC50	  curves	  following	  knockdown	  of	  RRM2.	  	  This	  figure	  plots	  
percentage	   of	   cells	   surviving	   against	   concentration	   of	   gemcitabine	  
following	   treatment	   with	   gemcitabine	   for	   24	   hours.	   	   There	   are	   4	  
curves	   representing	   the	   2	   original	   cell	   lines	   (AS	   and	   GR)	   and	   the	   2	  
corresponding	   knockdown	   cell	   lines	   (AS.KD	   and	   GR.KD).	   The	   IC50	  
values	  gained	  from	  these	  curves	  are	  also	  shown.	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compared	   to	   their	   original	   cell	   line,	   suggesting	   increased	   sensitivity	   to	  gemcitabine.	  	  	  
This	   increased	   sensitivity	   to	   gemcitabine	   is	   further	   confirmed	   when	   IC50	  values	  are	  derived	  from	  the	  curves.	   	  For	  the	  originally	  resistant	  cell	   line	  GR,	  the	   knockdown	   has	   taken	   the	   IC50	   value	   from	   greater	   than	   300,000nM	   to	  29,500nM,	  which	  is	  a	  ten-­‐‑fold	  decrease.	  	  	  
For	  the	  original	  Suit-­‐‑2	  cell	  line	  AS,	  the	  knockdown	  of	  RRM2	  has	  reduced	  the	  IC50	  value	  from	  0.1nM	  to	  0.004nM,	  which	  is	  greater	  than	  a	  ten-­‐‑fold	  drop.	  
These	  results	  show	  a	  significant	  effect	  on	  resistance	  by	  manipulation	  of	   the	  RRM2	  expression	  of	  the	  cells.	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  Treating	  with	  exogenous	  A1AT	  
To	   further	   investigate	   a	   potential	   link	   between	   A1AT	   and	   resistance,	   cells	  were	   treated	   with	   exogenous	   A1AT	   protein	   at	   various	   concentrations	   to	  assess	  any	  effect	  on	  resistance	  to	  gemcitabine.	  	  	  
For	  this	  experiment	  two	  96-­‐‑well	  plates	  were	  seeded	  with	  suit-­‐‑2	  AS	  cells	  and	  grown	  for	  two	  days;	  one	  plate	  with	  A1AT	  added	  to	  the	  culture	  media	  and	  one	  plate	  without.	   	   The	   concentration	   of	  A1AT	  was	   extrapolated	   from	   the	   dose	  used	   clinically:	   usually	   60mg/kg,	   therefore	   estimating	   the	   cell	  mass	   on	   the	  base	  of	  a	  96-­‐‑well	  plate	  to	  be	  between	  0.1g	  and	  1g,	  25μg	  /plate	  was	  used.	  
The	  two	  plates	  were	  then	  subjected	  to	  various	  concentrations	  of	  gemcitabine	  consistent	   with	   previous	   experiments	   and	   subjected	   to	   MTS	   assay	   at	   72	  hours.	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Figure	  49:   MTS	   assay	   following	   exogenous	   A1AT	   treatment.	   A	  
photograph	   of	   a	   96-­‐‑well	   plate	   from	   the	   described	   experiment,	  
following	   treatment	   of	   AS	   cells	   with	   or	   without	   A1AT	   and	   varying	  
concentrations	  of	  gemcitabine.	  The	  above	  plate	  has	  been	  treated	  with	  
A1AT,	   the	   lower	  without.	   The	  plates	  are	   otherwise	   treated	   similarly,	  
with	  increasing	  concentrations	  of	  gemcitabine	  from	  left	  to	  right,	  and	  a	  
control	   lane	   on	   the	   far	   right	   of	   media	   only.	   The	   colour	   or	   the	  
equivalent	  columns	  of	  each	  plate	  are	  very	  similar.	  	  
The	   figure	   above	   show	   first	   the	   2	   96-­‐‑well	   plates	   (upper	   plate	   treated	  with	  A1AT	  and	  the	  lower	  without)	  following	  MTS	  assay,	  which	  shows	  no	  change	  in	  depth	   of	   colour	   between	   plates	   visible	   to	   the	   naked	   eye.	   	   The	   table	   below	  then	  shows	  the	  values	  following	  spectrophotometry	  analysis	  of	  the	  same	  96-­‐‑well	  plates,	  showing	  very	  similar	  readings	  between	  the	  2	  plates.	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Gemcitabine	  concentration	  
(nM)	   %	  Control	   	  	  
	  	   With	  A1AT	   No	  A1AT	  
0.001	   100.9	   100.1	  
0.01	   99.1	   99.1	  
0.1	   84.7	   99.5	  
1	   98.5	   98.4	  
10	   51.3	   62.0	  
100	   33.0	   33.2	  
1000	   30.0	   25.7	  
10000	   29.7	   24.8	  
100000	   29.6	   25.9	  
1000000	   26.8	   21.4	  
Table	  23:   Spectrophotometry	   of	   MTS	   96-­‐‑well	   plates	   using	   AS	  
cells	   following	   exogenous	   A1AT	   treatment.	   Values	   show	  
measured	   depth	   of	   colour	   adjusted	   to	   show	   percentage	   of	  
cells	  alive	  vs	  control	  for	  96-­‐‑well	  plate	  treated	  with	  or	  without	  
A1AT	  for	  48	  hours	  prior	  to	  and	  during	  treatment	  with	  varying	  
concentrations	  of	  gemcitabine.	  	  
	  
Figure	  50:   Cytotoxicity	   curves	   created	   from	   the	   values	   in	   the	   above	  
table,	   showing	   very	   similar	   curves	   for	   both	   96-­‐‑well	   plates	   (i.e.	   no	  
change	  in	  resistance	  to	  gemcitabine).	  These	  curves	  are	  consistent	  with	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The	  knockdown	  experiments	  demonstrated	  successful	  reduction	  in	  the	  RNA	  expression	  of	  SERPINA1,	  and	  also	  reduction	  in	  the	  protein	  expression	  of	  both	  GSTP	  and	  RRM2.	  
However,	  the	  decrease	  in	  SERPINA1	  expression	  had	  no	  effect	  on	  the	  response	  to	  gemcitabine	  in	  either	  cell	  line.	  	  The	  decrease	  in	  GSTP	  also	  failed	  to	  have	  an	  effect	  on	  gemcitabine	  resistance.	  
The	   decrease	   in	   RRM2	   showed	   a	   significant	   increase	   in	   sensitivity	   (or	  decreased	   resistance)	   to	   gemcitabine	   in	   the	   region	   of	   a	   ten-­‐‑fold	   change	   for	  both	   the	   parental	   ‘sensitive’	   Suit-­‐‑2	   cell	   line	   (AS)	   and	   the	   clonally	   resistant	  Suit-­‐‑2	  cell	  line	  (GR).	  
These	  results	  suggest	  a	  role	  for	  RRM2	  in	  the	  cellular	  response	  to	  gemcitabine.	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4.4  ICC	  and	  IHC	  for	  RRM2	  
  Overview	  
A	   link	   between	  RRM2	   levels	   and	   resistance	   had	   now	  been	   shown,	   and	  had	  been	   established	   as	   a	   causative	   link	   by	   manipulating	   levels	   via	   siRNA	  knockdown.	  	  The	  next	  step	  was	  to	  optimise	  the	  RRM2	  antibody	  for	  use	  in	  ICC	  and	  then	  IHC	  with	  a	  view	  to	  the	  future	  staining	  of	  human	  tissue	  microarrays	  and	  assessing	  for	  a	  possible	  link	  with	  survival.	  
	  
  Immunocytochemistry	  (ICC)	  for	  RRM2	  
The	   RRM2	   antibody	   was	   optimised	   and	   ICC	   performed	   on	   various	   cells	   to	  demonstrate	  that	  ICC	  was	  successful.	  	  ICC	  was	  performed	  as	  per	  the	  methods	  using	   an	   RRM2	   antibody	   concentration	   of	   1:1000.	   	   The	   figure	   below	  demonstrates	   this.	   	  Example	  pictures	  show	  the	  different	  amount	  of	  staining	  (brown	   colour)	   achieved	   either	   without	   or	   with	   knockdown	   of	   the	   RRM2	  protein.	  	  The	  upper	  left	  pane	  is	  the	  original	  Suit-­‐‑2	  cells	  and	  the	  upper	  right	  is	  one	  of	   the	  negative	  controls	  (using	  off-­‐‑target	  siRNA).	   	  The	   lower	   two	  panes	  are	   pictures	   of	   the	   staining	   achieved	   following	   successful	   knockdown	   of	  RRM2.	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Figure	  51:   Example	  ICC	  for	  RRM2.	  	  The	  figure	  shows	  4	  pictures	  of	  plates	  
of	  parental	  Suit-­‐‑2	  cells	  (AS),	  all	  stained	  for	  the	  presence	  of	  the	  RRM2	  
protein,	  after	  a	  knockdown	  experiment	  for	  RRM2.	  	  The	  upper	  left	  pane	  
(A)	   is	   the	   original	   cell,	   the	   upper	   right	   pane	   (B)	   is	   the	   cells	   treated	  
with	   off-­‐‑target	   siRNA	   (i.e.	   negative	   control),	   the	   lower	   left	   and	   right	  
panes	  (C	  and	  D)	  both	  show	  cells	  following	  knockdown	  of	  RRM2.	  	  
The	   pictures	   show	   obviously	   less	   brown	   staining	   of	   the	   lower	   panes	  compared	  with	   the	   upper	   (i.e.	  more	   blue	   rather	   than	   brown).	   	   This	   shows	  that	   there	   is	   less	   RRM2	   present	   in	   the	   knockdown	   cells,	   and	   also	   shows	  successful	  staining	  for	  RRM2.	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  Immunohistochemistry	  (IHC)	  for	  RRM2	  
IHC	   was	   performed	   on	   human	   tissue	   again	   using	   an	   RRM2	   antibody	  concentration	  of	  1:1000.	  
	  
Figure	  52:   Example	  of	   IHC	  staining	  for	  RRM2	  using	  human	  tissue.	  The	  
upper	  pane	  (A)	  shows	  a	  photograph	  of	  human	  pancreatic	  tissue,	  with	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  Conclusion	  
Successful	   staining	   for	   RRM2	   in	   human	   tissue	   (as	   shown	   above)	   is	   an	  important	   step	   in	   taking	   the	  work	   of	   this	   thesis	   forward.	   	   It	  will	   allow	   the	  staining	   of	   human	   tissue	   microarrays,	   and	   comparing	   the	   level	   of	   staining	  with	   the	   treatment	   and	   survival	   data	   for	   those	   patients,	   with	   the	   hope	   of	  demonstrating,	  or	  refuting,	  a	  link	  between	  RRM2	  expression	  and	  gemcitabine	  resistance	  in	  human	  PDAC.	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5   Discussion	  
5.1  Summary	  	  
The	   objective	   of	   this	   thesis	   was	   to	   investigate	   mechanisms	   of	   gemcitabine	  resistance,	  by	  building	  on	  previous	  work	  which	  had	  highlighted	  a	  number	  of	  potential	   genes	   and	   proteins	   differentially	   expressed	   between	   relatively	  sensitive	  and	  resistant	  cell	  lines.	  
The	   initial	   step	   was	   to	   confirm	   this	   differential	   expression.	   	   This	   was	  successful	  for	  the	  SERPIN	  A1	  gene	  which	  codes	  for	  A1AT	  by	  the	  use	  of	  qRT-­‐‑PCR	   which	   showed	   75.4%	   and	   80.0%	   decreased	   expression	   of	   SERPIN	   A1	  RNA	  in	  KR	  and	  GR	  resistant	  cells	  respectively	  compared	  with	  native	  AS	  Suit-­‐‑2	  cells.	  	  	  
It	  was	   also	   successfully	   shown	   that	   the	   KR	   cell	   line	   on	  which	   the	   previous	  work	  was	   based	   showed	   19.6%	   decreased	   expression	   compared	   to	   the	   AS	  cell	   line.	   	   The	   GR	   cell	   line	   in	   this	   case	   showed	   similar	   expression	   to	   AS.	  	  Differential	  expression	  of	  GSTP	  was	  also	  shown	  by	  the	  results	  but	  to	  a	  slightly	  lesser	  degree	  (12%	  decrease	  for	  GR	  and	  15%	  decrease	  in	  KR	  cells	  compared	  to	  AS).	  	  	  
Following	  this,	  siRNA	  knockdown	  of	  both	  SERPIN	  A1	  and	  the	  gene	  coding	  for	  GSTP	  had	  no	  effect	  on	  resistance	  to	  gemcitabine.	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Knockdown	   of	   RRM2	   expression	   was	   shown	   to	   increase	   sensitivity	   to	  gemcitabine	  in	  both	  AS	  and	  GR	  cell	   lines.	   	  The	  gemcitabine	  IC50	  for	  AS	  cells	  fell	   from	  0.1nM	  to	  0.004nM	  and	   the	  gemcitabine	   IC50	   for	  GR	  cells	   fell	   from	  >300.000nM	   to	   29,500nM.	   	   Both	   of	   these	   represent	   a	   greater	   that	   ten-­‐‑fold	  drop	  in	  resistance.	  
Conditions	   were	   subsequently	   optimised	   to	   allow	   IHC	   probing	   of	   human	  tissue	  slides	  for	  RRM2.	  
	  
5.2  Clinical	  relevance	  and	  further	  work	  
With	  respect	   to	  RRM2,	   the	   results	  are	  conflicting.	   	  The	   transiently	   resistant	  cell	  line	  KR	  had	  decreased	  levels	  of	  RRM2,	  whereas	  knockdown	  in	  the	  AS	  and	  GR	  cell	  lines	  caused	  a	  reduction	  in	  resistance	  to	  gemcitabine.	  	  The	  majority	  of	  published	  studies	  have	  described	   low	   levels	  of	  RRM2	  being	  associated	  with	  decreased	  resistance	  to	  gemcitabine	  or	  vice	  versa116,170,172,177–179.	  
This	   suggests	   either	   the	   KR	   cell	   line	   had	   developed	   another	  mechanism	   of	  resistance	  and	  the	  differing	  levels	  of	  RRM2	  are	  an	  innocent	  bystander,	  or	  the	  interaction	  between	  gemcitabine	  and	  RRM2	  is	  more	  complex.	  	  	  
Gemcitabine	   is	   known	   to	   exert	   its	   effects	   in	   two	   main	   ways.	   Firstly,	   by	  competitive	   incorporation	   into	   DNA	   instead	   of	   the	   natural	   nucleotide,	   in	  which	   case	   a	   lower	   level	   of	   RRM2	   producing	   a	   smaller	   pool	   of	   natural	  nucleotide	   would	   indeed	   enhance	   its	   effectiveness	   and	   reduce	   resistance.	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The	  outcome	  of	  this	  pathway	  is	  DNA	  damage	  leading	  to	  cell	  death.	  	  This	  is	  in	  agreement	   with	   the	   majority	   of	   the	   literature	   and	   the	   knockdown	   results	  from	  this	  thesis.	  
The	  second	  pathway	  is	  by	  inhibition	  of	  RNR.	  	  This	  again	  reduces	  the	  pool	  of	  natural	   nucleotide,	   initially	   leading	   to	   the	   same	   effect	   as	   above,	   with	   DNA	  damage	  and	  cell	  death.	  	  However,	  if	  the	  initial	  amount	  of	  RRM2	  is	  so	  low	  that	  the	  inhibitory	  effect	  of	  gemcitabine	  on	  RNR	  essentially	  prevents	  any	  natural	  nucleotide	   production,	   this	   would	   lead	   to	   DNA	   production	   ceasing	   and	   a	  cytostatic	   rather	   than	   a	   cytocidal	   effect.	   	   This	   would	   allow	   the	   cells	   to	  weather	  the	  storm	  of	  a	  pulse	  of	  gemcitabine	  therapy,	  ready	  to	  start	  dividing	  once	  more	  when	  gemcitabine	  levels	  fall.	  	  This	  pulsatile	  level	  of	  gemcitabine	  is	  what	  would	  occur	  during	  clinical	  treatment.	  
If	  this	  theory	  is	  true,	  then	  gemcitabine	  resistance	  could	  increase	  when	  levels	  of	  RRM2	  are	  either	  too	  high	  or	  too	  low,	  but	  sensitivity	  increase	  when	  levels	  are	  ‘just	  right’,	  an	  observation	  which	  has	  been	  termed	  the	  ‘Goldilocks	  effect’.	  	  This	   effect	   could	   also	   explain	   the	   seemingly	   conflicting	   results	   mentioned	  above.	  	  	  
Either	  way,	   these	   results	   add	   to	   a	   growing	   evidence	  base	   that	  RRM2	   levels	  can	   affect	   resistance	   to	   gemcitabine,	   and	  need	   to	   be	   investigated	   in	   human	  tissue	   in	   the	   context	   of	   randomised	   trials,	   to	   identify	   if	   it	   can	   be	   used	   as	   a	  marker	  for	  personalised	  chemotherapy.	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Since	  the	  experiments	  described	  in	  this	  thesis,	  this	  work	  on	  human	  tissue	  has	  been	  undertaken	  at	  the	  university	  of	  Liverpool	  using	  IHC	  probing	  for	  RRM2.	  Tissue	  microarrays	  from	  the	  ESPAC	  trials	  have	  been	  examined	  for	  both	  RNA	  and	   protein	   expression	   of	   RRM2	   and	   these	   levels	   compared	   with	   survival	  data.	   	  This	  has	  been	  performed	  by	  Karen	  Aughton	  and	  Nils	  Ellander	  and	  the	  results	  are	  yet	  to	  be	  published.	  
The	   above	   results	   validated	   the	   findings	   of	   the	   microarrays	   for	   the	   RNA	  expression	  of	  SERPIN	  A1,	  however	  they	  fail	  to	  show	  an	  effect	  on	  resistance	  of	  manipulating	  lower	  expression	  of	  SERPIN	  A1.	  	  This	  could	  be	  for	  a	  number	  of	  reasons	   including;	  SERPIN	  A1	  does	  not	  have	  a	  direct	  effect	  on	  RRM2	   levels	  and	   is	   an	   incidental	   finding,	   or	   perhaps	   the	   knockdown	   of	   the	   SERPIN	   A1	  RNA	  production	  did	  not	  have	  an	  effect	  on	  protein	  levels,	  or	  SERPIN	  A1	  could	  be	  one	  of	  a	  number	  of	  changes	  within	  the	  cell	  which	  only	  together	  produce	  resistance.	  
Given	   the	   recent	   increase	   in	   interest	   in	   A1AT	   levels	   and	   pancreatic	  cancer149,150,152,	   it	   would	   seem	   that	   the	   results	   within	   this	   thesis	   deserve	  further	  investigation,	  particularly	  in	  light	  of	  the	  clonally	  resistant	  cell	  line	  GR	  displaying	  decreased	  levels.	  	  This	  further	  work	  is	  currently	  being	  discussed	  at	  the	  university	  of	  Liverpool.	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5.3  Conclusion	  
RRM2	  levels	  have	  been	  shown	  to	  affect	  gemcitabine	  resistance	  in	  pancreatic	  cancer	   in	   vitro	   and	   need	   to	   be	   further	   investigated	   in	   vivo	   to	   assess	   for	   a	  potential	  effect	  on	  survival.	  
SERPIN	  A1/A1AT	   levels	   have	   been	   shown	   to	   be	   differentially	   expressed	   in	  resistant	   pancreatic	   cancer	   cell	   lines	   in	   vitro,	   but	   further	   investigation	   is	  required	  to	  assess	  the	  relevance	  of	  this	  decreased	  expression.	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